<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen30">
		<pathogen_name>Plasmodium spp.</pathogen_name>
		<taxon_id>5820</taxon_id>
		<pathogenesis refs="reference244 reference245 reference246">Malaria in humans develops via exoerythrocytic (hepatic) and erythrocytic phases. When an infected mosquito pierces a person's skin to take a blood meal, sporozoites in the mosquito's saliva enter the bloodstream and migrate to the liver. Within 30 minutes of being introduced into the human host, they infect hepatocytes, multiplying asexually and asymptomatically for a period of 6–15 d. During this &quot;dormant&quot; time in the liver, the sporozoites are often referred to as &quot;hypnozoites&quot;. Once in the liver, these organisms differentiate to yield thousands of merozoites which, following rupture of their host cells, escape into the blood and infect red blood cells, thus beginning the erythrocytic stage of the life cycle. The parasite escapes from the liver undetected by wrapping itself in the cell membrane of the infected host liver cell. Within the erythrocytes, the parasites multiply further, periodically breaking out of their hosts to invade fresh erythrocytes. Several such amplification cycles occur, resulting in the classical waves of fever. Some merozoites turn into male and female gametocytes. If a mosquito pierces the skin of an infected person, it potentially picks up gametocytes within the blood. Fertilization and sexual recombination of the parasite occurs in the mosquito's gut, thereby defining the mosquito as the definitive host of the disease. New sporozoites develop and travel to the mosquito's salivary gland, completing the cycle. Pregnant women are especially attractive to the mosquitoes, and malaria in pregnant women is an important cause of stillbirths, infant mortality and low birth weight (Talman et al., 2004)(Bledsoe, 2005)(Sturm et al., 2006).</pathogenesis>
		<disease_name>Malaria</disease_name>
		<protective_immunity refs="reference250 reference251">Plasmodia are relatively protected from attack by the body's immune system because for most of its life cycle it resides within liver and blood cells and is relatively invisible to immune surveillance. However, circulating infected blood cells are destroyed in the spleen. To avoid this fate, P. falciparum displays adhesive proteins on the surface of the infected blood cells, causing blood cells to stick to the walls of small blood vessels, thereby sequestering the parasite from passage through the general circulation and the spleen and giving rise to hemorrhagic complications. Endothelial venules can be blocked by the attachment of masses of these infected red blood cells (RBCs). The blockage of these vessels causes placental and cerebral malaria. Although the RBC surface adhesive proteins (called PfEMP1, for Plasmodium falciparum erythrocyte membrane protein 1) are exposed to the immune system, they do not serve as good immune targets because of their extreme diversity; there are at least 60 variations of the protein within a single parasite and perhaps limitless versions within parasite populations (Chen et al., 2000)(Adams et al., 2002).</protective_immunity>
		<host_range refs="reference247 reference248 reference249">The vast majority of malaria cases occur in children under the age of 5 years; pregnant women are also especially vulnerable. Despite efforts to reduce transmission and increase treatment, there has been little change in which areas are at risk of this disease since 1992. Precise statistics are unknown, as the majority of cases are undocumented. Although HIV/malaria co-infection produces less severe symptoms than the interaction between HIV and TB, HIV and malaria do contribute to each other's spread. This effect comes from malaria increasing viral load and HIV infection increasing a person's susceptibility to malaria infection. Malaria is presently endemic in a broad band around the equator, in areas of the Americas, many parts of Asia, and much of Africa; however, it is in sub-Saharan Africa where 85– 90% of malaria fatalities occur. The geographic distribution of malaria within large regions is complex, and malarial and malaria-free areas are often found close to each other. In drier areas, outbreaks of malaria can be predicted with reasonable accuracy by mapping rainfall (Breman, 2001)(Greenwood et al., 2005)(Hay et al., 2004).</host_range>
		<introduction refs="reference240 reference241 reference242 reference243">Malaria is a vector-borne infectious disease that is widespread in tropical and subtropical regions, causing disease in approximately 400 million people and killing 1-3 million, most of them young children in Sub-Saharan Africa. It is one of the most common infectious diseases, caused by protozoan parasites of the genus Plasmodium. The most serious forms of the disease are caused by P. falciparum and P. vivax, but other related species (P. ovale, P. malariae, and sometimes P. knowlesi) can also infect humans. This group of human-pathogenic Plasmodium spp. is usually referred to as malaria parasites and are transmitted by female Anopheles mosquitoes. The parasites multiply within red blood cells, causing symptoms of anemia, as well as other general symptoms such as fever, chills, nausea, flu-like illness, and in severe cases, coma and death. No vaccine is currently available for malaria; preventative drugs must be taken continuously to reduce the risk of infection. These prophylactic drug treatments are often too expensive for most people living in endemic areas. Most adults from endemic areas have a degree of long-term recurrent infection and also of partial resistance, which reduces with time and such adults may become susceptible to severe malaria if they have spent a significant amount of time in non-endemic areas (Joy et al., 2003)(Escalante et al., 1998)(Kaufman et al., 2005)(Meis et al., 1983).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine4314">
		<vaccine_name>BDES-PfCSP (baculovirus dual expression system)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004801</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3328">(Iyori et al., 2013)</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4310">
		<vaccine_name>ChAd63 -PvTRAP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004797</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3324">(Bauza et al., 2014)   the recombinant ChAd63 vectors expressing P. vivax TRAP (PvTRAP).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine232">
		<vaccine_name>FMP1/AS02A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000777</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference426">The Plasmodium falciparum vaccine candidate FMP2.1/AS02A , a recombinant E coli-expressed protein based upon the apical membrane antigen-1 (AMA-1 ) of the 3D7 clone formulated with the AS02A adjuvant (Polhemus et al., 2007).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference426">FMP2.1 antigen represents amino acids #83-531 of the P. falciparum (clone 3D7) AMA-1 protein. Just prior to immunization, the lyophilized FMP2.1 protein was mixed with AS02A such that approximately 8, 20 or 40 μg of FMP2.1 was delivered in a final volume of 0.5 mL of AS02A (Polhemus et al., 2007).</preparation>
		<route refs=""></route>
		<antigen refs="reference572 reference426">Apical membrane antigen 1 (AMA-1)  is an asexual blood stage antigen. AMA-1 is considered to be an important candidate malaria vaccine antigen (Morais et al., 2006)(Polhemus et al., 2007).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering137" gene_id="gene139">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response491" host_id="host2">
			<immune_response refs="reference426">All volunteers seroconverted after second immunization as determined by ELISA. Immune sera recognized sporozoites and merozoites by immunofluorescence assay (IFA), and exhibited both growth inhibition and processing inhibition activity against homologous (3D7) asexual stage parasites. Post-immunization, peripheral blood mononuculear cells exhibited FMP2.1-specific lymphoproliferation and IFN-γ and IL-5 ELISPOT assay responses (Polhemus et al., 2007).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference426">An open-label, staggered-start, dose-escalating Phase I trial was conducted in 23 malaria-naïve volunteers who received 8, 20 or 40 μg of FMP2.1 in a fixed volume of 0.5 mL of AS02A on a 0, 1, and 2 month schedule. Nineteen of 23 volunteers received all three scheduled immunizations (Polhemus et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="">The most frequent solicited local and systemic adverse events associated with immunization were injection site pain (68%) and headache (29%). There were no significant laboratory abnormalities or vaccine-related serious adverse events.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine207">
		<vaccine_name>MSP3-LSP with aluminium hydroxide</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000773</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference522 reference524">aluminium hydroxide (Sirima et al., 2007). In another phase I clinical trial study using MSP3-LSP, two adjuvants were used, including Montanide ISA 720 and  aluminum hydroxide (Audran et al., 2005). However, it showed that it was unacceptably reactogenic when it was combined with Montanide (Audran et al., 2005).</adjuvant>
		<storage refs=""></storage>
		<virulence refs="">No.</virulence>
		<preparation refs=""></preparation>
		<route refs=""></route>
		<antigen refs="reference522 reference524">The merozoite surface protein-3 long synthetic peptide (MSP3-LSP) comprises the amino acid sequence 186-276 of the Plasmodium falciparum protein MSP3 (Sirima et al., 2007). The C-terminal conserved region of Plasmodium falciparum merozoite surface protein 3 (MSP3) is the trigger antigen of a protective immune response mediated by cytophilic antibodies (Audran et al., 2005).</antigen>
		<host_response host_response_id="host_response265" host_id="host2">
			<immune_response refs="reference522">Humoral immune responses (IgG, IgG subclasses, IgM) to MSP3-LSP peptide were similar in the two groups following vaccination. Some cell-mediated immune responses appeared to differ between the two vaccine groups. After the second dose of MSP3-LSP, there appeared to be a marked increase in the lymphocyte proliferation index and IFN-gamma in response to stimulation with MSP3-LSP (Sirima et al., 2007).</immune_response>
			<host_strain refs="">healthy male adults Africans</host_strain>
			<vaccination_protocol refs="reference522">A Phase 1b single-blind controlled trial was performed in the village of Balonghin in Burkina Faso. Thirty male volunteers aged 18-40 years were randomised to receive either three doses of 30 microg MSP3-LSP or 0.5 ml of tetanus toxoid vaccine . The second and third vaccine doses were given 28 and 112 days after the first dose . Participants for 1 year were followed for one year (Sirima et al., 2007).</vaccination_protocol>
			<persistence refs="reference522">Immune response did not wane appreciably up to 365 days post-vaccination (Sirima et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference522">There were no serious adverse events in either vaccine group. In both groups participants reported local reactions at the site of injection when compared to an earlier trial in European volunteers. Only one systemic adverse event ( tachycardia ) was identified which occurred immediately after the first vaccination in one individual receiving MSP3-LSP. No clinically significant biological abnormalities following vaccination were observed (Sirima et al., 2007).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs="reference522">In summary, this Phase 1b single-blind controlled trial showed that three doses of 30 microg MSP3-LSP when administered subcutaneously on days 0 , 28 and 112 are well-tolerated by adult males previously exposed to natural P falciparum infection. MSP3-LSP is able to stimulate an enhanced cell-mediated immune response in individuals with some degree of preexisting immunity (Sirima et al., 2007).</description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4309">
		<vaccine_name>MVA-PvTRAP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004796</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3324">(Bauza et al., 2014) the recombinant MVA vectors expressing P. vivax TRAP (PvTRAP) .</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4311">
		<vaccine_name>NILV-Py CSP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004798</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3325">(Coutant et al., 2012) nonintegrative lentiviral vectors (NILV) encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP), and challenged with sporozoites one month later. 50% (37.5-62.5) of the animals were fully protected. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization.</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4313">
		<vaccine_name>NYVAC-CSP (malaria)</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004800</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3327">(Lanar et al., 1996)  NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine4306">
		<vaccine_name>NYVAC-Pf7</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004794</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3321">(Ockenhouse et al., 1998)</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine3952">
		<vaccine_name>P. berghei DNA vaccine CSP-3p28</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004594</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pBLUESCRIPT [Ref2779:Bergmann-Leitner et al., 2007]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs="reference2779">CSP and 3 copies of the p28 fragment of C3d (Bergmann-Leitner et al., 2007)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1629" gene_id="gene633">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1598" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2779">Vaccination with CSP-3p28 resulted in better (100%) protection than CSP alone (60%) against P. berghei sporozoites at the 6-week challenge (p = 0.043) suggesting that the addition of 3 copies of the p28 peptide to CSP results in the generation of a better vaccine (Bergmann-Leitner et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3949">
		<vaccine_name>P. berghei DNA vaccine encoding PbCSP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004591</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pcDNA3.1 [Ref2776:Yoshida et al., 2000]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1626" gene_id="gene633">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1595" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2776">Protection obtained by gene gun delivery into the liver once (73%) was significantly higher than that by the material into the skin twice (31%) (Yoshida et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1105">
		<vaccine_name>P. berghei MSP1 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004065</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Alum</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs="">Recombinant MSP1 (rPbMSP1)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering595" gene_id="gene641">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response862" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="">Lyophilized rPbMSP1 was mixed with alum on the day of injection. Each vaccine formulation, containing 10 ug was administered through IP route to mice .</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1231">Eight out of ten mice vaccinated with rMSP1 in alum survived challenge with P. berghei (Wan et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1231">For challenge study, mice were intraperitoneally inoculated with parasitized erythrocytes at a density of either 10^6 or 10^5 parasitized
erythrocytes per mouse (Wan et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1102">
		<vaccine_name>P. chabaudi AMA1 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004194</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Montanide ISA720</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs="">Recombinant ectodomain of P. chabaudi adami (DS stain) AMA1 (denoted rAMA1B)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering592" gene_id="gene653">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response859" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1242">Groups of three to five mice were immunized i.p. with 15 µg of rAMA1B emulsified in Montanide ISA720. Four weeks later, a booster immunization was given using the same amount of rAMA1B emulsified with Montanide ISA720. Controls were immunized with PBS emulsified in Montanide ISA720 (Xu et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1242">Immunized mice demonstrated significantly lower peak parasitemias compared with PBS-immunized mice, showing that rAMA1B immunization confers protection against challenge with P. chabaudi (Xu et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1242">Ten days after being given a booster immunization the mice were challenged i.v. with 1 x 10^5 P. chabaudi adami parasitized erythrocytes (Xu et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1103">
		<vaccine_name>P. falciparum CS expressed in irradiated P. berghei as  Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004195</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>non-specified injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">non-specified injection</route>
		<antigen refs="">CSP from P. falciparum</antigen>

		<gene_engineering gene_engineering_id="gene_engineering593" gene_id="gene634">
			<type>Recombinant vector construction</type>
			<description refs="reference1224">P. berghei ANKA cloned lines were transfected with the P. falciparum CSP gene (Grüner et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response860" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/cJ</host_strain>
			<vaccination_protocol refs="reference1224">In order to induce sterile immunity in all the animals, BALB/cJ mice were immunized with 12,000 rad-irradiated P. berghei sporozoites as follows: one dose of 75,000 sporozoites followed by two booster doses of 25,00 of P. berghei sporozoites on days 15 and 21. In [BALB/c×C57BL/6] F1 mice immunisation was made with 3 injections of 10,000 P. berghei irradiated sporozoites at days 0, 15 and 21 (Grüner et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1224">Mice immunized with irradiated sporozoites were protected from challenge (Grüner et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1224">Control mice and mice immunized with irradiated sporozoites (transfected with P. falciparum CS)  were challenged intravenously with 5,000 P. berghei or P. berghei [PfCS] sporozoites (Grüner et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine210">
		<vaccine_name>P. falciparum DNA and MVA encoding ME-TRAP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000747</vo_id>
		<type>DNA vaccine</type>
		<status></status>
		<vector>pSG2 and MVA [Ref874:Dunachie et al., 2006]</vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="">The T-cell responses induced by this prime-boost regime , in animals and humans, are substantially greater than the sum of the responses induced by DNA or MVA vaccines used alone, leading to the term introduced here of &quot;synergistic&quot; prime-boost immunisation.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference874">DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP)  (Dunachie et al., 2006).</preparation>
		<route refs=""></route>
		<antigen refs="">Multiple epitope-thrombospondin-related adhesion protein (ME-TRAP)</antigen>

		<gene_engineering gene_engineering_id="gene_engineering136" gene_id="gene138">
			<type>Epitope construction used for delivery vector</type>
			<description refs="reference874">Multiple epitopes from the thrombospondin-related adhesion protein were prepared. The ME-TRAP were then introduced into three delivery vectors: DNA and modified vaccinia virus Ankara (MVA) (Dunachie et al., 2006).</description>
		</gene_engineering>
		<host_response host_response_id="host_response490" host_id="host2">
			<immune_response refs="">The vaccines were well tolerated and immunogenic, with the DDM-ME TRAP regimen producing strong ex vivo IFN-gamma ELISPOT responses</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference874">Sixteen healthy subjects who never had malaria (malaria-naive subjects) received two priming vaccinations with DNA, followed by one boosting immunization with MVA, with ME-TRAP (Dunachie et al., 2006).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference874">One of eight subjects receiving the DDM-ME TRAP regimen was completely protected against malaria challenge, with this group as a whole showing significant delay to parasitemia compared to controls (P = 0.045). The peak ex vivo IFN-gamma ELISPOT response in this group correlated strongly with the number of days to parasitemia (P = 0.033). Therefore, prime-boost vaccination with DNA and MVA encoding ME-TRAP resulted in partial protection against P. falciparum sporozoite challenge in the present study (Dunachie et al., 2006).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">Two weeks after the final vaccination, the subjects underwent P. falciparum sporozoite challenge, with six unvaccinated controls.</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1104">
		<vaccine_name>P. falciparum DNA Vaccine encoding EBA-175</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004196</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>expression plasmid vector VR1020</vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs="">P. falciparum EBA-175 RII</antigen>

		<gene_engineering gene_engineering_id="gene_engineering594" gene_id="gene835">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response861" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Aotus lemurinus lemurinus</host_strain>
			<vaccination_protocol refs="reference1490">Intradermal delivery of DNA vaccines was performed under light sedation with Ketamine at 20 mg/kg intramuscularly, using a 1 mL insulin syringe with a fused 29-gauge 0.5-inch needle. Monkeys received a total of 500 &amp;mu;g of plasmid DNA in saline in a series of four immunizations at weeks 0, 3, 6, and 47 on the lower back on six different sites. The maximal volume administered in any one site was 100 &amp;mu;l (Sim et al., 2001).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1490">One of three monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes (Sim et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1490">Aotus monkeys were challenged with 1 X 10^4 P. falciparum (FVO) infected erythrocytes (Sim et al., 2001).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine987">
		<vaccine_name>P. falciparum Hsp90 Protein Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011396</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1244">Freund's complete adjuvant (Bonnefoy et al., 1994).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering469" gene_id="gene657">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response741" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs="">S. sciureus</host_strain>
			<vaccination_protocol refs="reference1244">Monkeys were immunized on days 0, 21, and 42 with 120/~g of protein in PBS/0.1% SDS. Each dose consisted of 1.5ml
emulsified with Freund's complete adjuvant for the first immunization and Freund's incomplete adjuvant for the others, injected subcutaneously on multiple sites in the back. Control monkeys received the same treatment but without parasite proteins (Bonnefoy et al., 1994).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1244">The three control monkeys showed a rapid rise of parasitaemia  with a prepatent period of 2 days and required drug treatment within 7 days to prevent fatal outcome. Three immunized monkeys developed a reduced parasitaemia with a prepatent period of 2 to 6 days with a maximum peak of parasitaemia of 5-11.6% that dropped spontaneously. The two other immunized monkeys developed parasitaemia similar to the controls and were drug-cured at day 7 (Bonnefoy et al., 1994).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1244">All monkeys were challenged on day 56 by intravenous injection of 5 x 10^7 FUP/SP-infected monkey erythrocytes (Bonnefoy et al., 1994).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1096">
		<vaccine_name>P. falciparum LSA-3 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004193</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Montanide ISA51</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs="reference1489">Recombinant proteins GST-DG729, GST-NN and GST-PC were designed to cover 95% of the LSA-3 antigen and were used as a mixture (called LSA-3 GST-rec) (Daubersies et al., 2000).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering586" gene_id="gene834">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response853" host_id="host42">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1489">50 μg of recombinant LSA-3 peptides were emulsified in Montanide ISA51 and were injected subcutaneously into chimpanzees (Daubersies et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1489">Immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites (Daubersies et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1489">All chimpanzees were immunized at weeks 0, 4 and 8 and were challenged with 2 x 10^4 sporozoites at week 13 (Daubersies et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3103">
		<vaccine_name>P. falciparum MSA-2 subunit vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004269</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2044">merozoite antigen, MSA-2 (Pye et al., 1997).</antigen>
		<host_response host_response_id="host_response932" host_id="host17">
			<immune_response refs="reference2044">Sheep immunized with MSA-2 and SAF-1 had higher antibody response than sheep immunized with MSA-2 and alhydrogel (Pye et al., 1997).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2044">Sheep were immunized intramuscularly (i.m.) in the left rear leg, with a second immunization in the right rear leg 4 weeks later. A 100 μg antigen dose was delivered in 1.0 ml. Serum was prepared from bleeds taken prior to the first immunization, 3 or 4 weeks later (i.e. prior to the second dose), and a final bleed 2 weeks after the second immunization (Pye et al., 1997).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine234">
		<vaccine_name>P. falciparum MSP1 from transgenic mice with Freund's adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000775</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference520">It is likely for producing efficacious malarial vaccines in transgenic animals (Stowers et al., 2002).</description>
		<adjuvant refs="reference520">The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).</adjuvant>
		<storage refs=""></storage>
		<virulence refs="">None.</virulence>
		<preparation refs="reference520">Two strains of transgenic mice were generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1-42). One strain secretes an MSP1-42 with an amino acid sequence homologous to that of the FVO parasite line. In the other strain, an MSP1-42 where two putative N-linked glycosylation sites in the FVO sequence have been removed. Both forms of MSP142 were purified from whole milk to greater than 91% homogeneity at high yields (Stowers et al., 2002).</preparation>
		<route refs=""></route>
		<antigen refs="reference520">the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1) (Stowers et al., 2002).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering235" gene_id="gene143">
			<type>Recombinant protein preparation</type>
			<description refs="reference520">Generated by transgenic mice (Stowers et al., 2002).</description>
		</gene_engineering>
		<host_response host_response_id="host_response290" host_id="host5">
			<immune_response refs="reference520">There was a significant difference in the Endpoint ELISA titers to bvMSP142 between those animals vaccinated with bvMSP142 and TgMSP142 G (P = 0.008), and between those vaccinated with TgMSP142 NG and TgMSP142 G (P = 0.05). No differences in titers were observed between the bvMSP142 and TgMSP142 NG groups. No significant differences were seen in ELISA titers to other antigens (TgMSP142 NG, TgMSP142 G, or MSP119), nor were any significant differences seen in IFA titers against P. falciparum FVO parasites. Overall, antibody titers to none of the four antigens used as ELISA capture antigens (bvMSP142, TgMSP142 NG, TgMSP142 G, or MSP119) correlated with the primary outcome of protection as defined above (cumulative parasitemia until first monkey treated for anemia). However, antibody titers to bvMSP142 did correlate with days until treatment (r2 = 0.6241, P = 0.005) and inversely with parasitemia at time of treatment (r2 = -0.4206, P = 0.05) (Stowers et al., 2002).</immune_response>
			<host_strain refs="">owl monkey (Aotus nancymai)</host_strain>
			<vaccination_protocol refs="reference520">In total 28 monkeys were randomly assigned to groups of seven. The three vaccine groups received bvMSP1-42, TgMSP1-42 NG, and TgMSP1-42 G, respectively, and the fourth group placebo. Monkeys received three vaccinations of 100 µg of the respective recombinant protein 3 wk apart, following our established protocol. The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference520">Vaccination with the glycosylated version of milk-derived MSP1(42) conferred no protection compared with an adjuvant control. Vaccination with the nonglycosylated, milk-derived MSP1(42) successfully protected the monkeys, with 4/5 animals able to control an otherwise lethal infection with P falciparum compared with 1/7 control animals (Stowers et al., 2002).</protection_efficacy>
			<side_effects refs="reference520">During vaccination, three animals died (two in the TgMSP142 NG group and one in the TgMSP142 G group), unfortunately not a rare occurrence with these fragile monkeys. No animals died during the second study. When partially protected from P. falciparum malaria, it is a characteristic of Aotus monkeys that some protected animals will suffer from anemia (Stowers et al., 2002).</side_effects>
			<challenge_protocol refs="reference520">Vaccinated monkeys were challenged 15 days after the third vaccination by i.v. infusion of a freshly passaged preparation of 10^4 infected RBC of the highly virulent P. falciparum FVO strain. Monkeys were treated when parasitemia reached 5%, or their hematocrit fell below 20%. All monkeys not treated previously were treated on day 30. The treatment consisted of mefloquine administered in a single dose of 25 mg/kg of body mass by intubation. The second Aotus challenge trial followed the protocol outlined above, with the exceptions that only two groups (TgMSP142 NG and placebo) and a larger challenge inoculum were used (1 ml of 5 × 104 pRBCs/ml) (Stowers et al., 2002).</challenge_protocol>
			<description refs="reference520">Analysis of the different vaccines used suggested that the differing nature of the glycosylation patterns may have played a critical role in determining efficacy (Stowers et al., 2002). </description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine985">
		<vaccine_name>P. falciparum MSP3 Protein Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011440</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1226">Freund's complete adjuvant (Tsai et al., 2009).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering468" gene_id="gene636">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response739" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Aotus nancymai</host_strain>
			<vaccination_protocol refs="reference1226">Seven monkeys were vaccinated with 100 μg of EcMSP3, seven with 100 μg of control protein Pfs25, a parasite protein expressed during the mosquito stage of the life cycle. Each monkey received 0.125 mL of antigen emulsified in complete Freund's adjuvant at four sites, for a total of 0.5 mL, followed by two booster vaccinations with the same dose of antigen in a Montanide ISA51 (SEPPIC) formulation at 3-week intervals (Tsai et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1226">By day 11 post-challenge, the parasitemia in all but one monkey in the control group had reached the predetermined upper limit and were treated In contrast, no animals in the EcMSP3-vaccinated group required treatment by this time (Tsai et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1226">Seventeen days after the third vaccination, the monkeys were challenged by intravenous infusion of 5 × 10^4 P. falciparum FVO strain parasitized RBCs collected from a naïve donor monkey (Tsai et al., 2009).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3072">
		<vaccine_name>P. falciparum MSP4 with AFCo1 Adjuvant</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004243</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Not specified</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Not specified</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response902" host_id="host3">
			<immune_response refs="reference1898">AFCo1 significantly enhanced the IgG and T-cell response against MSP4, with a potency equivalent to CFA, with the response being characterized by both IgG1 and IgG2a isotypes, increased interferon gamma production and a strong DTH response, consistent with the ability of AFCo1 to induce Th1-like immune responses (Bracho et al., 2009).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference1898">MIce were immunized at 14-day intervals with three doses of 10 μg MSPs (Bracho et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine1121">
		<vaccine_name>P. falciparum pfCelTos protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004204</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>subcutaneous injection</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="">Montanide ISA 720</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">subcutaneous injection</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering606" gene_id="gene874">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response875" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Balb/c-J</host_strain>
			<vaccination_protocol refs="reference1641">Mice were immunized subcutaneously in the scruff of the neck three times with 25 or 10 or 1 µg/dose of recombinant PfCelTOS or saline emulsified in Montanide ISA 720 (Bergmann-Leitner et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="">Fourteen days after the final immunization, mice were challenged by subcutaneous inoculation (into the inguinal region) with 4,000 P. berghei sporozoites for Balb/c and 15,000 P. berghei sporozoites for CD-1 mice, dissected from infected mosquito salivary glands. The challenge dose was determined by titration studies in each mouse strain and compared to the different challenge routes. Infection was determined by the presence of blood stage parasites in Giemsa stained thin blood smears on day 6 and day 8 after challenge. Animals that were not infected at that time were tested again on day 14. Mice that remained un-infected by day 14 were classified as sterilely protected. We used this evaluation schedule because animals that are infected with P. berghei ANKA strain malaria parasites do not self-cure.</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine922">
		<vaccine_name>P. falciparum Pfen Protein Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011418</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1229">Freund's adjuvant  (Pal-Bhowmick et al., 2007).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering402" gene_id="gene639">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response680" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Swiss</host_strain>
			<vaccination_protocol refs="reference1229">Mice were injected intraperitoneally with r-Pfen emulsified in Freund's adjuvant at 21-day intervals (the first injection was 100 μg of r-Pfen in complete Freund's adjuvant, followed by 50 μg for the two boosters in incomplete Freund's adjuvant). In one control group, mice were injected in parallel with a recombinant Drosophila odorant binding protein OSF (as an irrelevant His-tagged protein control) emulsified in complete Freund's adjuvant. The other control group received no injections. After three immunizations, the antibody titers against r-Pfen were monitored (Pal-Bhowmick et al., 2007).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1229">All the control mice and the mice immunized with the irrelevant His-tagged protein developed a high degree of parasitemia (&gt;17% on average) by day 4 postchallenge, whereas r-Pfen-immunized mice showed &lt;1% parasitemia at that time point. The highest average parasitemia values were 70% and 40% for nonimmunized mice and mice injected with irrelevant His-tagged protein, respectively. However, among the mice immunized with r-Pfen, there was significant delay in the increase in parasitemia, and the highest average parasitemia was about 20% on day 8 postchallenge. The averages of these groups were compared using one-way analysis of variance, which showed that the mice immunized with enolase were significantly protected (Pal-Bhowmick et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1229">Mice having anti-r-Pfen antibody titers greater than 1:300,000 were then challenged with the lethal strain of P. yoelii (strain 17XL; 10^6 parasites per mouse), and parasitemia was monitored daily (Pal-Bhowmick et al., 2007).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3628">
		<vaccine_name>P. falciparum recombinant vector vaccine MVA.ME-TRAP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004399</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector>Recombinant fowlpox strain FP9 and recombinant MVA [Ref2302:Webster et al., 2005]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response1432" host_id="host2">
			<immune_response refs="reference2302">Vaccine regimes with FP9 as the priming agent induced significantly more CD8+ T cells in addition to the CD4+ T cells. This finding suggests that induced CD8+ T cell responses may be of particular value in vaccination against liver-stage malaria (Webster et al., 2005).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference2302">FFM Regime: FP9 priming, either once or twice, followed by MVA boosting (Webster et al., 2005).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0000286</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2302">Two of five subjects who went on to a malaria challenge conducted 14 days after their final vaccination were completely protected. These two subjects were entered, without further vaccinations, into a second malaria challenge 6 months later in which one subject (137) remained completely protected. In addition, all 17 subjects immunized with this FFM regime (FP9 priming, once or twice, followed by MVA boosting) who underwent challenge, overall, compared with nonvaccinees, had a significant delay in time to onset of parasitemia (Webster et al., 2005).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine919">
		<vaccine_name>P. falciparum Subunit SE36 Protein Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011415</vo_id>
		<type>Subunit vaccine</type>
		<status>Clinical trial</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1216">Aluminum hydroxide (Horii et al., 2010).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering400" gene_id="gene626">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response676" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs="">squirrel monkey (Saimiri sciureus)</host_strain>
			<vaccination_protocol refs="reference1216">The monkeys, weighing between 680 and 760 g at the beginning of the experiment, were divided into two groups. Group1 monkeys (R57, R59, and R61) received SE36/AHG and Group2 monkeys (R60 and R62) received PBS as a control by intra-muscular injection in their left thigh 5 and 3 weeks before challenge infection. Monkey R61 received a third injection on the 2 weeks before challenge infection. The dose used was 50 μg SE36 protein with 500 μg aluminum hydroxide gel (50/500) in 0.5 ml of PBS. Group2 monkeys (R60 and R62) received the same volume of PBS (Horii et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1216">Whereas two control monkeys developed 10–20% peak parasitemia, the parasitemia in the two immunized monkeys with higher antibody titers stayed at low values below 3% (Fig. 3B). One vaccinated monkey (Monkey R61), with the lowest antibody titer, developed 5% peak parasitemia but was able to control parasitemia by Day 7 onwards. Importantly, control monkeys did not raise anti-SE36 IgG titer even after the onset of parasitemia which parallels the less immunogenicity of SERA5 N-terminal domain observed in endemic areas. Thus, although the observed protection was not able to prevent infection, vaccinated monkeys had lower parasitemia and booster effects on antibody titers were observed after infection for all vaccinated monkeys (Horii et al., 2010).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1216">Two weeks after the last immunization, all monkeys were challenged with P. falciparum-infected red blood cells. Each of the five squirrel monkeys received 1 × 10^9 parasitized red blood cells. Parasitemia was monitored daily by counting 5000 RBCs in Giemsa-stained thin blood smears (Horii et al., 2010).</challenge_protocol>
			<description refs=""></description>
		</host_response>
		<host_response host_response_id="host_response678" host_id="host42">
			<immune_response refs="reference1216">Chimpanzee immunization experiment, likewise, indicated the immunogenicity of SE36/AHG and a long duration of antibody production over 1-year with only a gradual decrease. Three chimpanzees were immunized with GMP-grade SE36/AHG of either 10/100, 50/500 or 450/4500 dose. Throughout the study, all blood biochemistry results were normal according to human standards and no signs of systemic aberrations were observed, except for the commonly observed swelling at the administration sites (Horii et al., 2010).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1216">Three chimpanzees, named Satoru (7 years old male, 45 kg), Arare (10 years old female, 51 kg) and Mizuo (11 years old male, 60 kg) were born in Japan, and thus have no prior exposure to P. falciparum. Satoru, Arare and Mizuo received 10/100, 50/500 and 450/4500 SE36/AHG, respectively by subcutaneous injection on their backs after anesthetization with Ketamine hydrochloride (5 mg/kg) at Weeks 0, 4 and 8 (Horii et al., 2010).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine206">
		<vaccine_name>P. falciparum vaccine Combination B</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Combination B</brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000740</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs="reference422">The &quot;Combination B&quot; vaccine  resulted from a collaborative effort by the Papua New Guinea Institute for Medical Research along with the Australian Cooperative Research Center for Vaccine Technology in Queensland, The Walter and Eliza Hall Research Institute and the Swiss Tropical Institute (Girard et al., 2007). This vaccine has led to a considerable reduction of parasite density in the immunized children.</description>
		<adjuvant refs="reference518">Montanide ISA 720. It is an oil composition containing a natural metabolizable oil and a highly refined emulsifier from the mannide mono-oleate family (Genton et al., 2003).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference531 reference518">Combination B is a malaria vaccine that comprises recombinant P falciparum blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720 (Genton et al., 2003a). The three vaccine candidate antigens were produced by recombinant DNA technology. All three antigens were expressed in Escherichia coli with histidine tags to facilitate purification by nickel chelate chromatography. Two of the antigens, 190LCS.T3 (Ro 45-2067) and Ag1624 (Ro 46-2924), corresponded to parts of the well-characterized merozoite surface proteins MSP1 and MSP2, respectively. The MSP1 antigen was the 190L fragment from the K1 parasite line, comprising the relatively conserved blocks 3 &amp; 4 of MSP1 fused with a universal T cell epitope derived from the circumsporozoite protein of P. falciparum. The MSP2 antigen corresponded to the near full-length MSP2 sequence of the 3D7 cloned line. Ag1505H (Ro 45-2164) consisted of the C-terminal 70% of RESA of the FCQ-27/PNG parasite line. All three antigens were supplied in separate vials at a concentration of 160 μg/ml of saline-Montanide ISA720 emulsion. Prior to use the three formulations were mixed and diluted with additional emulsion to give a dose of 15 μg of each antigen in a total volume of 0.55 ml (Genton et al., 2003).</preparation>
		<route refs=""></route>
		<antigen refs="reference518">The vaccine Combination B contains three recombinant asexual blood-stage Plasmodium falciparum proteins: merozoite surface protein (MSP) 1, MSP2 and ring-infected erythrocyte surface antigen (RESA)  (Genton et al., 2003). </antigen>

		<gene_engineering gene_engineering_id="gene_engineering143" gene_id="gene144">
			<type>Recombinant protein preparation</type>
			<description refs="reference518">The vaccine Combination B contains peptides from the ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering144" gene_id="gene143">
			<type>Recombinant protein preparation</type>
			<description refs="reference518">The vaccine Combination B contains MSP1 peptides (Genton et al., 2003).</description>
		</gene_engineering>
		<host_response host_response_id="host_response267" host_id="host2">
			<immune_response refs="reference518">The vaccine induced significant antibody responses to all three antigens but triggered an IFN-γ response to MSP1 only. At Week 12, the IFN-γ response to MSP1 was substantially higher in the vaccine group where No SP had been given (Genton et al., 2003)</immune_response>
			<host_strain refs="">Papua New Guinean children</host_strain>
			<vaccination_protocol refs="reference518">To insure safety, the enrolment and immunisations were done sequentially, with 10 days observation between each sub-cohort. It was started with one block (3 No SP+vaccine, 3 No SP+placebo, 3 SP+vaccine, 3 SP+placebo) of the older age group, then the remaining four blocks (12 No SP+vaccine, 12 No SP+placebo, 12 SP+vaccine, 12 SP+placebo) of this stratum, then one block of the younger age group, and then the remaining four blocks of this stratum. Children were given either SP or a sugar tablet (indistinguishable tablets provided by Hoffman La-Roche). During Week 0 they were injected i.m. in the left lateral thigh with the vaccine or placebo. Four weeks after the first injection, they received a second injection i.m. in the right lateral thigh (Genton et al., 2003).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="reference518">No serious or severe AEs occurred. Moderate AEs were seen in 3% of the vaccine and 3% of the placebo recipients after first injection and in 12 and 10% after second injection (Genton et al., 2003).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs="">This is a phase I-IIb double-blind randomised placebo-controlled trial was undertaken in 120 children aged 5-9 years.</description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3953">
		<vaccine_name>P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004595</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>VR1020 prime, recombinant canarypox viruses boost [Ref2780:Rogers et al., 2001]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1630" gene_id="gene1745">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1631" gene_id="gene1743">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1632" gene_id="gene1746">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering1633" gene_id="gene1744">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1599" host_id="host5">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2780">Following challenge with 100 P. knowlesi sporozoites, 1 of 12 experimental monkeys was completely protected and the mean parasitemia in the remaining monkeys was significantly lower than that in 4 control monkeys (Rogers et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine208">
		<vaccine_name>P. vivax PVS25 with Montanide ISA-720</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000776</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference528">Montanide ISA-720 an adjuvant suitable for human vaccination trials (Arevalo-Herrera et al., 2005).</adjuvant>
		<storage refs=""></storage>
		<virulence refs="">Not virulent.</virulence>
		<preparation refs="reference528">To produce a recombinant protein, Pvs25 was expressed in S. cerevisiae in a secreted form. Briefly, P. vivax genomic DNA from the Salvador I strain was used to amplify the gene fragment encoding the Pvs25 regions (Ala23-Leu195), which was inserted into the yeast episomal plasmid YEpRPEU-3 that encodes a secretory {alpha} factor containing a 6-His tail.12 Supernatants of fermentation were recovered by tangential microfiltration, concentrated by ultrafiltration, and extensively dialyzed. The retentate was incubated overnight at 4°C with Ni-nitrilotriacetic acid agarose. Proteins were purified by chromatography (Arevalo-Herrera et al., 2005). </preparation>
		<route refs=""></route>
		<antigen refs="reference528">P. vivax protein Pvs25 is the vaccine antigen. It is a protein composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering139" gene_id="gene141">
			<type>Recombinant protein preparation</type>
			<description refs="reference528">Pvs25 was cloned and purified from yeast (Arevalo-Herrera et al., 2005).</description>
		</gene_engineering>
		<host_response host_response_id="host_response266" host_id="host5">
			<immune_response refs="reference528">Antigen-specific antibody responses to the Pvs25 protein as determined by ELISA were evident by day 30 after the first immunization at low levels (61–478 units of anti-Pvs25). By day 60, at the time of the first boosting dose, responses of most animals were similar and by day 90, antibodies were boosted in all but two animals. Only one monkey had an apparent boost with the third antigen injection given on day 120. All animals had maximum antibody levels by day 150. These levels started to decrease by day 180, but were still detectable 10 months after the first immunization (Arevalo-Herrera et al., 2005).</immune_response>
			<host_strain refs="">owl monkey (Aotus lemurinus griseimembra)</host_strain>
			<vaccination_protocol refs="reference528">Male and female adult, malaria-naive Aotus monkeys were randomly allocated into two groups. An experimental group of six animals (group A) were immunized with the recombinant Pvs25 vaccine. A control group of three animals (group B) were immunized with adjuvant alone. Both groups were immunized on days 0, 60, and 120. Group A was inoculated with a total volume of 500 µL of vaccine formulated as 100 µg of the Pvs25 recombinant protein in Montanide ISA-720 in a 7:3 antigen:adjuvant ratio. Group B was injected with distilled water containing no protein and mixed in the same adjuvant following the same procedure. The immunization was performed by the subcutaneous route distributed in five different sites of the thorax and abdomen of each animal (Arevalo-Herrera et al., 2005).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference528">All monkeys developed patent parasitemia by day 453, approximately two weeks after intravenous challenge. The peak of parasitemia for most of the monkeys was observed between days 462 and 464 with parasitemias and ranged from 0.1% to 1.3% as determined by thin blood smear. Gametocytes were first evident between days 458 and 460 and remained at detectable levels in all animals until day 468. Plasma samples obtained on days 447, 462, 482, and 503 after parasite challenge were negative for antibodies directed to the Pvs25 recombinant protein by ELISA. Gametocytes that developed in both groups were infectious to mosquitoes as determined in an MFA conducted with monkey blood drawn on day 460 in which plasma from AB human control sera was replaced by sera from infected monkeys. This result supports the viability and functionality of the circulating gametocytes from both the Pvs25-immunized and the control animals.

Mosquitoes fed with P. vivax gametocyte-carrying human blood in the presence of either normal monkey plasma or normal AB human sera (negative controls) produced positive infections with an arithmetic mean of oocysts per midgut ranging between 0.3 and 3.8 and 0.2 and 1.0 oocysts, respectively. However, plasma from the Pvs25-immunized Aotus tested individually were highly inhibitory and completely blocked the development of oocysts, in all assays (reduction of the oocysts number &gt; 98%) using three different P. vivax human isolates. Plasma from monkeys in the Montanide ISA-720 control group showed similar inhibition to the normal monkey plasma (negative control). Therefore, boosting of antibodies to Pvs25 is not caused by the parasite infection, this Pvs25 vaccine can be used as a malaria transmission-blocking vaccine (Arevalo-Herrera et al., 2005).</protection_efficacy>
			<side_effects refs="reference528">No adverse side effects were encountered here (Arevalo-Herrera et al., 2005).</side_effects>
			<challenge_protocol refs="reference528">Approximately 10 months after the last immunization (day 440) when specific antibodies to Pvs25 are no longer detected by ELISA, all monkeys were challenged with the P. vivax Salvador I strain by intravenous injection of 105 parasitized red blood cells. Total parasitemia and gametocytemia were followed every other day using thick and thin blood smears stained with Giemsa. Parasite concentrations were expressed as the number of gametocytes per microliter and the percentage of red blood cells parasitized by asexual parasite forms.19 Monkeys were bled post-challenge (days 447–503) to evaluate the presence of antibodies to Pvs25 by ELISA. In addition, the infectivity of circulating gametocytes was tested by feeding of An. albimanus mosquitoes with parasitized monkey red blood cells mixed with normal AB human sera using the MFA on days 460 (Arevalo-Herrera et al., 2005).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3951">
		<vaccine_name>P. yoelii DNA vaccine encoding MSP1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004593</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pJW4304 [Ref2778:Sakai et al., 2003]</vector>
		<route>Gene gun</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2778">IL-12 (Sakai et al., 2003)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Gene gun</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1628" gene_id="gene628">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1597" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2778">MSP1 vaccine alone conferred partial protection. Vaccination with MSP1 + IL-12 conferred the strongest protective immunity against the infection. Only two of the six mice immunized with MSP1 alone survived, while five of the six mice immunized with MSP1 + IL-12 survived (Sakai et al., 2003).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine927">
		<vaccine_name>P. yoelii DNA vaccine encoding PyHEP17 Protein</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004162</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>nkCMVintpolyli [Ref1597:Doolan et al., 1996]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering410" gene_id="gene644">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response870" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/cByJ, A/J, B10.BR, B10.Q and C57BL/6</host_strain>
			<vaccination_protocol refs="reference1597">Female 6- to 8-wk-old mice were immunized three times at 3-wk intervals intramuscularly in each tibialis anterior muscle with 50 μg of PyHEP17 DNA in 50 μl of saline or unmodified nkCMVintpolyli plasmid. 2 wk after the third immunization, mice were challenged by tail-vein injection with 100 infectious sporozoites or 200 infected erythrocytes (Doolan et al., 1996).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3948">
		<vaccine_name>P. yoelii DNA vaccine encoding PySSP2</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004590</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>nkCMVint or VR1012 [Ref2775:Hoffman et al., 1997]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1625" gene_id="gene1741">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1594" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2775">The full-length gene of PySSP2 in the nkCMVint vector induced specific antibodies and protected 50% of immunized mice. Subsequently, outbred CD-l mice were immunized with nkCMVint and VR1012 vector based PySSP2 DNA vaccines and as many as 33% were protected (Hoffman et al., 1997).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3947">
		<vaccine_name>P. yoelii DNA vaccine pDIP/PyCSP. 1</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004589</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>pBC12/CMV/IL-2 [Ref2774:Hoffman et al., 1994]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1624" gene_id="gene635">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1593" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2774">Mice immunized with three doses of pDIP/PyCSP.1 and challenged with 5 × 105 P. yoelii sporozoites had a significant reduction in liver stage infection compared with mice immunized with the empty plasmid. Most importantly, 9 of 16 mice were protected against challenge (Hoffman et al., 1994).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3950">
		<vaccine_name>P. yoelii DNA vaccine pPyHsp60-VR1012</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004592</vo_id>
		<type>DNA vaccine</type>
		<status>Research</status>
		<vector>VR1012 [Ref2777:Sanchez et al., 2001]</vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference2777">GM-CSF (Sanchez et al., 2001)</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering1627" gene_id="gene1742">
			<type>DNA vaccine construction</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response1596" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2777">In experiment 1, 40% of mice immunized with the combination of pPyHsp60-VR1012 and pmurGM-CSF did not develop parasitemia during the 14 days postchallenge. Only this group had statistically significant protection on day 14 as compared with the pooled controls (two-tailed Fisher's exact test: P = 0.031 , group 1.B versus group 1.H + group 1.I).  However, in experiment 2 (identical immunization schedule), immunized mice only experienced delayed parasitemia, rather than protection from parasitemia (Sanchez et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine984">
		<vaccine_name>P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011439</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Orally</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Orally</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering467" gene_id="gene652">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response738" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs="reference1241">One group of mice was treated by gavage with 25 μg of EcMSP4/5, and the other group was treated by gavage with 25 μg of EcMSP4/5 plus an amount of GST-PyMSP119 equivalent to 25 μg of PyMSP119 (Wang et al., 2004).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1241">Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection. All of the eight immunized mice survived the challenge, with peak parasitemia levels between 0.2 and 55.2% (Wang et al., 2004).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1241">In order to examine the protective efficacy of the induced antibodies, the immunized mice were challenged at 2 weeks after the sixth immunization with a lethal dose of 10^5 P. yoelii YM parasites (Wang et al., 2004).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3105">
		<vaccine_name>P. yoelii TyCS-VLP Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004271</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference2047">CD8+ T cell epitope (SYVPSAEQI) of the circumsporozoite (CS) protein of Plasmodium yoelii (Oliveira-Ferreira et al., 2000).</antigen>
		<host_response host_response_id="host_response934" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference2047">All the immunizations with TyCS-VLP carrying the CTL epitope of the P. yoelii circumsporozoite protein (SYVPSAEQI), except the dose response and the route of immunization experiments, consisted of 50 mg per mouse injected intramuscularly (i.m.) in the leg quadriceps (Oliveira-Ferreira et al., 2000).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2047">2/8 mice immunized with the TyCs-VLP vaccine were protected from challenge with P. yoelii sporozoites (Oliveira-Ferreira et al., 2000).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference2047">Mice were challenged with 75 sporozoites per mice administered i.v. (Oliveira-Ferreira et al., 2000).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine931">
		<vaccine_name>Plasmodium berghei CS Protein Subunit Vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0011549</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intraperitoneal injection (i.p.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intraperitoneal injection (i.p.)</route>
		<antigen refs="reference1223">A tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)2D of the malaria parasite Plasmodium berghei circumsporozoite protein (P4c-Mal) (Kaba et al., 2009).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering415" gene_id="gene633">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response689" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">BALB/c, C57BL/6</host_strain>
			<vaccination_protocol refs="reference1223">Mice were randomly divided into groups of 5 or 10 and immunized i.p. three times at 14-day intervals. Where indicated, a positive control group was immunized with irradiated P. berghei sporozoites (Kaba et al., 2009).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1223">More than 95% of mice immunized with P4c-Mal, both with and without Montanide ISA-720, or R-PbCSP in Montanide ISA-720 did not develop any parasitemia and thus showed complete protection against challenge with viable sporozoites (Fig. 2B). This ability to prevent parasitemia and thus prevent malaria following sporozoite challenge is equivalent to what is only achieved with the whole, irradiated sporozoite immunization regime. In contrast, as few as 5% of animals administered saline, saline and Montanide ISA-720, or R-PbCSP in saline did not develop parasites and survived until 11 days post challenge. No animal was observed with blood stage parasites that did not die naturally or was killed according to protocol. These results show that immunization with P4c-Mal had a significant ability to induce a protective immune response in the presence as well as in the absence of adjuvant (Kaba et al., 2009).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1223">P. berghei sporozoites (ANKA strain), maintained by cyclical transmission in mice and Anopheles stephensi, were dissected from mosquitoes 21–23 days after their infectious blood meal and used within 6 h. Fourteen days after the final immunization or at other specific times on long-term memory experiments, mice were challenged with a lethal dose of live P. berghei sporozoites by i.v. inoculation. C57BL/6, MHC KO, and nude mice were injected with 1000 sporozoites and BALB/c mice were injected with 4000 sporozoites per mouse (Kaba et al., 2009).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3196">
		<vaccine_name>Plasmodium berghei p36p mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0003008</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering727" gene_id="gene1027">
			<type>Gene mutation</type>
			<description refs="reference1971">This p36p mutant is from Plasmodium berghei (Douradinha et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1021" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1971">A p36p mutant is attenuated in mice (Douradinha et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1971">A p36p mutant provides protection in mice from challenge with wild type Plasmodium berghei (Douradinha et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3195">
		<vaccine_name>Plasmodium FabB/FabF mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0003007</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering726" gene_id="gene1081">
			<type>Gene mutation</type>
			<description refs="reference2068">This FabB/FabF mutant is from Plasmodium (Butler et al., 2011).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1020" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference2068">A FabB/FabF genetically attenuated parasite is attenuated in mice (Butler et al., 2011).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference2068">A FabB/FabF genetically attenuated parasite induces complete protection in mice from challenge with wild type Plasmodium (Butler et al., 2011).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3197">
		<vaccine_name>Plasmodium yoelii p36/p52 mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id></vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering728" gene_id="gene1083">
			<type>Gene mutation</type>
			<description refs="reference1972">This p36/p52 mutant is from Plasmodium yoelii (Labaied et al., 2007).</description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering729" gene_id="gene1082">
			<type>Gene mutation</type>
			<description refs="reference1972">This p36/p52 mutant is from Plasmodium yoelii (Labaied et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1022" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1972">A p36/p52 mutant is attenuated in mice (Labaied et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1972">A p36/p52 mutant induces protection in mice from challenge with wild type Plasmodium (Labaied et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine3198">
		<vaccine_name>Plasmodium yoelii UIS3 mutant vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0003011</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs=""></antigen>

		<gene_engineering gene_engineering_id="gene_engineering730" gene_id="gene1029">
			<type>Gene mutation</type>
			<description refs="reference1973">This UIS3 mutant is from Plasmodium yoelii (Tarun et al., 2007).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1023" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs="reference1973">A UIS3 mutant is attenuated in mice (Tarun et al., 2007).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1973">A UIS3 mutant provided complete protection in mice after two doses from challenge with wild type Plasmodium yoelii (Tarun et al., 2007).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4301">
		<vaccine_name>rBCGMSP1-15</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004791</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intravenous injection (i.v.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intravenous injection (i.v.)</route>
		<antigen refs="reference3316">MSP1-15 as a fusion protein with the α antigen of Mycobacterium kansasii (α-k), which is secreted from the rBCG vaccine vector (Matsumoto et al., 1998).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering1661" gene_id="gene628">
			<type>Recombinant vector construction</type>
			<description refs="reference3316">A 2.4-kbp fragment containing an α-k–MSP1-15 hybrid gene was subcloned into pSO246. The final construct (designated pSOMSP1-15) was transformed into BCG Tokyo by electroporation (Matsumoto et al., 1998).</description>
		</gene_engineering>
		<host_response host_response_id="host_response1735" host_id="host3">
			<immune_response refs=""></immune_response>
			<host_strain refs="">C57BL/6, C3H/He, A/J</host_strain>
			<vaccination_protocol refs="reference3316">C3H/He mice were immunized intravenously with 10^6 CFU of rBCGMSP1-15 in 200 μl of PBS containing 0.1% PBS-T80. A control group of mice was injected with 106 CFU of BCG in 200 μl of PBS-T80 or PBS-T80 only. 30 days later, the same amount of each sample was injected intraperitoneally to boost the immune response (Matsumoto et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs="">VO_0003057</immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference3316">3 out of 7 mice immunized with GST-MSP1-15 in RAS and 2 out of 8 mice immunized with GST-MSP1-15 in IFA survived the infection. 6 out of 7 mice immunized with rBCGMSP1-15 survived the infection. Data showed the three adjuvants examined are effective for vaccination with MSP1-15, while their efficacy levels differ. The rBCG system was the most effective for vaccination (Matsumoto et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference3316">Mice were challenged with 10^4 P. yoelii 17XL-parasitized erythrocytes intravenously or intraperitoneally 1 month after the final immunization (Matsumoto et al., 1998).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine204">
		<vaccine_name>Recombinant ABRA protein vaccine</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000778</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference429">Complete Freund's adjuvant (CFA) was used as  the first adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA) (Kushwaha et al., 2001).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="">The four fragments of ABRA, including N-terminal [ABRA (N); aa 24–369], middle [ABRA (M); aa 370–507], N-terminal + middle [ABRA (P); aa 24–507] and the C-terminal [ABRA (C); aa 508–743], were expressed as fusions with either maltose binding protein (MBP) or 6X histidine tag at their amino terminii using pMALc-2 vector from NEB (New England Biolabs, Beverly, MA, USA) or pQE30 vector (Qiagen GmbH, Germany), respectively. These recombinant proteins were purified to near homogeneity by affinity chromatography of the soluble fraction, concentrated, and the purity of the protein judged by SDS-PAGE. </preparation>
		<route refs=""></route>
		<antigen refs="reference429">The acidic basic repeat antigen (ABRA) of Plasmodium falciparum is a vaccine candidate against erythrocytic stages of malaria (Kushwaha et al., 2001).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering135" gene_id="gene137">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response248" host_id="host3">
			<immune_response refs="reference429">Results showed that ABRA (M), ABRA (C) and ABRA (P) were highly immunogenic in these animals; end point titres greater than 10^5 were observed in these constructs. Mice were immunized using standard methods. Relative concentrations of the antibodies elicited by them in mice at different intervals of immunization were measured at a dilution of 1 : 3000. ABRA (N) and ABRA (C) did not show a boostable antibody response; two secondary immunizations did not result in any increase in the antibody titre. Immunogenicity studies with these constructs in rabbits and mice indicated that the N-terminal region is the least immunogenic part of ABRA. T-cell proliferation experiments in mice immunized with these constructs revealed that the T-cell epitopes were localized in the middle portion of the protein (Kushwaha et al., 2001).</immune_response>
			<host_strain refs="">BALB/c</host_strain>
			<vaccination_protocol refs="reference429">Groups of BALB/c mice were immunized by i.p. injection with ABRA protein/MBP emulsified in complete Freund's adjuvant (CFA). Control mice received only PBS in the adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA). Sera were collected from each group and treated as described earlier (Kushwaha et al., 2001).</vaccination_protocol>
			<persistence refs="reference429">Humoral and cell-mediated response was still robust up to 70 days post-immunization (Kushwaha et al., 2001).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference429">The purified immunoglobulin G specific to middle and C-terminal fragments prevented parasite growth at levels approaching 80-90% (Kushwaha et al., 2001).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs="reference430">This antibody response was the focus of intense interest when it was found that mice could be rendered resistant to sporozoite challenge by passive immunisation with monoclonal antibodies against circumsporozoite protein  (Kwiatkowski et al., 1997).</description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine200">
		<vaccine_name>RTS,S/AS02A</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0000774</vo_id>
		<type>Subunit vaccine</type>
		<status></status>
		<vector></vector>
		<route></route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference539">AS02 (Alonso et al., 2004).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference535 reference539">RTS,S/AS02 is a pre-erythrocyte sporozoite-stage malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum RTS,S fused to HBsAg , incorporating a new adjuvant (AS02) (Bojang et al., 2001)(Alonso et al., 2004).</preparation>
		<route refs=""></route>
		<antigen refs="reference539">RTS,S is the pre-erythrocyte sporozoite-stage Plasmodium falciparum antigen. It is a circumsporozoite surface protein (Alonso et al., 2004).</antigen>
		<host_response host_response_id="host_response268" host_id="host2">
			<immune_response refs="reference539">Prevaccination anti-circumsporozoite antibody titres were low in the study children. The vaccine was immunogenic, inducing specific antibody levels after dose three, decaying over 6 months to about a quarter of the initial level, but remaining well above baseline values. Antibody levels in the control group remained low over the follow-up period. The vaccine also induced high levels of antibodies against HBsAg (&gt;97% seroprotection). For both circumsporozoite and HBsAg, immunogenicity of the vaccine was greater in children younger than 24 months of age (Alonso et al., 2004).</immune_response>
			<host_strain refs="">Mozambique children</host_strain>
			<vaccination_protocol refs="reference539">A double-blind, phase IIb, randomised controlled trial was performed in Mozambique in 2022 children aged 1–4 years. The study included two cohorts of children living in two separate areas which underwent different follow-up schemes. Participants were randomly allocated three doses of either RTS,S/AS02A candidate malaria vaccine or control vaccines. The primary endpoint, determined in cohort 1 (n=1605), was time to first clinical episode of P falciparum malaria (axillary temperature ≥37·5°C and P falciparum asexual parasitaemia &gt;2500 per μL) over a 6-month surveillance period. Efficacy for prevention of new infections was determined in cohort 2 (n=417) (Alonso et al., 2004).</vaccination_protocol>
			<persistence refs="reference539">Vaccine efficacy in extending time to first infection was determined in cohort 2. 323 children had first episodes of asexual P falciparum parasitaemia (157 in the RTS,S/AS02A group and 166 in the control group), yielding a vaccine efficacy estimate of 45.0% (95% CI 31.4–55.9; p&lt;0.0001). The mean density of asexual-stage parasites at the time of first infection was similar for the control and RTS,S/AS02A groups (3950 vs 3016 per μL, p=0.354). With the same methods as those used to assess persistence of efficacy for cohort 1, the model with the best fit suggested waning efficacy of the vaccine over time, which stabilised at about 40%. The prevalence of asexual P falciparum parasitaemia at the end of follow-up was lower in the RTS,S/AS02A group than in the control group (52.3% vs 65.8%; p=0.019), and prevalence of anaemia at month 8·5 was 2.7% in the control group and 0% in the RTS,S/AS02A group (p=0.056) (Alonso et al., 2004).</persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference539">Vaccine efficacy for the first clinical episodes was 29.9% (95% CI 11.0-44.8; p=0.004). At the end of the 6-month observation period, prevalence of P falciparum infection was 37% lower in the RTS,S/AS02A group compared with the control group (11.9% vs 18.9%; p=0.0003). Vaccine efficacy for severe malaria was 57.7% (95% CI 16.2-80.6; p=0.019). In cohort 2, vaccine efficacy for extending time to first infection was 45.0% (31.4-55.9; p&lt;0.0001) (Alonso et al., 2004).</protection_efficacy>
			<side_effects refs="reference539">RTS,S/AS02A and control vaccines were safe and well tolerated. More than 92% of children in both groups received all three doses. Local and general solicited adverse events were of short duration and were mostly mild or moderate in intensity. Grade 3 local or general adverse events were uncommon and of short duration. Local injection-site pain that limited arm motion arose after seven (0.2%) doses in the RTS,S/AS02A group and after one (0.03%) dose in the control vaccine group, and injection-site swelling of more than 20 mm happened after 224 (7.7%) and 14 (0.5%) doses, respectively. General solicited adverse events (fever, irritability, drowsiness, anorexia) that prevented normal activities arose after 55 (1.9%) doses in the RTS,S/AS02A group and 23 (0.8%) doses in the control group. At least one unsolicited adverse event was reported by 653 (64.5%) children in the RTS,S/AS02A group and 597 (59.1%) in the control group. 429 serious adverse events were reported: 180 (17.8%) in the RTS,S/AS02A group and 249 (24.7%) in the control group. 15 children died during the study, five (0.6%) in the RTS,S/AS02A group and ten (1.2%) in the control group. Four of those who died had malaria as a significant contributing factor and all four were in the control group. No serious adverse event or death was judged to be related to vaccination (Alonso et al., 2004).</side_effects>
			<challenge_protocol refs="reference539">Children were not challenged (Alonso et al., 2004)</challenge_protocol>
			<description refs="reference539">Development of an effective malaria vaccine could greatly contribute to disease control. RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. The RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic (Alonso et al., 2004).</description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine4312">
		<vaccine_name>SAd-ME.TRAP</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004799</vo_id>
		<type>Recombinant vector vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs="reference3326">(Reyes-Sandoval et al., 2008) AdC7 and AdC9 elicited strong immunogenicity ( approximately 20% of CD8(+) T cells in spleen), equivalent to or outperforming AdH5 and inducing sterile protection in 92% (C9), 83% (H5 and C7) and 67% (C6) of the mice, providing the first evidence of single-dose protection to Plasmodium berghei.</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
	</vaccine>
	<gene gene_id="gene137">
        <gene_name>ABRA</gene_name>
        <strain>Plasmodium falciparum Camp</strain>
        <vo_id>VO_0010926</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>160047</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>swissprot:: P22620; GI:113005</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>p101/acidic basic repeat antigen</protein_name>
        <protein_pi>4.52</protein_pi>
        <protein_weight>83059.95</protein_weight>
        <protein_length>824</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>PFL1385c |MSP-9|Acid-Basic Repeat Antigen, ABRA, 101 kd malaria antigen, 2277.t00277, p101|Merozoite Surface Protein 9, MSP-9|Plasmodium falciparum|chr 12|STANFORD||Manual
ATGATGAACA TGAAAATTGT TTTATTCAGT TTATTGCTCT TTGTCATAAG ATGGAATATT
ATTAGTTGTA ATAAAAACGA CAAGAACCAA GGTGTTGATA TGAATGTTTT GAATAATTAT
GAAAATTTAT TTAAATTTGT TAAATGTGAA TATTGTAATG AACATACTTA TGTTAAAGGT
AAGAAAGCTC CTTCAGATCC TCAATGTGCT GATATAAAAG AAGAATGCAA AGAATTACTT
AAGGAAAAAC AATACACAGA TTCAGTTACA TATTTAATGG ATGGTTTTAA ATCAGCAAAT
AATTCAGCAA ATAATGGTAA AAAAAATAAC GCTGAAGAAA TGAAAAATTT AGTAAATTTC
TTACAATCTC ATAAGAAATT AATTAAAGCA TTAAAAAAGA ATATTGAAAG TATACAAAAT
AAGAAACACT TAATTTATAA AAACAAATCA TATAATCCAT TATTACTTTC TTGTGTTAAA
AAAATGAATA TGTTAAAAGA AAATGTTGAC TATATTCAAA AAAATCAAAA CTTATTTAAA
GAATTAATGA ATCAAAAAGC TACCTACTCT TTTGTTAATA CCAAAAAAAA AATTATTTCT
TTAAAATCAC AAGGTCATAA AAAAGAAACC TCACAAAATC AAAATGAAAA TAACGACAAT
CAAAAATATC AAGAAGTTAA TGATGAAGAT GATGTAAATG ATGAAGAAGA TACAAACGAT
GACGAAGATA CTAACGATGA AGAAGATACA AACGATGACG AAGATACAAA TGATGACGAA
GATACTAACG ATGAAGAAGA TACTAACGAC GAAGAAGATC ATGAAAATAA TAATGCTACA
GCATACGAAT TAGGTATCGT CCCAGTTAAC GATGTGTTAA ATGTTAATAT GAAAAATATG
ATAACAGGAA ATAATTTTAT GGATGTTGTT AAAAATACAT TAGCTCAATC AGGTGGATTA
GGAAGTAATG ATTTAATAAA TTTCTTAAAT CAAGGTAAAG AAATAGGAGA AAATTTATTA
AACATAACAA AGATGAACTT GGGAGATAAG AATAATCTTG AAAGTTTTCC TTTAGATGAA
TTAAATATGT TAAAAGATAA TTTAATAAAC TATGAATTCA TATTAGATAA TTTGAAAACA
AGTGTTTTAA ATAAATTAAA AGATTTATTA TTAAGATTAT TATACAAAGC ATATGTATCA
TATAAGAAAA GAAAAGCTCA AGAAAAAGGA TTACCAGAAC CTACTGTTAC TAATGAAGAA
TATGTTGAAG AATTAAAGAA AGGTATTCTA GATATGGGTA TCAAATTATT ATTTAGTAAA
GTTAAAAGCC TATTAAAAAA ATTAAAAAAT AAAATATTCC CTAAGAAAAA AGAAGATAAT
CAAGCAGTAG ATACCAAAAG TATGGAAGAA CCCAAAGTTA AAGCACAACC AGCTCTTAGA
GGTGTTGAAC CAACGGAAGA TTCTAATATT ATGAACAGTA TTAATAATGT TATGGATGAA
ATTGATTTCT TTGAAAAAGA ATTAATCGAA AATAATAATA CACCTAATGT TGTACCACCA
ACTCAATCAA AAAAAAAAAA CAAAAATGAA ACTGTATCTG GTATGGATGA AAATTTTGAT
AATCATCCTG AAAATTATTT TAAAGAAGAA TATTATTATG ATGAAAATGA TGATATGGAA
GTAAAAGTTA AAAAAATAGG TGTCACATTA AAAAAATTTG AACCACTTAA AAATGGAAAT
GTTAGTGAAA CCATTAAATT GATTCATTTA GGAAATAAAG ATAAAAAACA CATTGAAGCT
ATAAACAACG ATATTCAAAT TATTAAACAA GAATTACAAG CTATTTATAA TGAACTTATG
AATTATACAA ATGGAAACAA AAATATTCAA CAAATATTTC AACAAAATAT TCTAGAAAAT
GATGTTCTTA ATCAAGAAAC GGAGGAAGAA ATGGAAAAAC AAGTTGAAGC AATCACCAAG
CAAATAGAAG CTGAAGTGGA TGCCCTCGCA CCAAAAAATA AGGAAGAAGA AGAAAAAGAA
AAGGAAAAAG AAGAAAAAGA AAAAGAAGAA AAAGAAAAAG AAAAAGAAGA AAAAGAAAAA
GAAGAAAAAG AAAAAGAAGA AAAAGAAAAA GAAGAAAAAG AAGAAGAAAA AAAAGAAAAA
GAAGAAGAAC AAGAAGAAGA AGAAGAAGAA GAAATAGTAC CAGAAAATTT GACAACTGAA
GAATCAAAAT AA</dna_sequence>
        <protein_sequence>>AAA29462.1 p101/acidic basic repeat antigen [Plasmodium falciparum]
MMNMKIVLFSLLLFVIRWNIISCNKNDKNQGVDMNVLNNYENLFKFVKCEYCNEHTYVKGKKAPSDPQCA
DIKEECKELLKEKQYTDSVTYLMDGFKSANNSANNGKKNNAEEMKNLVNFLQSHKKLIKALKKNIESIQN
KKHLIYKNKSYNPLLLSCVKKMNMLKENVDYIQKNQNLFKELMNQKATYSFVNTKKKIISLKSQGHKKET
SQNQNENNDNQKYQEVNDEDDVNDEEDTNDDEDTNDEEDTNDDEDTNDDEDTNDEEDTNDEEDHENNNAT
AYELGIVPVNDVLNVNMKNMITGNNFMDVVKNTLAQSGGLGSNDLINFLNQGKEIGENLLNITKMNLGDK
NNLESFPLDELNMLKDNLINYEFILDNLKTSVLNKLKDLLLRLLYKAYVSYKKRKAQEKGLPEPTVTNEE
YVEELKKGILDMGIKLLFSKVKSLLKKLKNKIFPKKKEDNQAVDTKSMEEPKVKAQPALRGVEPTEDSNI
MNSINNVMDEIDFFEKELIENNNTPNVVPPTQSKKKNKNETVSGMDENFDNHPENYFKEEYYYDENDDME
VKVKKIGVTLKKFEPLKNGNVSETIKLIHLGNKDKKHIEAINNDIQIIKQELQAIYNELMNYTNGNKNIQ
QIFQQNILENDVLNQETEEEMEKQVEAITKQIEAEVDALAPKNKEEEEKEKEKEKEKEEKEKEEKEKEEK
EKEKEEKEKEKEEKEEEKKEKEEEQEEEEEEIVPENLTTEESK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Protective antigen [Ref429:Kushwaha et al., 2001]</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene653">
        <gene_name>AMA-1</gene_name>
        <strain>Plasmodium chabaudi</strain>
        <vo_id>VO_0011237</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1469500</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:302876</xrefs>
        <taxonomy_id>5825</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>apical membrane antigen 1</protein_name>
        <protein_pi>8.37</protein_pi>
        <protein_weight>37252.97</protein_weight>
        <protein_length>415</protein_length>
        <protein_note>DK is a cloned line derived from 556KA</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAB36511.1 apical membrane antigen 1, partial [Plasmodium chabaudi]
DLIPKENTERSHKLINPWEKFMEKYDIEKVHGSGIRVDLGEDARVENQDYRIPSGKCPVMGKGITIQNSK
VSFLTRVATGNQKVREGGLAFPQTDVNISPITIDNLKLMYKDHKEILALNDMSLCAKHASFYVPGTNVNT
AYRHPAVYDKSNKTCYILYVAAQENMGPRYCSNEEDNENQPFCFTPEKKDEYKNLSYLTKNLREDWETSC
PNKSIQNAKFGVWVDGYCSEYQKKEVHDNKTLLECNQIVFNESASDQPKQYEKHLEDTAKIRRGIVDRNG
KLIGEALLPIGSYRADQVKSKGKGYNWANYDKKTKKCYIFNKKPTCLINDKDFVATTALS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami [Ref1242:Xu et al., 2000].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene139">
        <gene_name>AMA1 from P. falciparum 3D7</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id>VO_0010923</vo_id>
        <ncbi_gene_id>810891</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>124804478</ncbi_protein_id>
        <gene_locus_tag>PF3D7_1133400</gene_locus_tag>
        <gene_refseq>LN999945</gene_refseq>
        <protein_refseq>XP_001348015</protein_refseq>
        <pdb_id>1Z40</pdb_id>
        <xrefs>UniProt:P22621</xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>11</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1293855</gene_start>
        <gene_end>1295723</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Apical membrane antigen 1 (AMA1); PF11_0344; AMA-1, Pf83, RMA1, RMA 1, rhoptry membrane antigen</protein_name>
        <protein_pi>5.23</protein_pi>
        <protein_weight>69161.85</protein_weight>
        <protein_length>622</protein_length>
        <protein_note>This is apical membrane antigen 1 (AMA1), or designated at PF11_0344 [Ref576:PF11_0344 in GeneDB].</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_037282.1:1293855-1295723 Plasmodium falciparum 3D7 chromosome 11, complete sequence
AATGAGAAAATTATACTGCGTATTATTATTGAGCGCCTTTGAGTTTACATATATGATAAACTTTGGAAGA
GGACAGAATTATTGGGAACATCCATATCAAAATAGTGATGTGTATCGTCCAATCAACGAACATAGGGAAC
ATCCAAAAGAATACGAATATCCATTACACCAGGAACATACATACCAACAAGAAGATTCAGGAGAAGACGA
AAATACATTACAACACGCATATCCAATAGACCACGAAGGTGCCGAACCCGCACCACAAGAACAAAATTTA
TTTTCAAGCATTGAAATAGTAGAAAGAAGTAATTATATGGGTAATCCATGGACGGAATATATGGCAAAAT
ATGATATTGAAGAAGTTCATGGTTCAGGTATAAGAGTAGATTTAGGAGAAGATGCTGAAGTAGCTGGAAC
TCAATATAGACTTCCATCAGGGAAATGTCCAGTATTTGGTAAAGGTATAATTATTGAGAATTCAAATACT
ACTTTTTTAACACCGGTAGCTACGGGAAATCAATATTTAAAAGATGGAGGTTTTGCTTTTCCTCCAACAG
AACCTCTTATGTCACCAATGACATTAGATGAAATGAGACATTTTTATAAAGATAATAAATATGTAAAAAA
TTTAGATGAATTGACTTTATGTTCAAGACATGCAGGAAATATGATTCCAGATAATGATAAAAATTCAAAT
TATAAATATCCAGCTGTTTATGATGACAAAGATAAAAAGTGTCATATATTATATATTGCAGCTCAAGAAA
ATAATGGTCCTAGATATTGTAATAAAGACGAAAGTAAAAGAAACAGCATGTTTTGTTTTAGACCAGCAAA
AGATATATCATTTCAAAACTATACATATTTAAGTAAGAATGTAGTTGATAACTGGGAAAAAGTTTGCCCT
AGAAAGAATTTACAGAATGCAAAATTCGGATTATGGGTCGATGGAAATTGTGAAGATATACCACATGTAA
ATGAATTTCCAGCAATTGATCTTTTTGAATGTAATAAATTAGTTTTTGAATTGAGTGCTTCGGATCAACC
TAAACAATATGAACAACATTTAACAGATTATGAAAAAATTAAAGAAGGTTTCAAAAATAAGAACGCTAGT
ATGATCAAAAGTGCTTTTCTTCCCACTGGTGCTTTTAAAGCAGATAGATATAAAAGTCATGGTAAGGGTT
ATAATTGGGGAAATTATAACACAGAAACACAAAAATGTGAAATTTTTAATGTCAAACCAACATGTTTAAT
TAACAATTCATCATACATTGCTACTACTGCTTTGTCCCATCCCATCGAAGTTGAAAACAATTTTCCATGT
TCATTATATAAAGATGAAATAATGAAAGAAATCGAAAGAGAATCAAAACGAATTAAATTAAATGATAATG
ATGATGAAGGGAATAAAAAAATTATAGCTCCAAGAATTTTTATTTCAGATGATAAAGACAGTTTAAAATG
CCCATGTGACCCTGAAATGGTAAGTAATAGTACATGTCGTTTCTTTGTATGTAAATGTGTAGAAAGAAGG
GCAGAAGTAACATCAAATAATGAAGTTGTAGTTAAAGAAGAATATAAAGATGAATATGCAGATATTCCTG
AACATAAACCAACTTATGATAAAATGAAAATTATAATTGCATCATCAGCTGCTGTCGCTGTATTAGCAAC
TATTTTAATGGTTTATCTTTATAAAAGAAAAGGAAATGCTGAAAAATATGATAAAATGGATGAACCACAA
GATTATGGGAAATCAAATTCAAGAAATGATGAAATGTTAGATCCTGAGGCATCTTTTTGGGGGGAAGAAA
AAAGAGCATCACATACAACACCAGTTCTGATGGAAAAACCATACTATTA

</dna_sequence>
        <protein_sequence>>XP_001348015.1 apical membrane antigen 1 [Plasmodium falciparum 3D7]
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQNSDVYRPINEHREHPKEYEYPLHQEHTYQQEDSGEDE
NTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIEEVHGSGIRVDLGEDAEVAGT
QYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGGFAFPPTEPLMSPMTLDEMRHFYKDNKYVKN
LDELTLCSRHAGNMIPDNDKNSNYKYPAVYDDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAK
DISFQNYTYLSKNVVDNWEKVCPRKNLQNAKFGLWVDGNCEDIPHVNEFPAIDLFECNKLVFELSASDQP
KQYEQHLTDYEKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLI
NNSSYIATTALSHPIEVENNFPCSLYKDEIMKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKC
PCDPEMVSNSTCRFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDKMKIIIASSAAVAVLAT
ILMVYLYKRKGNAEKYDKMDEPQDYGKSNSRNDEMLDPEASFWGEEKRASHTTPVLMEKPYY

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1745">
        <gene_name>AMA1 from P. knowlesi</gene_name>
        <strain>Plasmodium knowlesi strain H</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>221056402</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:240241
EnsemblGenomes-Gn:PKH_093110
EnsemblGenomes-Tr:PKH_093110
GOA:B3L5E1
InterPro:IPR003298
InterPro:IPR024056
UniProtKB/TrEMBL:B3L5E1</xrefs>
        <taxonomy_id>5851</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>apical merozoite antigen 1</protein_name>
        <protein_pi>6.98</protein_pi>
        <protein_weight>62359.812</protein_weight>
        <protein_length>647</protein_length>
        <protein_note>apical membrane antigen 1; Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>XP_002259339.1 apical merozoite antigen 1 [Plasmodium knowlesi strain H]
MNKIYYILFLSAQCLVHMGKCERNQKTTRLTRSANNASLEKGPIIERSIRMSNPWKAFMEKYDLERAHNS
GIRIDLGEDAEVGNSKYRIPAGKCPVFGKGIVIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITI
ANLKERYKENADLMKLNDIALCKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCSP
DSQNKDAMFCFKPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNCEEIPYVNEVEARSLR
ECNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIKSAFLPVGAFNSDNFKSKGRGYNWANFDSV
NNKCYIFNTKPTCLINDKNFFATTALSHPQEVDNEFPCSIYKDEIEREIKKQSRNMNLYSVDKERIVLPR
IFISTDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKENNEVIIKEEFKEDYENPDGKHKKKMLLIII
GVTGAVCVVAVASLFYFRKKAQDDKYDKMDQAEAYGKTANTRKDEMLDPEASFWGEDKRASHTTPVLMEK
PYY

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene141">
        <gene_name>cjaA</gene_name>
        <strain>P. vivax SouthernMex-62 isolate</strain>
        <vo_id>VO_0010957</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id></ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id>1Z27</pdb_id>
        <xrefs>CDD:270412
GOA:P94643
InterPro:IPR001638
UniProtKB/TrEMBL:P94643</xrefs>
        <taxonomy_id>197</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi>4.9</protein_pi>
        <protein_weight>29158.88</protein_weight>
        <protein_length>324</protein_length>
        <protein_note>Substrate binding domain of ABC cysteine transporter; the type 2 periplasmic binding protein fold; cd13694</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|154184258:1-660 Plasmodium vivax isolate SouthernMex-62 ookinete surface protein (Pvs25) gene, complete cds
ATGAACTCCTACTACAGCCTCTTCGTTTTTTTCCTCGTCCAAATTGCGCTAAAGTATAGCAAGGCAGCCG
TCACGGTAGACACCATATGCAAAAATGGACAGCTGGTTCAAATGAGTAACCACTTTAAGTGTATGTGTAA
CGAAGGGCTGGTGCACCTTTCCGAAAATACATGTGAAGAAAAAAATGAATGCAAGAAAGAAACCCTAGGC
AAAGCATGCGGGGAATTTGGCCAGTGTATAGAAAACCCAGACCCAGCAAAGGTAAACATGTACAAATGTG
GTTGCATTGAGGGCTACACTTTGAAGGAAGACACTTGTGTGCTTGATGTATGTCAATACAAAAATTGTGG
AGAAAGTGGCGAATGCATTGTTGAGTACCTCTCGGAAACCCAAAGTGCAGGTTGCTCATGTGCTATTGGC
AAAGTCCCCAATCCAGAAGATGAGAAAAAATGTACCAAAACGGGAGAAACTGCTTGTCAATTGAAATGTA
ACACAGATAATGAAGTCTGCAAAAATGTTGAAGGAGTTTACAAGTGCCAGTGTATGGAAGGCTTTACGTT
CGACAAAGAGAAAAATGTATGCCTTTCCTATTCTGTATTTAACATCCTAAACTACTCCCTCTTCTTTATC
ATCCTGCTTGTCCTTTCGTACGTCATATAA</dna_sequence>
        <protein_sequence>>CAA71822.1 cjaA [Campylobacter jejuni]
MKKMLLSIFTTFVAVFLAACGGNSDSGASNSLERIKQDGVVRIGVFGDKPPFGYVDEKGVNQGYDIVLAK
RIAKELLGDENKVQFVLVEAANRVEFLKSNKVDIILANFTQTPERAEQVDFCLPYMKVALGVAVPQDSNI
SSIEDLKDKTLLLNKGTTADAYFTKEYPDIKTLKYDQNTETFAALIDQRGDALSHDNTLLFAWVKEHPEF
KMAIKELGNKDVIAPAVKKGDKELKEFIDNLITKLGEEQFFHKAYDETLKSHFGDDVKADDVVIEGGKI

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene633">
        <gene_name>CS from P. berghei str. ANKA</gene_name>
        <strain>Plasmodium berghei ANKA</strain>
        <vo_id>VO_0011217</vo_id>
        <ncbi_gene_id>3428738</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1269284025</ncbi_protein_id>
        <gene_locus_tag>PBANKA_040320</gene_locus_tag>
        <gene_refseq>LK023119</gene_refseq>
        <protein_refseq>XP_022712148</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>5823</taxonomy_id>
        <chromosome>4</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>126554</gene_start>
        <gene_end>127576</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name></protein_name>
        <protein_pi>5.2</protein_pi>
        <protein_weight>35858.22</protein_weight>
        <protein_length>340</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_036162.1:126554-127576 Plasmodium berghei ANKA genome assembly PBANKA01, chromosome : 4
TTTAATTAAAGAATACTAATACTAATAATATTACAAATCCTAATGAATTGCTTACAATATTAAATATACT
TGAACATTTATCCATTTTACAAATTTCAGTATCAATATCTTCTAAGGTCAAATCTTCTGCTTTCTTATTT
GAACCTTTTCGTTTTCTAACTCTTATACCAGAACCACATGTTACGTTACATTGAGACCATTCCTCTGTGA
TACTATCCCTGATCTGTTTAACAAATTCTAGTATTTTTTCCGCGCTTGGGATATAAGAATCGTCATTATT
ATTATTTTTGTTATTGTTATTACCACCTGGCTGTGGTTGTGGCTGTGGTCGTGGCTGTGGTTGTGGCTGT
GGCTGTGGTTGTGGCTGTGGCTGTGGTTGTGGCTGCGGCCGTGGCTGTGGTTGTGGATTGTTATTTCCTT
GTGGTGGTGCTGGGTCATTTGGGTTTGGTGGTGGTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGG
GTTTGGTGGTGGTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTT
GCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGGTGGGTCAT
TTGCGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGGTC
ATTTGGGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGTGGTTGTTTCAATTTATTATTACGC
TCTATTTTTTCGTTTTTTTTCTCATTTTTTTTTCCTTCGGGAGCATCGGCAAGTAATCTGTTGACTGTAT
TTCGATTGTATATTTTTCCATTCTTAGAGTTAAGCACGTGATACAATTTATTATCATTTCCTTCATTGTA
ACATAGCTCGTTTAAGTTCCTTTGGGCTTGGATGCTTTTATTTTGTCCATATCCTGGAAGTAGAGAATTA
ACTAATAAAAGTGACGCTACAACTAAAATGGTACACTTCTTCA

</dna_sequence>
        <protein_sequence>>XP_022712148.1 circumsporozoite (CS) protein [Plasmodium berghei ANKA]
MKKCTILVVASLLLVNSLLPGYGQNKSIQAQRNLNELCYNEGNDNKLYHVLNSKNGKIYNRNTVNRLLAD
APEGKKNEKKNEKIERNNKLKQPPPPPNPNDPPPPNPNDPPPPNPNDPPPPNPNDPPPPNANDPPPPNAN
DPAPPNANDPAPPNANDPAPPNANDPAPPNANDPPPPNPNDPAPPNANDPPPPNPNDPAPPQGNNNPQPQ
PRPQPQPQPQPQPQPQPQPQPRPQPQPQPGGNNNNKNNNNDDSYIPSAEKILEFVKQIRDSITEEWSQCN
VTCGSGIRVRKRKGSNKKAEDLTLEDIDTEICKMDKCSSIFNIVSNSLGFVILLVLVFFN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. Researchers used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite (CS) protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared.  [Ref1223:Kaba et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene634">
        <gene_name>CS from P. falciparum</gene_name>
        <strain>Plasmodium falciparum</strain>
        <vo_id>VO_0011218</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>552191</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:278517</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>circumsporozoite protein</protein_name>
        <protein_pi>4.85</protein_pi>
        <protein_weight>44428.05</protein_weight>
        <protein_length>502</protein_length>
        <protein_note>Thrombospondin type 1 domain; pfam00090</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAA63422.1 circumsporozoite protein, partial [Plasmodium falciparum]
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQENWYSLKKNSR
SLGENDDGNNNNGDNGREGKDEDKRDGNNEDNEKLRKPKHKKLKQPGDGNPDPNANPNVDPNANPNVDPN
ANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNAN
PNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKHIEQYLKKI
QNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYENDIEKKICKMEKCSSVFNVVNSSIGLIMVLSF
LFLN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>We employed a P. berghei parasite line that expresses a heterologous CSP (CS) from P. falciparum in order to assess the role of the CSP in the protection conferred by vaccination with radiation-attenuated P. berghei parasites. Our data demonstrated that sterile immunity could be obtained despite the absence of immune responses specific to the CSP expressed by the parasite used for challenge [Ref1224:Grüner et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene635">
        <gene_name>CS from P. yoelii str. 17XNL</gene_name>
        <strain>Plasmodium yoelii yoelii 17XNL</strain>
        <vo_id>VO_0011219</vo_id>
        <ncbi_gene_id>3830374</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>83317409</ncbi_protein_id>
        <gene_locus_tag>PY03168</gene_locus_tag>
        <gene_refseq>AABL01000897</gene_refseq>
        <protein_refseq>XP_731149</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>352914</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>0</gene_start>
        <gene_end>413</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name></protein_name>
        <protein_pi>4.57</protein_pi>
        <protein_weight>14411.64</protein_weight>
        <protein_length>137</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NW_865424.3:1-413 Plasmodium yoelii yoelii str. 17XNL MALPY00900, whole genome shotgun sequence
CCACCCCAACAACCACCCCAACAACCACCACAACAGCCACCACAACAGCCACCACAACAGCCACCACAAC
AGCCACCACAACAACCACGCCCACAGCCAGATGGTAATAACAACAATAACAATAATAATGGTAATAATAA
TGAAGATTCTTATGTCCCAAGCGCGGAACAAATACTAGAATTTGTTAAACAGATAAGTAGTCAACTCACA
GAGGAATGGTCTCAATGTAGTGTAACCTGTGGTTCTGGTGTAAGAGTTAGAAAACGAAAAAATGTAAACA
AGCAACCAGAAAATTTGACCTTAGAGGATATTGATACTGAAATTTGTAAAATGGATAAATGTTCAAGTAT
ATTTAATATTGTAAGCAATTCATTAGGATTTGTAATATTATTAGTATTAGTATTCTTTAATTA

</dna_sequence>
        <protein_sequence>>XP_731149.1 circumsporozoite protein, partial [Plasmodium yoelii yoelii 17XNL]
PPQQPPQQPPQQPPQQPPQQPPQQPPQQPRPQPDGNNNNNNNNGNNNEDSYVPSAEQILEFVKQISSQLT
EEWSQCSVTCGSGVRVRKRKNVNKQPENLTLEDIDTEICKMDKCSSIFNIVSNSLGFVILLVLVFFN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Study showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. yoelii conferred sterile protection against challenge with wild type P. berghei sporozoites [Ref1225:Mauduit et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1743">
        <gene_name>CSP from P. knowlesi</gene_name>
        <strain>Plasmodium knowlesi strain H</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>221060580</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:319368
EnsemblGenomes-Gn:PKH_134120
EnsemblGenomes-Tr:PKH_134120
GOA:B3LAV3
InterPro:IPR001841
InterPro:IPR013083
UniProtKB/TrEMBL:B3LAV3</xrefs>
        <taxonomy_id>5851</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>circumsporozoite protein, putative</protein_name>
        <protein_pi>5.61</protein_pi>
        <protein_weight>73901.662</protein_weight>
        <protein_length>795</protein_length>
        <protein_note>RING finger, H2 subclass, found in the PA-TM-RING ubiquitin ligase family; cd16454</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>XP_002260935.1 circumsporozoite protein, putative [Plasmodium knowlesi strain H]
MSISEHTGNEVSIAERKKKEEGSGGVINDKNVSPTDDGESMPHPMEKMKGAANDEKSVEVENCAPVGENE
LRSSVLCVGCSGEASHIEEGSAKFVGEENPRTEVDSDKKAQPEGILNEVKNVKNEIDVEKKHKTQISNND
TYVENAPNDNTCGEGCSNPHMNHDNKACDNGDDNDKIPNTGGTSNGGVIPNISGVLNVEDDCPLDEGNFS
ADDRPEENADSTSSFMLEEDINLSRRAYRNFHICSIFIHGTLLLMVTLLMGILCHDFIKLSPISQKEKTM
TYFCGLLLSMLALHLCLNLYMSLVLLRQSEVSKMLKSVEAKIHVIVLVYFSMCAYIYFFEDKYYPISSTF
SFAIILAIIYYFMPIFLYIILRLLFIVVILVLVFVKRKSPTPKKILKKLKIMKYVEYRKYCEEEACFGSA
YFTNWKELNGEGVSAPREATTTTAMEGGHIIATSGGDNKGEEVSSGDSTSNRNAEGKTISTATSCIRDIS
ANGSGHPKGGDPPSSSPNDRPTRSGNSSTRSNLERHLFYDRAGVAIGRGGGSDNRGGTRPNDRGRDDPAN
GNHQNGSDNANKHPPASYDNNCDAPNTSGEENGERNGGPNKDGKSAAVFEYFQKVLKKKNNSVQNDNVKV
VHENNMEEHSFHINIECSDYVCSICCVEYLNEDDICILPCNYLHYYHKECIFKWLKRNNDCPLCRKPIGK
I

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene835">
        <gene_name>eba-175</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id>VO_0012382</vo_id>
        <ncbi_gene_id>2654998</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>296004911</ncbi_protein_id>
        <gene_locus_tag>PF3D7_0731500</gene_locus_tag>
        <gene_refseq>AL844506</gene_refseq>
        <protein_refseq>XP_001349207</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>7</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1358054</gene_start>
        <gene_end>1362928</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name></protein_name>
        <protein_pi>5.47</protein_pi>
        <protein_weight>168527.84</protein_weight>
        <protein_length>1502</protein_length>
        <protein_note>Also known as eba 175; eba175</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_004328.3:1358054-1362928 Plasmodium falciparum 3D7 chromosome 7
AATGAAATGTAATATTAGTATATATTTTTTTGCTTCCTTCTTTGTGTTATATTTTGCAAAAGCTAGGAAT
GAATATGATATAAAAGAGAATGAAAAATTTTTAGACGTGTATAAAGAAAAATTTAATGAATTAGATAAAA
AGAAATATGGAAATGTTCAAAAAACTGATAAGAAAATATTTACTTTTATAGAAAATAAATTAGATATTTT
AAATAATTCAAAATTTAATAAAAGATGGAAGAGTTATGGAACTCCAGATAATATAGATAAAAATATGTCT
TTAATAAATAAACATAATAATGAAGAAATGTTTAACAACAATTATCAATCATTTTTATCGACAAGTTCAT
TAATAAAGCAAAATAAATATGTTCCTATTAACGCTGTACGTGTGTCTAGGATATTAAGTTTCCTGGATTC
TAGAATTAATAATGGAAGAAATACTTCATCTAATAACGAAGTTTTAAGTAATTGTAGGGAAAAAAGGAAA
GGAATGAAATGGGATTGTAAAAAGAAAAATGATAGAAGCAACTATGTATGTATTCCTGATCGTAGAATCC
AATTATGCATTGTTAATCTTAGCATTATTAAAACATATACAAAAGAGACCATGAAGGATCATTTCATTGA
AGCCTCTAAAAAAGAATCTCAACTTTTGCTTAAAAAAAATGATAACAAATATAATTCTAAATTTTGTAAT
GATTTGAAGAATAGTTTTTTAGATTATGGACATCTTGCTATGGGAAATGATATGGATTTTGGAGGTTATT
CAACTAAGGCAGAAAACAAAATTCAAGAAGTTTTTAAAGGGGCTCATGGGGAAATAAGTGAACATAAAAT
TAAAAATTTTAGAAAAAAATGGTGGAATGAATTTAGAGAGAAACTTTGGGAAGCTATGTTATCTGAGCAT
AAAAATAATATAAATAATTGTAAAAATATTCCCCAAGAAGAATTACAAATTACTCAATGGATAAAAGAAT
GGCATGGAGAATTTTTGCTTGAAAGAGATAATAGATCAAAATTGCCAAAAAGTAAATGTAAAAATAATAC
ATTATATGAAGCATGTGAGAAGGAATGTATTGATCCATGTATGAAATATAGAGATTGGATTATTAGAAGT
AAATTTGAATGGCATACGTTATCGAAAGAATATGAAACTCAAAAAGTTCCAAAGGAAAATGCGGAAAATT
ATTTAATCAAAATTTCAGAAAACAAGAATGATGCTAAAGTAAGTTTATTATTGAATAATTGTGATGCTGA
ATATTCAAAATATTGTGATTGTAAACATACTACTACTCTCGTTAAAAGCGTTTTAAATGGTAACGACAAT
ACAATTAAGGAAAAGCGTGAACATATTGATTTAGATGATTTTTCTAAATTTGGATGTGATAAAAATTCCG
TTGATACAAACACAAAGGTGTGGGAATGTAAAAAACCTTATAAATTATCCACTAAAGATGTATGTGTACC
TCCGAGGAGGCAAGAATTATGTCTTGGAAACATTGATAGAATATACGATAAAAACCTATTAATGATAAAA
GAGCATATTCTTGCTATTGCAATATATGAATCAAGAATATTGAAACGAAAATATAAGAATAAAGATGATA
AAGAAGTTTGTAAAATCATAAATAAAACTTTCGCTGATATAAGAGATATTATAGGAGGTACTGATTATTG
GAATGATTTGAGCAATAGAAAATTAGTAGGAAAAATTAACACAAATTCAAATTATGTTCACAGGAATAAA
CAAAATGATAAGCTTTTTCGTGATGAGTGGTGGAAAGTTATTAAAAAAGATGTATGGAATGTGATATCAT
GGGTATTCAAGGATAAAACTGTTTGTAAAGAAGATGATATTGAAAATATACCACAATTCTTCAGATGGTT
TAGTGAATGGGGTGATGATTATTGCCAGGATAAAACAAAAATGATAGAGACTCTGAAGGTTGAATGCAAA
GAAAAACCTTGTGAAGATGACAATTGTAAACGTAAATGTAATTCATATAAAGAATGGATATCAAAAAAAA
AAGAAGAGTATAATAAACAAGCCAAACAATACCAAGAATATCAAAAAGGAAATAATTACAAAATGTATTC
TGAATTTAAATCTATAAAACCAGAAGTTTATTTAAAGAAATACTCGGAAAAATGTTCTAACCTAAATTTC
GAAGATGAATTTAAGGAAGAATTACATTCAGATTATAAAAATAAATGTACGATGTGTCCAGAAGTAAAGG
ATGTACCAATTTCTATAATAAGAAATAATGAACAAACTTCGCAAGAAGCAGTTCCTGAGGAAAGCACTGA
AATAGCACACAGAACGGAAACTCGTACGGATGAACGAAAAAATCAGGAACCAGCAAATAAGGATTTAAAG
AATCCACAACAAAGTGTAGGAGAGAACGGAACTAAAGATTTATTACAAGAAGATTTAGGAGGATCACGAA
GTGAAGACGAAGTGACACAAGAATTTGGAGTAAATCATGGAATACCTAAGGGTGAGGATCAAACGTTAGG
AAAATCTGACGCCATTCCAAACATAGGCGAACCCGAAACGGGAATTTCCACTACAGAAGAAAGTAGACAT
GAAGAAGGCCACAATAAACAAGCATTGTCTACTTCAGTCGATGAGCCTGAATTATCTGATACACTTCAAT
TGCATGAAGATACTAAAGAAAATGATAAACTACCCCTAGAATCATCTACAATCACATCTCCTACGGAAAG
TGGAAGTTCTGATACAGAGGAAACTCCATCTATCTCTGAAGGACCAAAAGGAAATGAACAAAAAAAACGT
GATGACGATAGTTTGAGTAAAATAAGTGTATCACCAGAAAATTCAAGACCTGAAACTGATGCTAAAGATA
CTTCTAACTTGTTAAAATTAAAAGGAGATGTTGATATTAGTATGCCTAAAGCAGTTATTGGGAGCAGTCC
TAATGATAATATAAATGTTACTGAACAAGGGGATAATATTTCCGGGGTGAATTCTAAACCTTTATCTGAT
GATGTACGTCCAGATAAAAATCATGAAGAGGTGAAAGAACATACTAGTAATTCTGATAATGTTCAACAGT
CTGGAGGAATTGTTAATATGAATGTTGAGAAAGAACTAAAAGATACTTTAGAAAATCCTTCTAGTAGCTT
GGATGAAGGAAAAGCACATGAAGAATTATCAGAACCAAATCTAAGCAGTGACCAAGATATGTCTAATACA
CCTGGACCTTTGGATAACACCAGTGAAGAAACTACAGAAAGAATTAGTAATAATGAATATAAAGTTAACG
AGAGGGAAGGTGAGAGAACGCTTACTAAGGAATATGAAGATATTGTTTTGAAAAGTCATATGAATAGAGA
ATCAGACGATGGTGAATTATATGACGAAAATTCAGACTTATCTACTGTAAATGATGAATCAGAAGACGCT
GAAGCAAAAATGAAAGGAAATGATACATCTGAAATGTCGCATAATAGTAGTCAACATATTGAGAGTGATC
AACAGAAAAACGATATGAAAACTGTTGGTGATTTGGGAACCACACATGTACAAAACGAAATTAGTGTTCC
TGTTACAGGAGAAATTGATGAAAAATTAAGGGAAAGTAAAGAATCAAAAATTCATAAGGCTGAAGAGGAA
AGATTAAGTCATACAGATATACATAAAATTAATCCTGAAGATAGAAATAGTAATACATTACATTTAAAAG
ATATAAGAAATGAGGAAAACGAAAGACACTTAACTAATCAAAACATTAATATTAGTCAAGAAAGGGATTT
GCAAAAACATGGATTCCATACCATGAATAATCTACATGGAGATGGAGTTTCCGAAAGAAGTCAAATTAAT
CATAGTCATCATGGAAACAGACAAGATCGGGGGGGAAATTCTGGGAATGTTTTAAATATGAGATCTAATA
ATAATAATTTTAATAATATTCCAAGTAGATATAATTTATATGATAAAAAATTAGATTTAGATCTTTATGA
AAACAGAAATGATAGTACAACAAAAGAATTAATAAAGAAATTAGCAGAAATAAATAAATGTGAGAACGAA
ATTTCTGTAAAATATTGTGACCATATGATTCATGAAGAAATCCCATTAAAAACATGCACTAAAGAAAAAA
CAAGAAATCTGTGTTGTGCAGTATCAGATTACTGTATGAGCTATTTTACATATGATTCAGAGGAATATTA
TAATTGTACGAAAAGGGAATTTGATGATCCATCTTATACATGTTTCAGAAAGGAGGCTTTTTCAAGTATG
ATATTCAAATTTTTAATAACAAATAAAATATATTATTATTTTTATACTTACAAAACTGCAAAAGTAACAA
TAAAAAAAATTAATTTCTCATTAATTTTTTTTTTCTTTTTTTCTTTTTAGGTATGCCATATTATGCAGGA
GCAGGTGTGTTATTTATTATATTGGTTATTTTAGGTGCTTCACAAGCCAAATATCAAAGGTTAGAAAAAA
TAAATAAAAATAAAATTGAGAAGAATGTAAATTAAATATATATATATATATATATATATATATATTGTAT
TATATATTTTTTTTTTATAGTTCTGAAGGAGTTATGAATGAGAATAATGAGAATAATTTTTTATTTGAAG
TTACTGATAATTTAGATAAATTATCCAATATGTGTAATACAAATATAAAAAAAAATAATAAATAAATAAA
TAATTACAAGGAAATAAAAATGATATATATTATTACATTATGTTTGTTTACTTTTATATTATCCTATAAT
ATTTATTTTTATTTTATGTTTTTTTTTTTTCAGTCAATCAACAAGTACAGGAAACTAATATCAACGATTT
TTCTGAATACCATGAGGATATAAATGATATTAATTTTAAGAAATG

</dna_sequence>
        <protein_sequence>>XP_001349207.2 erythrocyte binding antigen-175 [Plasmodium falciparum 3D7]
MKCNISIYFFASFFVLYFAKARNEYDIKENEKFLDVYKEKFNELDKKKYGNVQKTDKKIFTFIENKLDIL
NNSKFNKRWKSYGTPDNIDKNMSLINKHNNEEMFNNNYQSFLSTSSLIKQNKYVPINAVRVSRILSFLDS
RINNGRNTSSNNEVLSNCREKRKGMKWDCKKKNDRSNYVCIPDRRIQLCIVNLSIIKTYTKETMKDHFIE
ASKKESQLLLKKNDNKYNSKFCNDLKNSFLDYGHLAMGNDMDFGGYSTKAENKIQEVFKGAHGEISEHKI
KNFRKKWWNEFREKLWEAMLSEHKNNINNCKNIPQEELQITQWIKEWHGEFLLERDNRSKLPKSKCKNNT
LYEACEKECIDPCMKYRDWIIRSKFEWHTLSKEYETQKVPKENAENYLIKISENKNDAKVSLLLNNCDAE
YSKYCDCKHTTTLVKSVLNGNDNTIKEKREHIDLDDFSKFGCDKNSVDTNTKVWECKKPYKLSTKDVCVP
PRRQELCLGNIDRIYDKNLLMIKEHILAIAIYESRILKRKYKNKDDKEVCKIINKTFADIRDIIGGTDYW
NDLSNRKLVGKINTNSNYVHRNKQNDKLFRDEWWKVIKKDVWNVISWVFKDKTVCKEDDIENIPQFFRWF
SEWGDDYCQDKTKMIETLKVECKEKPCEDDNCKRKCNSYKEWISKKKEEYNKQAKQYQEYQKGNNYKMYS
EFKSIKPEVYLKKYSEKCSNLNFEDEFKEELHSDYKNKCTMCPEVKDVPISIIRNNEQTSQEAVPEESTE
IAHRTETRTDERKNQEPANKDLKNPQQSVGENGTKDLLQEDLGGSRSEDEVTQEFGVNHGIPKGEDQTLG
KSDAIPNIGEPETGISTTEESRHEEGHNKQALSTSVDEPELSDTLQLHEDTKENDKLPLESSTITSPTES
GSSDTEETPSISEGPKGNEQKKRDDDSLSKISVSPENSRPETDAKDTSNLLKLKGDVDISMPKAVIGSSP
NDNINVTEQGDNISGVNSKPLSDDVRPDKNHEEVKEHTSNSDNVQQSGGIVNMNVEKELKDTLENPSSSL
DEGKAHEELSEPNLSSDQDMSNTPGPLDNTSEETTERISNNEYKVNEREGERTLTKEYEDIVLKSHMNRE
SDDGELYDENSDLSTVNDESEDAEAKMKGNDTSEMSHNSSQHIESDQQKNDMKTVGDLGTTHVQNEISVP
VTGEIDEKLRESKESKIHKAEEERLSHTDIHKINPEDRNSNTLHLKDIRNEENERHLTNQNINISQERDL
QKHGFHTMNNLHGDGVSERSQINHSHHGNRQDRGGNSGNVLNMRSNNNNFNNIPSRYNLYDKKLDLDLYE
NRNDSTTKELIKKLAEINKCENEISVKYCDHMIHEEIPLKTCTKEKTRNLCCAVSDYCMSYFTYDSEEYY
NCTKREFDDPSYTCFRKEAFSSMPYYAGAGVLFIILVILGASQAKYQSSEGVMNENNENNFLFEVTDNLD
KLSNMFNQQVQETNINDFSEYHEDINDINFKK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>1 of 3 Monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes [Ref1490:Sim et al., 2001].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1081">
        <gene_name>FabB/FabF</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3885996</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>296004726</ncbi_protein_id>
        <gene_locus_tag>PFF1275c</gene_locus_tag>
        <gene_refseq>AL844505</gene_refseq>
        <protein_refseq>XP_966246</protein_refseq>
        <pdb_id>1OB1</pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>6</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1061115</gene_start>
        <gene_end>1062891</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name></protein_name>
        <protein_pi>9.25</protein_pi>
        <protein_weight>50967.34</protein_weight>
        <protein_length>473</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|86176855:1061115-1062891 Plasmodium falciparum 3D7 chromosome 6
ATCACTTTACAATTTTTTTGAAAAGTAATGCTGTGTTATGGCCTCCAAATCCCAAATTTGTATTGAGAGA
TATATCAATATTTTCCTTTGCATGAATATATTTATTAGGTGTATAATTTAGATCACAATCTGGGTCCTTA
TATTCATAATTAATAGTAGGTGGTATAATATTTGTTTGCATAGTTTTAAGACATACAATAGATTCTATAG
CTCCAGCAGCACCTATACAATGTCCTGTCATACTTTTAGTTGATGATATATATAATTTGTATGCATGATC
TTTGAAAACATTTTTAAAAACCTTGGTTTCTATTTTATCATTTAAATTTGTTGAAGTACCATGTGCATTA
ATATATTTAACGTCATTTATGTTTATATTTGCATTTTTTAATGCTTTATGAATAGAATTTGTTAAACCTT
TCCCATTAGGTTCTGGTGCAGTAATATGGTATGCATCACATTCTGAAGAATATGAAATAATTTCTCCATA
TATTGGTGCATTTCTTTTTATTGCATGTTCGTATGATTCTAGAATTAAGATGCCTGAACCTTCTCCCATA
ACGAAACCACTTCTTTTTAAATCGAAGGGTCTACAACCTTTTTTTGGATTATCGTTATAACCTGTACATA
AAGCCTTTAATGAATTGAATCCAGCAAAACTTATAGGAGTTATACTAGCTTCAGTTCCACCACATATCAT
AACATCATACTCTTTATATTTTATATATCTATAGGCTTCACCTATTGTGTTACCAGACGTAGCACATGCA
CTTAACATACCAAGAGAGATCCCTCTAATATTGTTTTCGATAGATACATATCCAGATGGAGTATTTGCTA
TCATTGCAGGTATTAAATATGGTGTTATTCTTTTATGTCCTTTTTCATACATTGTTTTCATTTCTTTTTC
TAAAAATCTTAGTCCACCTATGCCACTACCTATGATAGTACCTGTTTTATCTTTGTCTAATTTTTCCAAA
TTTAGTTTTGCATCGTCTAAAGCTAAACGTGTGGCTGCGACTGCATAATGAGTACAATCATCATTACGAT
TAACATCTTTTTTATTTGTGTAATAATCACTAGGATTAAAATCGCTTTTCTTTATTTCACTACCAATACC
ACATGACATACCGGTTATATCAAATTTTGTAATTTTATCTATTGATGTATATCCATTTATAATATTATTC
CAAAAATGTTCTATGCCAATCCCTAATCCAGTTACTACCCCTACACCTGTGCACACCACTCTAGAAGTCT
AAATAAAAAATAAAAGAATTAAGAAAATTAAAATATATATAAAAATAAATGTATAGCATATTATTACTTT
AATCATTTTTTACAATTTGTATATATCACATTTTATAAAACTATATAAATATAAATATATATATATATAT
ATATATATATTATATATATTATATATTTTATTTAGTACTTCACAAAGATTTTTCATTTCTCTCGAATTGT
ACAACTTGAAACCTTTAAAATAATTCTTGGATATTCCAGGTATACCCCTTTTAATGAAGGCATACCTTTT
ACTGTTAACCTACATATGAAAATACATGGAGTATATATTATGACATGATTAATGTTTTTTTTTTTTTTTT
TTTTTTTTTCTTTTCTACATCTAATATTCATATGGCACATGCATATGTTTGAAAGGGGAAACATATATTA
ACTATTATGTTTGTTTTATTTTATTTTTAGAATTGTAGCATTACTTGTAGCACATAAAAGAACAGGAAAT
AATATATTTTTATAATGTATTTTCTCA</dna_sequence>
        <protein_sequence>>gi|296004726|ref|XP_966246.2| 3-oxoacyl-acyl-carrier protein synthase I/II [Plasmodium falciparum 3D7]
MRKYIIKIYYFLFFYVLQVNSKRYAFIKRGIPGISKNYFKGFKLYNSREMKNLCETSRVVCTGVGVVTGL
GIGIEHFWNNIINGYTSIDKITKFDITGMSCGIGSEIKKSDFNPSDYYTNKKDVNRNDDCTHYAVAATRL
ALDDAKLNLEKLDKDKTGTIIGSGIGGLRFLEKEMKTMYEKGHKRITPYLIPAMIANTPSGYVSIENNIR
GISLGMLSACATSGNTIGEAYRYIKYKEYDVMICGGTEASITPISFAGFNSLKALCTGYNDNPKKGCRPF
DLKRSGFVMGEGSGILILESYEHAIKRNAPIYGEIISYSSECDAYHITAPEPNGKGLTNSIHKALKNANI
NINDVKYINAHGTSTNLNDKIETKVFKNVFKDHAYKLYISSTKSMTGHCIGAAGAIESIVCLKTMQTNII
PPTINYEYKDPDCDLNYTPNKYIHAKENIDISLNTNLGFGGHNTALLFKKIVK</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A genetically attenuated parasite (GAP) with a mutation in the FabB/FabF gene is attenuated in mice by arresting in the late liver stage.  It also conferred complete protection in mice from challenge with wild type Plasmodium [Ref2068:Butler et al., 2011].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene644">
        <gene_name>HEP17</gene_name>
        <strain>Plasmodium yoelii</strain>
        <vo_id>VO_0011228</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1399353</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:284100</xrefs>
        <taxonomy_id>5861</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>hepatocyte erythrocyte protein 17 kDa</protein_name>
        <protein_pi>10.09</protein_pi>
        <protein_weight>17587.89</protein_weight>
        <protein_length>243</protein_length>
        <protein_note>Circumsporozoite-related antigen (CRA); pfam06589</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAC47199.1 hepatocyte erythrocyte protein 17 kDa [Plasmodium yoelii]
MKINIASIIFIIFSLCLVNDAYGKNKYGKNGKYGSQNVIKKHGEPVINVQDLISDMVRKEEEIVKLTKNK
KSLRKINVALATALSVVSAILLGGAGLVMYNTEKGRRPFQIGKSKKGGSAMARDSSFPMNEESPLGFSPE
EMEAVASKFRESMLKDGVPAPSNTPNVQN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Immunization of mice with subunit vaccines based on the Plasmodium yoelii 17kDa hepatocyte erythrocyte protein (PyHEP17), orthologue of Plasmodium falciparum exported protein 1 (PfExp1), induces antigen-specific immune responses and protects against sporozoite challenge [Ref1233:Dobaño and Doolan, 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1742">
        <gene_name>HSP60 from P. yoelii</gene_name>
        <strain>Plasmodium yoelii strain 17X(NL)</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>3885993</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:185455
CDD:239460</xrefs>
        <taxonomy_id>5861</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>heat shock protein 60</protein_name>
        <protein_pi>6.86</protein_pi>
        <protein_weight>58029.5</protein_weight>
        <protein_length>643</protein_length>
        <protein_note>Heat shock protein 60; Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAC78150.1 heat shock protein 60 [Plasmodium yoelii]
MLSRLCGKTIQNGNADKCVSMLNKIQKRNVAKDIRFGSDARTAMLIGCNKLADAVSVTLGPKGRNVIIEQ
SFGSPKITKDGVTVAKSIEFNKKLANLGAQMVKQVAANTNDKAGDGTTTATILARSIFQQGCKAVDSGMN
PMDLLRGINKGVEKVLEYLNSIKKDVTTTEEIFNVASISANGDKNIGQLIADTMKKVGKEGTITVTEGKT
LQHELEIVEGIKFDRGYISPYFINNSKDQKVELDKPYILIHEKKISSVKSLLPVLEHVLQNQSSLLVIAE
DVDSDALATLIVNKLRLGLKICAVKAPGFGEHRKALIHDIAVMTGSKVITEEAGLKLDDPDVISYLGKAK
SINVSKDNTLIMEGEGKKEEISERCESIRNAIKNNTSDYEKEKLQERLAQITGGVALIKVGGISEVEVNE
IKDRIQDALCATKAAVEEGIVPGGGSALLFASKELDSVQTDNYDQRVGVNIIKDACKAPIKQIAENAGHE
GSVVAGNILKEKNSNMGFNAQEGKYVNMIESGIIDPTKVVKTAISDAASIASLLTTTEVAIVDSKDGKSE
EMPSHMNSVNPMGDMGGMY

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene657">
        <gene_name>Hsp90</gene_name>
        <strain>Plasmodium falciparum</strain>
        <vo_id>VO_0011241</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1093612</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:240341
CDD:214643
CDD:238030
CDD:278607</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name></protein_name>
        <protein_pi>4.63</protein_pi>
        <protein_weight>82921.42</protein_weight>
        <protein_length>796</protein_length>
        <protein_note>heat shock protein 83 kDa (Hsp83); Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>prf||2104278A heat shock protein 90
MSTETFAFNADIRQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESITDTQKLSAEPEFFIRIIPDK
TNNTLTIEDSGIGMTKNDLINNLGTIARSGTKAFMEAIQASGDISMIGQFGVGFYSAYLVADHVVVISKN
NDDEQYVWESAAGGSFTVTKDETNEKLGRGTKIILHLKEDQLEYLEEKRIKDLVKKHSEFISFPIKLYCE
RQNEKEITASEEEEEGEGEGEREGEEEEEEKKKKTGEDKNADESKEENEDEEKKEDNEEDDNKTDHPKVE
DVTEELENAEKKKKEKRKKKIHTVEHEWEELNKQKPLWMRKPEEVTNEEYASFYKSLTNDWEDHLAVKHF
SVEGQLEFKALLFIPKRAPFDMFENRKKRNNIKLYVRRVFIMDDCEEIIPEWLNFVKGVVDSEDLPLNIS
RESLQQNKILKVIKKNLIKKCLDMFSELAENKENYKKFYEQFSKNLKLGIHEDNANRTKITELLRFQTSK
SGDEMIGLKEYVDRMKENQKDIYYITGESINAVSNSPFLEALTKKGFEVIYMVDPIDEYAVQQLKDFDGK
KLKCCTKEGLDIDDSEEAKKDFETLKAEYEGLCKVIKDVLHEKVEKVVVGQRITDSPCVLVTSEFGWSAN
MERIMKAQALRDNSMTSYMLSKKIMEINARHPIISALKQKADADKSDKTVKDLIWLLFDTSLLTSGFALE
EPTTFSKRIHRMIKLGLSIDEEENNDIDLPPLEETVDATDSKMEEVD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>A monkey vaccination trial using a Plasmodium falciparum protein fraction containing antigens of 90-110 kDa is reported.   Three monkeys out of five resisted a heavy challenge dose of highly virulent parasites.  Hsp90 was found in the immunoprecipitates obtained with SERP antisera. Interestingly, the response to hsp90 correlated with protection, high antibody titres being found only in the protected monkeys [Ref1244:Bonnefoy et al., 1994].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene834">
        <gene_name>LSA-3</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id>VO_0012381</vo_id>
        <ncbi_gene_id>812783</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>124801463</ncbi_protein_id>
        <gene_locus_tag>PF3D7_0220000</gene_locus_tag>
        <gene_refseq>LN999943</gene_refseq>
        <protein_refseq>XP_001349701</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>2</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>796751</gene_start>
        <gene_end>801585</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>Liver stage antigen 3</protein_name>
        <protein_pi>3.86</protein_pi>
        <protein_weight>156020.34</protein_weight>
        <protein_length>1558</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_037280.1:796751-801585 Plasmodium falciparum 3D7 chromosome 2, complete sequence
AATGACAAATAGTAATTACAAATCAAATAATAAAACATATAATGAAAATAATAATGAACAAATAACTACC
ATATTTAATAGAACAAATATGAATCCGATAAAAAAATGTCATATGAGAGAAAAAATAAATAAGTACTTTT
TTTTGATCAAAATTTTGACATGCACCATTTTAATATGGGCTGTACAATATGCTAATAACGTAAGATAAAA
AACTAAATAATAAATATAAATAAAAAAAAAAAAAAAAAAAAAAAAAATCAACTATATAGTATGTATAATA
TATATATATATATATATATATATATATTTATTTTTATTTATTTATTAATTTTTTTTTTTTTTATATTATC
TTTTTAGTCTGATATAAACAAGAGTTGGAAAAAAAATACGTATGTAGATAAGAAATTGAATAAACTATTT
AACAGAAGTTTAGGAGAATCTCAAGTAAATGGTGAATTAGCTAGTGAAGAAGTAAAGGAAAAAATTCTTG
ACTTATTAGAAGAAGGAAATACATTAACTGAAAGTGTAGATGATAATAAAAATTTAGAAGAAGCCGAAGA
TATAAAGGAAAATATCTTATTAAGTAATATAGAAGAACCAAAAGAAAATATTATTGACAATTTATTAAAT
AATATTGGACAAAATTCAGAAAAACAAGAAAGTGTATCAGAAAATGTACAAGTCAGTGATGAACTTTTTA
ATGAATTATTAAATAGTGTAGATGTTAATGGAGAAGTAAAAGAAAATATTTTGGAGGAAAGTCAAGTTAA
TGACGATATTTTTAATAGTTTAGTAAAAAGTGTTCAACAAGAACAACAACACAATGTTGAAGAAAAAGTT
GAAGAAAGTGTAGAAGAAAATGACGAAGAAAGTGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATG
ACGACGAAAGTGTAGCCTCAAGTGTTGAAGAAAGTATAGCTTCAAGTGTTGATGAAAGTATAGATTCAAG
TATTGAAGAAAATGTAGCTCCAACTGTTGAAGAAATCGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCA
AGTGTTGTAGAAAGTGTGGCTCCAAGTGTTGAAGAAAGTGTAGAAGAAAATGTTGAAGAAAGTGTAGCTG
AAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGC
TGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAATCGTA
GCTCCAACTGTTGAAGAAAGTGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAAGTG
TAGCTCCAAGTGTTGAAGAAATTGTAGTTCCAACTGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAT
CGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAACTGTTGAAGAA
AGTGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAAGTGTAGCTCCAAGTGTTGAAG
AAATTGTAGTTCCAACTGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGA
AGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTT
GAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTG
TTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAC
AGTTGAAGAAATCGTAGCTCCAACAGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCA
ACTGTTGAAGAAAGTGTTGCTGAAAACGTTGCAACAAATTTATCAGACAATCTTTTAAGTAATTTATTAG
GTGGTATCGAAACTGAGGAAATAAAGGACAGTATATTAAATGAGATAGAAGAAGTAAAAGAAAATGTAGT
CACCACAATACTAGAAAACGTAGAAGAAACTACAGCTGAAAGTGTAACTACTTTTAGTAACATATTAGAG
GAGATACAAGAAAATACTATTACTAATGATACTATAGAGGAAAAATTAGAAGAACTCCACGAAAATGTAT
TAAGTGCCGCTTTAGAAAATACCCAAAGTGAAGAGGAAAAGAAAGAAGTAATAGATGTAATTGAAGAAGT
AAAAGAAGAGGTCGCTACCACTTTAATAGAAACTGTGGAACAGGCAGAAGAAGAGAGCGCAAGTACAATT
ACGGAAATATTTGAAAATTTAGAAGAAAATGCAGTAGAAAGTAATGAAAATGTTGCAGAGAATTTAGAGA
AATTAAACGAAACTGTATTTAATACTGTATTAGATAAAGTAGAGGAAACAGTAGAAATTAGCGGAGAAAG
TTTAGAAAACAATGAAATGGATAAAGCATTTTTTAGTGAAATATTTGATAATGTAAAAGGAATACAAGAA
AATTTATTAACAGGTATGTTTCGAAGTATAGAAACCAGTATAGTAATCCAATCAGAAGAAAAGGTTGATT
TGAATGAAAATGTGGTTAGTTCGATTTTAGATAATATAGAAAATATGAAAGAAGGTTTATTAAATAAATT
AGAAAATATTTCAAGTACTGAAGGTGTTCAAGAAACTGTAACTGAACATGTAGAACAAAATGTATATGTG
GATGTTGATGTTCCTGCTATGAAAGATCAATTTTTAGGAATATTAAATGAGGCAGGAGGGTTGAAAGAAA
TGTTTTTTAATTTGGAAGATGTATTTAAAAGTGAAAGTGATGTAATTACTGTAGAAGAAATTAAGGATGA
ACCGGTTCAAAAAGAGGTAGAAAAAGAAACTGTTAGTATTATTGAAGAAATGGAAGAAAATATTGTAGAT
GTATTAGAGGAAGAAAAAGAAGATTTAACAGACAAGATGATAGATGCAGTAGAAGAATCCATAGAAATAT
CTTCAGATTCTAAAGAAGAAACTGAATCTATTAAAGATAAAGAAAAAGATGTTTCACTAGTTGTTGAAGA
AGTTCAAGACAATGATATGGATGAAAGTGTTGAGAAAGTTTTAGAATTGAAAAATATGGAAGAGGAGTTA
ATGAAGGATGCTGTTGAAATAAATGACATTACTAGCAAACTTATTGAAGAAACTCAAGAGTTAAATGAAG
TAGAAGCAGATTTAATAAAAGATATGGAAAAATTAAAAGAATTAGAGAAAGCATTATCAGAAGATTCTAA
AGAAATAATAGATGCAAAAGATGATACATTAGAAAAAGTTATTGAAGAGGAACATGATATAACGACGACG
TTGGATGAAGTTGTAGAATTAAAAGATGTCGAAGAAGACAAGATCGAAAAAGTATCTGATTTAAAAGATC
TTGAAGAAGATATATTAAAAGAAGTAAAAGAAATCAAAGAACTTGAAAGTGAAATTTTAGAAGATTATAA
AGAATTAAAAACTATTGAAACAGATATTTTAGAAGAGAAAAAAGAAATAGAAAAAGATCATTTTGAAAAA
TTCGAAGAAGAAGCTGAAGAAATAAAAGATCTTGAAGCAGATATATTAAAAGAAGTATCTTCATTAGAAG
TTGAAGAAGAAAAAAAATTAGAAGAAGTACACGAATTAAAAGAAGAGGTAGAACATATAATAAGTGGTGA
TGCGCATATAAAAGGTTTGGAAGAAGATGATTTAGAAGAAGTAGATGATTTAAAAGGAAGTATATTAGAC
ATGTTAAAGGGAGATATGGAATTAGGGGATATGGATAAGGAAAGTTTAGAAGATGTAACAGCAAAACTTG
GAGAAAGAGTTGAATCCTTAAAAGATGTTTTATCTAGTGCATTAGGCATGGATGAAGAACAAATGAAAAC
AAGAAAAAAAGCTCAAAGACCTAAATTGGAAGAAGTATTATTAAAAGAAGAGGTTAAAGAAGAACCAAAG
AAAAAAATAACAAAAAAGAAAGTAAGGTTTGATATTAAGGATAAGGAACCAAAAGATGAAATAGTAGAAG
TTGAAATGAAAGATGAAGATATAGATGAAGATATAGAAGAAGATGTAGAAGAAGATATAGAAGAAGATAA
AGTTGAAGATATAGATGAAGATATAGATGAAGATATAGATGAAGATATAGGTGAAGACAAAGATGAAGTT
ATAGATTTAATAGTCCAAAAAGAGAAACGCATTGAAAAGGTTAAAGAGAAAAAGAAAAAATTAGAAAAAA
AAGTTGAAGAAGGTGTTAGTGGTCTTAAAAAACACGTAGACGAAGTAATGAAATATGTTCAAAAAATTGA
TAAAGAAGTTGATAAAGAAGTATCTAAAGCTTTAGAATCAAAAAATGATGTTACTAATGTTTTAAAACAA
AATCAAGATTTTTTTAGTAAAGTTAAAAACTTCGTAAAAAAATATAAAGTATTTGCTGCACCATTCATAT
CTGCCGTTGCAGCATTTGCATCATATGTAGTTGGGTTCTTTACATTTTCTTTATTTTCATCATGTGTAAC
AATAGCTTCTTCAACTTACTTATTATCAAAAGTTGACAAAACTATAAATAAAAATAAGGAGAGACCGTTT
TATTCATTTGTATTTGATATCTTTAAGAATTTAAAACATTATTTACAACAAATGAAAGAAAAATTTAGTA
AAGAAAAAAATAATAATGTAATAGAAGTAACAAACAAAGCTGAGAAAAAAGGTAATGTACAGGTAACAAA
TAAAACCGAGAAAACAACTAAAGTTGATAAAAATAATAAAGTACCGAAAAAAAGTAGAACGCAAAAATCA
AAATA

</dna_sequence>
        <protein_sequence>>XP_001349701.1 liver stage antigen 3 [Plasmodium falciparum 3D7]
MTNSNYKSNNKTYNENNNEQITTIFNRTNMNPIKKCHMREKINKYFFLIKILTCTILIWAVQYANNSDIN
KSWKKNTYVDKKLNKLFNRSLGESQVNGELASEEVKEKILDLLEEGNTLTESVDDNKNLEEAEDIKENIL
LSNIEEPKENIIDNLLNNIGQNSEKQESVSENVQVSDELFNELLNSVDVNGEVKENILEESQVNDDIFNS
LVKSVQQEQQHNVEEKVEESVEENDEESVEENVEENVEENDDESVASSVEESIASSVDESIDSSIEENVA
PTVEEIVAPTVEEIVAPSVVESVAPSVEESVEENVEESVAENVEESVAENVEESVAENVEESVAENVEES
VAENVEESVAENVEEIVAPTVEESVAPTVEEIVAPSVEESVAPSVEEIVVPTVEESVAENVEEIVAPSVE
EIVAPSVEEIVAPTVEESVAPTVEEIVAPSVEESVAPSVEEIVVPTVEESVAENVEESVAENVEEIVAPS
VEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPTVEEIVA
PTVEEIVAPSVEEIVAPTVEESVAENVATNLSDNLLSNLLGGIETEEIKDSILNEIEEVKENVVTTILEN
VEETTAESVTTFSNILEEIQENTITNDTIEEKLEELHENVLSAALENTQSEEEKKEVIDVIEEVKEEVAT
TLIETVEQAEEESASTITEIFENLEENAVESNENVAENLEKLNETVFNTVLDKVEETVEISGESLENNEM
DKAFFSEIFDNVKGIQENLLTGMFRSIETSIVIQSEEKVDLNENVVSSILDNIENMKEGLLNKLENISST
EGVQETVTEHVEQNVYVDVDVPAMKDQFLGILNEAGGLKEMFFNLEDVFKSESDVITVEEIKDEPVQKEV
EKETVSIIEEMEENIVDVLEEEKEDLTDKMIDAVEESIEISSDSKEETESIKDKEKDVSLVVEEVQDNDM
DESVEKVLELKNMEEELMKDAVEINDITSKLIEETQELNEVEADLIKDMEKLKELEKALSEDSKEIIDAK
DDTLEKVIEEEHDITTTLDEVVELKDVEEDKIEKVSDLKDLEEDILKEVKEIKELESEILEDYKELKTIE
TDILEEKKEIEKDHFEKFEEEAEEIKDLEADILKEVSSLEVEEEKKLEEVHELKEEVEHIISGDAHIKGL
EEDDLEEVDDLKGSILDMLKGDMELGDMDKESLEDVTAKLGERVESLKDVLSSALGMDEEQMKTRKKAQR
PKLEEVLLKEEVKEEPKKKITKKKVRFDIKDKEPKDEIVEVEMKDEDIDEDIEEDVEEDIEEDKVEDIDE
DIDEDIDEDIGEDKDEVIDLIVQKEKRIEKVKEKKKKLEKKVEEGVSGLKKHVDEVMKYVQKIDKEVDKE
VSKALESKNDVTNVLKQNQDFFSKVKNFVKKYKVFAAPFISAVAAFASYVVGFFTFSLFSSCVTIASSTY
LLSKVDKTINKNKERPFYSFVFDIFKNLKHYLQQMKEKFSKEKNNNVIEVTNKAEKKGNVQVTNKTEKTT
KVDKNNKVPKKSRTQKSK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites [Ref1489:Daubersies et al., 2000].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene143">
        <gene_name>MSP-1</gene_name>
        <strain>Plasmodium falciparum</strain>
        <vo_id>VO_0010958</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>94420988</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:289698
CDD:304395</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>merozoite surface protein 1</protein_name>
        <protein_pi>4.55</protein_pi>
        <protein_weight>13136.57</protein_weight>
        <protein_length>192</protein_length>
        <protein_note>clinical isolate</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ABF18819.1 merozoite surface protein 1, partial [Plasmodium falciparum]
MLNISQHQCVKKQCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADATCTEEDSG
SSRKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Aotus monkeys were challenged with the virulent Vietnam Oak Knoll (FVO) strain of P. falciparum.  Vaccination of A. nancymai with yMSP1(19) induced protective immune responses.  Both of the A. nancymai vaccinated with yMSP1(19) self-resolved an otherwise lethal infection [Ref1222:Kumar et al., 1995].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene641">
        <gene_name>MSP1 from P. berghei</gene_name>
        <strain>Plasmodium berghei</strain>
        <vo_id>VO_0011225</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>1762646</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>5821</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>merozoite surface protein 1</protein_name>
        <protein_pi>4.24</protein_pi>
        <protein_weight>9906.72</protein_weight>
        <protein_length>184</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAC47502.1 merozoite surface protein 1, partial [Plasmodium berghei]
SGQSSTEPASTGTPSSGEVSTGTSTGGASAGVTNTGAATTGTSTGGASAGVTNTGAATTGTTGTGAATTG
TTGAEAVTTGNTGAEVTQVQIVPTLTPEEKKKKMDGLYAQI

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice vaccinated with recombinant rMSP1 (rPbMSP1), which was generated from Plasmodium berghei, in alum mounted significant protective immunity against challenge infection (P &gt; 0.01). On day 121 after the booster, three out of ten mice immunized with rPbMSP1 in PBS survived parasite infection (P &gt; 0.05) and eight out of ten mice vaccinated with r MSP1 in alum did (P &gt; 0.01). Hence, immunization with MSP1 in alum obviously has conferred protective effects, which prevented death from P. berghei lethal infection in mice (P &gt; 0.01) [Ref1231:Wan et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1746">
        <gene_name>MSP1 from P. knowlesi</gene_name>
        <strain>Plasmodium knowlesi strain H</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>221054886</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:284802
CDD:289698
CDD:289699
EnsemblGenomes-Gn:PKH_072850
EnsemblGenomes-Tr:PKH_072850
GOA:B3L2X8
InterPro:IPR010901
InterPro:IPR024730
InterPro:IPR024731
UniProtKB/TrEMBL:B3L2X8</xrefs>
        <taxonomy_id>5851</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>merozoite surface protein 1, MSP-1</protein_name>
        <protein_pi>5.06</protein_pi>
        <protein_weight>192886.042</protein_weight>
        <protein_length>1931</protein_length>
        <protein_note>Merozoite surface protein 1 (MSP1) C-terminus; pfam07462</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>XP_002258582.1 merozoite surface protein 1, MSP-1 [Plasmodium knowlesi strain H]
MKALLFLFSLIFFVTKCQCETEDYKQLLVKLDKLEGLVVDGYELFHKNKISLDNIDAVQNIDGNNVNALA
YKIRDIVGKYLELQIPGHGNLLHMIRELALDANGLKYLVENYEEFNQLMHVINFNYDLLRAKLNDMCAHE
YCKIPEHLKISAKELDMLKKVVLGYRKPLDNIKDDIGKMEAFINKNKETINNINQLITAENAKIVGHPIN
GVNVTGASSDAVANTGTPVAAAAGAAAAAVPGAIASPSPVESSTPENYDQKKVIFQAIYNFIFYTNQLEE
AQKLMQVLEKRVKLLKEHKSIKALLEQIATEKNNLTTNNATTGGATTIPEEVQKKIADLEKQIVAIAKTV
NFDMDGLFTNVEELEYYLREKAKMAGTLIGPESSQSTGTPGKAVPTLKETYPYGITYALPERTIYELIEK
FGSEESFGDLQNPDNGRQPNKGIIINETKRKTLVDKIMSKIKLEEEKLPKLKKEYDEKMEQYKQKVQDFL
PTLKYFYEGKLDNTLVGSKFDEFKNKREAYMKEKEELEKCTYEQSINLINKLKKQLTYLVDYTLKKDVTE
DEINYFSDLEWKLKNEIYELAKEVRKNENKLIMENKFDFSGVLELQIHKVLMIKKIGALKNVQNLLKNAK
LKDKLYIPKVYKTGQKPEPYYLIVLKKEIDKLKDFIPKIETMIATEKAKAPTEPVKVRAQSLRGASETAP
SEPPTATESGSTTSASTAVQQPTQQAAQAAQAASPVTVTQPTETVTQTPAPATETAGEAAQETSPVSPTA
PAVVSEAGTEGGEGTTEVVAQPEAASGETQTPTPGAVDASPAAPVPAGTPGTTDAAPEASVPAPAGSALP
ATTAPAAAAPAAPAMSKLEYLEKLLEFLKSSYACHKHIFLTNSTMNPELLKQYALTTDEEKKIKESACDE
LDLLFNVQNNLPSMYSIYDTMINDLQNLYIELYQKEMVYNIYKNKDTDTKIKAFLETLKSNAASVTPAVV
PAAAPVVTPAPAEPVVTPAPAPGQAAPAAAPTTTNPSTTPSGTTTNAVSPTTAVTPGAQDTTQTTTQDTT
VTEEGGVTVQASSEEEPETNIVNVEKIYEKHLSQMDKYNDYFIKFLESQKEKITSMTEEQANALGAEIEA
LKKKVQVSLDHYGKYKLKLERFLEKKNKISNSKEHIKKLTSLKNKLERKLNFLNNPTSVLKNYIIFFNKK
KEAEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEESLQKEDNYLNLEKFRVLSRMEGRLGNNI
NLEKENISYLSSGLHHVFTELKEIIKNKKYTGNDHAKNTTAVKEALQAYEELLPKVATQTASLPPVAPPA
VVPPVVPEAEAEAEAEAEAEPATSTQPATADTAAPTQTPAAPTQTPAEPATATATTGETAAAPAAPAPVE
VQNAEVKAQEYGEDYDKVITLPLFGNDEDDVEDQEEKQIITGEAENAQPENIVPEGINEYEVVYIKPLAG
MYKSIKKQLENHVAAFNTNITDMLDSRLKKRNYFLDVLDSELNPFKYSSSGEYIIKDPYKLLDLEQKKKL
LGSYQYIGASVDKDLITAKDGMEYYNKMGELYKQHLEAVNAQIKEIEASVPGEQSQLNAQKEELKKYLPF
LNSIQKEYESLVNMAHTYKENLKKFINNCQIEKKETEIIVKKLEDYTKIDENLEIYKKSKKESDVRSSGL
LEKLKNSKLINEEESKKVLSQLLNVQTQMLNMSSAHKCIDTNVPENAACYRYLDGTEEWRCLLGFKEVGG
KCVPASITCEENNGGCAPEAECTMDDKKEVECKCTKEGFEPLFEGVFCSSSSFLSLSFLLLILIFFLSME
L

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene628">
        <gene_name>MSP1 from P. yoelii str. 17XNL</gene_name>
        <strain>Plasmodium yoelii</strain>
        <vo_id>VO_0011212</vo_id>
        <ncbi_gene_id>3791597</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>82596427</ncbi_protein_id>
        <gene_locus_tag>PY17X_0834400</gene_locus_tag>
        <gene_refseq>LK934636</gene_refseq>
        <protein_refseq>XP_726257</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>5861</taxonomy_id>
        <chromosome>8</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1276003</gene_start>
        <gene_end>1281321</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name></protein_name>
        <protein_pi>5.05</protein_pi>
        <protein_weight>188296.05</protein_weight>
        <protein_length>1772</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_036180.1:1276003-1281321 Plasmodium yoelii genome assembly PY17X01, chromosome : 8
AATGAAGGTGATTGGACTTTTATTTTCTTTCGTTTTTTTTGCTATAAAATGCAAATCTGAAACAATTGAA
GTTTATAATGATCTCATTCAAAAGTTAGAAAAATTAGAATCATTGTCAGTGGATGGGTTAGAACTATTTC
AAAAAAGTCAAGTAATTATAAATGCAACACAACCAACTGAAACTATTGATCCATTTACAAATCATAACTT
TGCACAACAAGTACAAGATTTTGTTACAAAATTTGAAGGATTAGGATTTACAGAACAAACAGAATTAGTC
AATTTAATAAAAGCATTAACCCCAAATAGATATGGAGTAAAATATTTAATTGAAAGTAAAGAAGAATTTA
ATGGATTAATGCACGCAATAAATTTTTATTATGATGTACTTAGAGATAAATTAAATGATATGTGTGCAAA
TAATTATTGTGAAATTCCTGAACATCTTAAAATTAGTGAAGAAGAAACAGAAATGCTTAAAAAAGTAATT
TTAGGTTATAGAAAACCAATAGAAAATATTCAAGACGATATTGAAAAGTTAGAAATTTACATAGAAAGAA
ATAAAGAAACTGTTGCAGCTTTAAACGCTCTTATTGCTGAAGAAACAAAAAAAATACAACCTGAAGGTAA
CGAAGATTGCAATGACGCTAGTTGTGATAGCGATAAATATAATAAAAAAAAACCAATATACCAAGCTATG
TACAATGTTATATTTTACAAAAAACAATTAGCTGAAATACAAAAGGTTGTCGAAGTCTTAGAAAAACGAG
TTTCTACATTAAAGAAAAATGATGCCATCAAACCATTATGGCAACAAATTGAAGTTCTCAATGCTGCCCC
CGTCGTCACTGCCGAAACACAAATAGTTACAGGAGGACAATCTAGTACAGAACCAGGTAGTGGTGGATCA
AGTGCATCGGGAACAAGTTCATCAGGACAAGCTAGTGCAGGAACAGGTGTAGAACAAGCTAACACTGTAG
CATCTGTTACAGTAACACCTAGTGTAGGACAAAATGGTGAAGCATCAACTAATCCACAAACAGCTCAAGT
GCAACCCGTTCCAACTCTTACATTAGAAGAAAAACAGAAAAAAATAGCCGGACTTTATGCTCAAATTAAA
GAAATTGCAAAAACTATAAAATTCAACTTAGAAGGAATATTTGTAGATCCAATCGAATTAGAATATTTCA
AAAAAGAAAAAAAAAAAGAAAGTTGCAATTTATCAACTTCATCCTGTAAAAAAAATAAAGCATCCGAAAC
TATAATACCATTAACTATACGTTATCCAAATGGTATTAGTTACCCATTACCTGAAAATGATGTTTACAAT
AAAATTGCCAATAATGCCGCTGAAACAACATATGGTGATTTGACACATCCCGATAATACACCATTAACAG
GAGATTTAGCCACAAATGAACAAGCCAGAAAAGATCTAATAAAAGCTATTAAAAAGAAAATAAAAGCAGA
AGAAAAAAAATTAGAAACATTAAAAACGAATTATGATAATAAACTTACAGAATTTAATCAACAAAAAACT
CCATTCAAAGAAGCAGCTAAAGAATTTTATGAATCAAAATTTAGAAATAAATTGACTTCTGAAATTTTTG
AAAAATTCAAAACAAAAAGAGATGAATATATGACCAAGAAAACCGAATTAAACACTTGTGAATATGGAAA
TACTAAAGAATTAATTAATAAATTAAATAAACAACTTAATTATTTACAAGATTATTCATTAAGAAAAGAT
ATAATTAGTAATGAAATTGAATATTTTTCAAATAAAAAAAAAGAATTACAATATAATATTAATAGATTAG
CAGAAGCTGTTCAAGCAAAACAAAATGTATTAGTTGCATCAAAAGATGTACCACTTTCAACACTTGTAGA
ATTGCAAATACAAAAATCTTTATTAACAAAACAAATTGAGCAATTAAATAAAACTGAAGTATCTTTAAAC
AAAGCTCAATTAAAAGACAAACTATATGTTCCAAAAACATACGGTAATGAAGGAAAACCAGAACCATACT
ATTTAATAGCTGTAAAAAAAGAAGTTGACAGACTTGCCCAATTTATTCCAAAAATCGAAAGTATGATTGC
TAAAGAGAAGGAAAGAATGGAACAAGGACCTGCAATTACTGGAGAATCTGAAGAAGTACCATCTGGCCCT
AGTGCTGAATCATCAACAGATAGATCAACACAATCTTCAACATCCTCATCCTCATCCTCATCTTCAACCC
CAGCAGCAGCAGAATCCTCCTCAGCCACATTACCAGAAGCACCCGCACCAGCAGAAGCAGCATCCCCATC
AACAGAAGCATCAGAAGAAACAACAATACCCCCTACCACACAAGAAACACAACCATCACAAGCTGCATCA
TCCACAACACCTGCAAAACCAGTTATGACAAAATTATATTATCTTGAAAAATTACAAAAATTTTTAGTAT
TCTCATATTCATGCCATAAATACGTTTTACTACAAAACTCTACCATAAACAAAGATGCTTTAAGCAAATA
TGCTCTTACATCTGAAGAAGATAAAATAAGAACATTAAAAAGATGCAGTGAATTAGATGTATTATTAGCT
ATTCAAAATAATATGCCTACTATGTATTCACTTTATGAAAGTATAGTTGATGGTTTACAAAACATTTATA
CTGAATTATATGAAAAAGAAATGATGTATCATATATATAAATTAAAAGATGAAAACCCATCTATTAAATC
TTTATTGGTAAAAGCTGGCGTCATTGAACCAGAACCAGTAGCAGCACCAACACCAGTAACTCCAGCAGCA
ACAGAACAACAACAACAACAAGCAACACCTGATGTACAATCAGATGCACCAGCACCATCAGATGTCTCGC
AACAACCAGAAACACCAGTAACATCCACGACACCAGAGGTAACAACCTCAACAGAAGCATCATCATCAGC
ACCTGGCGAAGGTACACCATCAGGAGAAGCAGGAGCATCAGGAACAGAAGGAGCAACAGCATCTAACGCA
GCCACACCAGCAGGAACATCAGCATCAGGATCAGCAGCATCTAACGCAAGTACAACCTCAGATGTAACAC
CCCCAGCAGCAGCGGCAGCAGTACCATCAACATCTACACCAGCACCTGCACAACCACCAGCAGCAAATTC
TCAATCAGGAAACCCTGACTCAGGTATTAGATCACGAGCAGAAAGTGAAGAGGATATGCCTGCCGATGAT
TTTGAATTAGACAATTTATACAAATCTTACTTACAACAAATTGATGGAAATAATACTGAATTCATAAATT
TTATAAAATCTAAAAAAGAATTAATAAAAGCATTGACACCTGAAAAAGTTAATCAATTATATCTTGAAAT
CGCTCACTTAAAGGAATTATCAGAACATTATTATGATCGTTATTCTACATATAAATTAAAATTAGAAAGA
TTATATAACAAACATGAACAAATTCAACTAACCAATCGACAAATTAGAGATCTTAGTATATTGAAAGCAC
GATTATTAAAAAGAAAACAAACTCTTAATGGCGTATTTTATATATTAAATGGTTATGTAAATTTCTTTAA
CAAGAGAAGAGAAGCTGAAAAACAATATGTAGATAATGCATTAAAAAATACTGATATGTTATTAAAATAC
TACAAAGCTCGTACTAAATATTTTACTTCTGAAGCTGTTCCTTTAAAAACATTATCTAAAGCATCACTTG
ACAGAGAATCCAATTATTTGAAAATCGAAAAATTCAGAGCATACAGTCGATTAGAATTAAGATTAAAAAA
AAATATTAATTTAGGAAAGGAAAGAATTTCATATGTATCAGGAGGTTTACACCACGTATTTGAAGAATTT
AAAGAACTTATAAAAGATAAAGACTATACCGGAAAAAAAAACCCTGATAATGCCCCTGAAGTTACCAATG
CATTCGAACAATATAAAGAATTGCTTCCAAAGGGAGTAACAGTTTCAACTCCAGCAGTCGCAGTTACAAC
GACACTAGCAGCTGACGCACCAGCAACACCAGAAGGAGCAGTACCAGGAGCAGTACCAGGAGCTGTACCA
GGTGCAGTACCAGGAGCAGTACCAGGTGCAGTACCAGGATCAGGAACCGATACACGGGTAGCTGGAAGCA
GTGTTGATGATAATGAAGACGATGATATATATCAAATTGCAAGTGGTCAATCCGAAGATGCACCAGAAAA
AGATATTCTTTCCGAATTTACAAATGAAAGTTTGTATGTATACACAAAAAGGTTGGGTAGTACATATAAA
TCATTAAAGAAACACATGTTAAGAGAATTTTCAACAATTAAAGAAGACATGACAAATGGATTAAATAATA
AATCACAAAAAAGAAATGATTTCCTTGAAGTATTAAGCCATGAATTAGATTTATTCAAAGATTTAAGTAC
CAACAAATATGTTATTAGAAATCCATATCAATTATTAGATAATGATAAAAAAGACAAACAAATAGTAAAC
TTAAAATATGCTACTAAAGGTATAAATGAAGATATAGAAACAACTACTGACGGAATTAAATTCTTTAACA
AAATGGTTGAATTATACAACACTCAATTAGCTGCAGTAAAGGAACAAATTGCTACCATAGAAGCTGAAAC
TAACGATACCAATAAAGAAGAAAAAAAGAAATATATTCCAATCCTTGAAGATCTTAAAGGATTATATGAA
ACCGTAATAGGTCAAGCAGAAGAATATTCAGAAGAATTACAAAATAGACTTGATAATTATAAAAATGAAA
AAGCTGAATTTGAAATATTAACAAAAAATTTAGAAAAATACATACAAATTGACGAAAAACTTGACGAATT
TGTAGAACATGCAGAAAATAATAAACACATAGCCTCAATAGCTTTAAACAACTTAAATAAATCTGGTTTA
GTAGGAGAAGGTGAATCAAAGAAAATATTAGCAAAAATGCTTAACATGGATGGTATGGATTTATTAGGTG
TAGACCCTAAACATGTATGTGTTGATACAAGAGATATTCCTAAAAATGCTGGATGTTTTAGAGATGATAA
TGGTACTGAAGAATGGAGATGTTTATTAGGTTACAAAAAAGGTGAAGGTAATACATGTGTAGAAAATAAT
AATCCTACTTGTGATATCAACAATGGTGGATGTGATCCAACTGCTAGTTGTCAAAATGCGGAAAGTACGG
AAAATTCCAAAAAAATTATATGTACATGTAAAGAACCAACCCCTAATGCATATTATGAAGGTGTATTCTG
TAGTTCTTCCAGCTTTATGGGATTATCAATTTTATTAATTATCACATTAATTGTATTTAATATATTTTA

</dna_sequence>
        <protein_sequence>>XP_726257.1 merozoite surface protein 1 [Plasmodium yoelii]
MKVIGLLFSFVFFAIKCKSETIEVYNDLIQKLEKLESLSVDGLELFQKSQVIINATQPTETIDPFTNHNF
AQQVQDFVTKFEGLGFTEQTELVNLIKALTPNRYGVKYLIESKEEFNGLMHAINFYYDVLRDKLNDMCAN
NYCEIPEHLKISEEETEMLKKVILGYRKPIENIQDDIEKLEIYIERNKETVAALNALIAEETKKIQPEGN
EDCNDASCDSDKYNKKKPIYQAMYNVIFYKKQLAEIQKVVEVLEKRVSTLKKNDAIKPLWQQIEVLNAAP
VVTAETQIVTGGQSSTEPGSGGSSASGTSSSGQASAGTGVEQANTVASVTVTPSVGQNGEASTNPQTAQV
QPVPTLTLEEKQKKIAGLYAQIKEIAKTIKFNLEGIFVDPIELEYFKKEKKKESCNLSTSSCKKNKASET
IIPLTIRYPNGISYPLPENDVYNKIANNAAETTYGDLTHPDNTPLTGDLATNEQARKDLIKAIKKKIKAE
EKKLETLKTNYDNKLTEFNQQKTPFKEAAKEFYESKFRNKLTSEIFEKFKTKRDEYMTKKTELNTCEYGN
TKELINKLNKQLNYLQDYSLRKDIISNEIEYFSNKKKELQYNINRLAEAVQAKQNVLVASKDVPLSTLVE
LQIQKSLLTKQIEQLNKTEVSLNKAQLKDKLYVPKTYGNEGKPEPYYLIAVKKEVDRLAQFIPKIESMIA
KEKERMEQGPAITGESEEVPSGPSAESSTDRSTQSSTSSSSSSSSTPAAAESSSATLPEAPAPAEAASPS
TEASEETTIPPTTQETQPSQAASSTTPAKPVMTKLYYLEKLQKFLVFSYSCHKYVLLQNSTINKDALSKY
ALTSEEDKIRTLKRCSELDVLLAIQNNMPTMYSLYESIVDGLQNIYTELYEKEMMYHIYKLKDENPSIKS
LLVKAGVIEPEPVAAPTPVTPAATEQQQQQATPDVQSDAPAPSDVSQQPETPVTSTTPEVTTSTEASSSA
PGEGTPSGEAGASGTEGATASNAATPAGTSASGSAASNASTTSDVTPPAAAAAVPSTSTPAPAQPPAANS
QSGNPDSGIRSRAESEEDMPADDFELDNLYKSYLQQIDGNNTEFINFIKSKKELIKALTPEKVNQLYLEI
AHLKELSEHYYDRYSTYKLKLERLYNKHEQIQLTNRQIRDLSILKARLLKRKQTLNGVFYILNGYVNFFN
KRREAEKQYVDNALKNTDMLLKYYKARTKYFTSEAVPLKTLSKASLDRESNYLKIEKFRAYSRLELRLKK
NINLGKERISYVSGGLHHVFEEFKELIKDKDYTGKKNPDNAPEVTNAFEQYKELLPKGVTVSTPAVAVTT
TLAADAPATPEGAVPGAVPGAVPGAVPGAVPGAVPGSGTDTRVAGSSVDDNEDDDIYQIASGQSEDAPEK
DILSEFTNESLYVYTKRLGSTYKSLKKHMLREFSTIKEDMTNGLNNKSQKRNDFLEVLSHELDLFKDLST
NKYVIRNPYQLLDNDKKDKQIVNLKYATKGINEDIETTTDGIKFFNKMVELYNTQLAAVKEQIATIEAET
NDTNKEEKKKYIPILEDLKGLYETVIGQAEEYSEELQNRLDNYKNEKAEFEILTKNLEKYIQIDEKLDEF
VEHAENNKHIASIALNNLNKSGLVGEGESKKILAKMLNMDGMDLLGVDPKHVCVDTRDIPKNAGCFRDDN
GTEEWRCLLGYKKGEGNTCVENNNPTCDINNGGCDPTASCQNAESTENSKKIICTCKEPTPNAYYEGVFC
SSSSFMGLSILLIITLIVFNIF

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers found that the cysteine-rich, carboxyl-terminal region of the MSP-1 protein from the rodent malarial parasite Plasmodium yoelii yoelii can be expressed in a native configuration as a fusion protein in Escherichia coli. This recombinant polypeptide elicits antibodies in mice which recognize the native parasite MSP-1. Most significantly, both inbred and outbred mice immunized with the fusion protein in Ribi adjuvant are partially and in some cases completely protected against challenge infection with an otherwise lethal parasite strain [Ref1219:Daly and Long, 1993].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene636">
        <gene_name>msp3</gene_name>
        <strain>Plasmodium falciparum</strain>
        <vo_id>VO_0011220</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>113207288</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:284533
InterPro:IPR010784
UniProtKB/TrEMBL:Q0KGB6</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>merozoite surface protein 3</protein_name>
        <protein_pi>4.26</protein_pi>
        <protein_weight>33643.59</protein_weight>
        <protein_length>383</protein_length>
        <protein_note>Merozoite surface protein (SPAM); pfam07133</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>CAJ44236.1 merozoite surface protein 3, partial [Plasmodium falciparum]
SKEIVKKYNLNLRNAILNNNSQIENEENVNTTITGNDFSGGEFLWPGYTEELKAKKASEDAEKAANDAEN
ASKEAEEAAKEAVNLKESDKSYTKAKEACTAASKAKKAVETALKAKDDAEKSSKADSISTKTKEYAEKAK
NAYEKAKNAYQKANQAVLKAKEASSYDYILGWEFGGGVPEHKKEENMLSHLYVSSKDKENISKENDDVLD
EKEEEAEETEEEELEEKNEEETESEISEDEEEEEEEEEKEEENDKKKEQEKEQSNENNDQKKDMEAQNLI
SKNQNNNEKNVKEAAESIMKTLAG

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Immunization with a recombinant yeast-expressed Plasmodium falciparum merozoite surface protein 3 (MSP3) protected Aotus nancymai monkeys against a virulent challenge infection [Ref1226:Tsai et al., 2009].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene652">
        <gene_name>MSP4/5</gene_name>
        <strain>Plasmodium yoelii</strain>
        <vo_id>VO_0011236</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>49798469</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:289699</xrefs>
        <taxonomy_id>73239</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>merozoite surface protein 4/5</protein_name>
        <protein_pi>4.1</protein_pi>
        <protein_weight>18420.75</protein_weight>
        <protein_length>253</protein_length>
        <protein_note>EGF domain; pfam12947</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>AAT68597.1 merozoite surface protein 4/5, partial [Plasmodium yoelii yoelii]
VHEISLINTKKYQRNIFCAKRILGDPPSANPSTSLNQNEDNHNSNPDANKGNTNKSDKLNGDNIPNSQSK
SENTNLSESPKTGTASNPPQPEPSVQPGNTNGDSQNSIHSDDEEEDDEDEDDDEEDCSVNNGGCGENLLC
EKMESGIIKCSCPSGYKLNGTSCIELLSAHS

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection [Ref1241:Wang et al., 2004].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1027">
        <gene_name>P36p</gene_name>
        <strain>Plasmodium berghei str. ANKA</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3424772</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>68068733</ncbi_protein_id>
        <gene_locus_tag>PB000799.01.0</gene_locus_tag>
        <gene_refseq>CAAI01001447</gene_refseq>
        <protein_refseq>XP_676277</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>5823</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1477</gene_start>
        <gene_end>2586</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name></protein_name>
        <protein_pi>8.96</protein_pi>
        <protein_weight>24816.97</protein_weight>
        <protein_length>223</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|68142845:1477-2586 Plasmodium berghei strain ANKA contig PB_RP1657, whole genome shotgun sequence
CTTACTGCATTAATTTGATATCTTTAAAATTAAATCCTTTTTTCCCTGTCACATTAAAAGTAATATATCC
TTCCCTTTGAGCTGAAATACAATTTTTAACATCATCATCAAAAAATATTATTTCGTTAATATTAACAGAA
AATTCATTTCTTATCTGTAAAGAGAAACGAATAAAATAGGGAATATTTAACCATCTTACCCACACATTTA
TATATATAATTCATATTGTGAAAATATAAAAAAAATGTTACAGTTGATTATTATTTATAAATTTTTTTAG
AGACTATACCCTTTTTAAATGATAAGATTTGTCGTTGGACATTGGCTCTTTTAATCCAAGGGCCATATAT
TTTTTCGGTTCCTTATAATAACTAAAAAAATATGAACATAAAAAAGTAGTTTATATTTTCGCTAGTTTAT
GAGTTGTTTCGCTAGTTTTATGAATTTTGTGTATTTCGTATTACTAGGGGTAATATGCATAAACCCGTTC
TATTTTGGTTTCACAATTGCTATTTTTAATACAATGCTGAATTAATTCTTCTCCTGCGATCAAAGATGGT
GACTTTCCCTTACTATATCGAATCGTCTCGTCATCTATTCAGGCGTTAAATATGAAAATAAAAAAATGGT
CAGGTAAAATAAGAAATGATCAGGCAAAATAAGAAATGGTCAGGTAAAATAAGAAATGAAAACATGCTCA
CGCATTTCACCTGAAAACGTTGCAACAGTTATTTTAATATCATTTTCATAAAGCCTCTTTGATAAAATTT
TAAAAGCATTTGTGACAGATGTTCCTATATCTTCAATATCATTGAGTTTGTCGATATATCCACCTGTACA
ACCATGCAAAGAAAGGAGTTAAACATAAATAAGTGACAAAATATATGTGTGCGTACATATAGCCATTGCA
TATTATGTTACAAGTACCTGAGTGTTTTCCTATTAGGGTCAAGTCAAAATCGAAAACAGCCATCTTTATG
TTTATCTTTTTAAGGAGATCAACAAAGCCATGAATACCTTTAGATATAGAAACAAAATAAACAATTAAAT
GAAATAAAAATATGCACGTATAAAATATTATATATATAGCAGAAAGTCCTATAATTTTCA</dna_sequence>
        <protein_sequence>>gi|68068733|ref|XP_676277.1| P36-like protein [Plasmodium berghei strain ANKA]
MKIIGLSAIYIIFYTCIFLFHLIVYFVSISKGIHGFVDLLKKINIKMAVFDFDLTLIGKHSGGYIDKLND
IEDIGTSVTNAFKILSKRLYENDIKITVATFSDDETIRYSKGKSPSLIAGEELIQHCIKNSNCETKIERV
YAYYPYYYKEPKKYMALGLKEPMSNDKSYHLKRIRNEFSVNINEIIFFDDDVKNCISAQREGYITFNVTG
KKGFNFKDIKLMQ</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>Genetically attenuated P36p-deficient Plasmodium berghei sporozoites provide protection against sporozoites challenge in mice [Ref1971:Douradinha et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene639">
        <gene_name>PF10_0155 enolase</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id>VO_0011223</vo_id>
        <ncbi_gene_id>810313</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>124802328</ncbi_protein_id>
        <gene_locus_tag>PF3D7_1015900</gene_locus_tag>
        <gene_refseq>LN999944</gene_refseq>
        <protein_refseq>XP_001347440</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>10</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>637137</gene_start>
        <gene_end>639010</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name></protein_name>
        <protein_pi>6.54</protein_pi>
        <protein_weight>45501.97</protein_weight>
        <protein_length>446</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_037281.1:637137-639010 Plasmodium falciparum 3D7 chromosome 10, complete sequence
AATGGCTCATGTAATAACTCGTATTAATGCCCGTGAAATTTTAGGTATAGATATTTTAATGTTATATATT
TTTTCACTTTGTATATAAATACCTTATTATATGTTTTTAAATAAATGTATATTCAAAGAGCTATATTCAT
TTTTAACTTTTTTTATTTTATATTATAAGAATGAATATGATAGATAAATAAAGATATATATATTATATAT
ATATATATATATATATATTTATTTATTTATTTATTTATACATTAATGTATTAATATGTTTATTTTATGAA
TCCACGTGATATTTCTTTATGAATATGTATTCTATAGTTAACATATAATAATACATACGTATATAATAAG
AATAACATAAGAATAAAATTTTTTTTTATTTTTTTTTTTGTAATACAATAATTTTTTTGTGTATCATTTT
ATTTTATTTTATTTTTAATATCTGAACATATATAATTAAATGTGAAAATTATTTACAATATATATATATA
TATATATATATATATATATATGTTACATTATTACTAATATCTGTATTTTATTTATTTTCTGTTGTTATAT
ATTTTTTTTATATATAGATTCTAGAGGAAACCCAACTGTAGAAGTTGACTTAGAGACCAACTTAGGTATT
TTCAGAGCTGCCGTACCATCTGGTGCCTCCACTGGTATTTATGAAGCCTTAGAATTAAGAGATAATGACA
AGAGCAGGTACTTAGGAAAGGGTGTTCAAAAAGCTATCAAGAACATTAATGAAATTATTGCTCCAAAATT
GATTGGAATGAATTGTACTGAACAAAAGAAAATTGACAATTTAATGGTTGAAGAATTAGATGGAAGTAAA
AATGAATGGGGATGGTCAAAAAGTAAATTAGGAGCTAATGCTATTTTAGCTATATCCATGGCTGTATGTA
GAGCTGGTGCAGCTGCTAATAAAGTATCTTTATACAAATATTTGGCACAATTAGCTGGAAAGAAAAGTGA
CCAAATGGTATTACCAGTACCTTGTTTAAACGTTATCAATGGAGGATCCCATGCAGGAAACAAATTATCT
TTCCAAGAATTTATGATAGTGCCAGTTGGTGCTCCATCATTTAAAGAAGCCTTAAGATATGGTGCTGAAG
TATATCATACCTTAAAATCAGAAATTAAAAAGAAATATGGTATTGATGCAACCAATGTAGGTGATGAAGG
TGGATTTGCTCCAAATATATTAAACGCTAATGAAGCTCTTGATTTATTAGTAACTGCCATTAAATCAGCT
GGTTATGAAGGAAAGGTTAAAATTGCTATGGATGTTGCAGCTTCTGAATTTTACAACAGTGAAAACAAAA
CATACGATTTAGATTTCAAAACTCCAAATAATGACAAATCATTAGTTAAGACTGGAGCTCAATTAGTTGA
CTTATACATTGATTTAGTAAAGAAATATCCAATTGTTTCTATTGAAGATCCATTTGATCAAGATGATTGG
GAAAATTATGCTAAATTAACAGCAGCTATTGGAAAGGATGTTCAAATTGTTGGTGATGATTTATTAGTTA
CAAACCCAACCAGAATTACTAAAGCTCTTGAAAAAAATGCTTGCAATGCTTTACTTCTTAAAGTTAACCA
AATCGGTTCTATTACTGAAGCTATTGAAGCTTGCTTATTATCTCAAAAAAATAACTGGGGTGTTATGGTT
TCTCACAGATCTGGTGAAACCGAAGATGTTTTTATTGCTGATTTAGTTGTTGCTTTAAGAACCGGACAAA
TCAAAACAGGAGCACCATGCAGAAGTGAAAGAAACGCCAAATATAACCAATTATTAAGAATTGAAGAATC
TTTAGGAAACAATGCTGTTTTTGCTGGAGAAAAATTTAGATTACAATTAAATTA

</dna_sequence>
        <protein_sequence>>XP_001347440.1 enolase [Plasmodium falciparum 3D7]
MAHVITRINAREILDSRGNPTVEVDLETNLGIFRAAVPSGASTGIYEALELRDNDKSRYLGKGVQKAIKN
INEIIAPKLIGMNCTEQKKIDNLMVEELDGSKNEWGWSKSKLGANAILAISMAVCRAGAAANKVSLYKYL
AQLAGKKSDQMVLPVPCLNVINGGSHAGNKLSFQEFMIVPVGAPSFKEALRYGAEVYHTLKSEIKKKYGI
DATNVGDEGGFAPNILNANEALDLLVTAIKSAGYEGKVKIAMDVAASEFYNSENKTYDLDFKTPNNDKSL
VKTGAQLVDLYIDLVKKYPIVSIEDPFDQDDWENYAKLTAAIGKDVQIVGDDLLVTNPTRITKALEKNAC
NALLLKVNQIGSITEAIEACLLSQKNNWGVMVSHRSGETEDVFIADLVVALRTGQIKTGAPCRSERNAKY
NQLLRIEESLGNNAVFAGEKFRLQLN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Mice immunized with r-Pfen (recombinant P. falciparum enolase protein) showed protection against a challenge with the 17XL lethal strain of the mouse malarial parasite Plasmodium yoelii [Ref1229:Pal-Bhowmick et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene874">
        <gene_name>pfCelTOS</gene_name>
        <strain></strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>62954730</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:163532</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>PF cell-traversal protein</protein_name>
        <protein_pi>4.42</protein_pi>
        <protein_weight>18979.58</protein_weight>
        <protein_length>248</protein_length>
        <protein_note>lysine-2,3-aminomutase; TIGR03820</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>BAD97684.1 PF cell-traversal protein [Plasmodium falciparum]
MNALRRLPVICSFLVFLVFSNVLCFRGNNGHNSSSSLYNGSQFIEQLNNSFTSAFLESQSMNKIGDDLAE
TISNELVSVLQKNSPTFLESSFDIKSEVKKHAKSMLKELIKVGLPSFENLVAENVKPPKVDPATYGIIVP
VLTSLFNKVETAVGAKVSDEIWNYNSPDVSESEESLSDDFFD

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice [Ref1641:Bergmann-Leitner et al., 2010].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1083">
        <gene_name>Py36</gene_name>
        <strain>Plasmodium yoelii 17XNL</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>23479924</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:185624</xrefs>
        <taxonomy_id>73239</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>p36 protein</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length>231</protein_length>
        <protein_note>p36-lilke protein; Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>gi|23479924|gb|EAA16624.1| p36 protein [Plasmodium yoelii yoelii]
MSENSTIEGNDIGEKVAAIKKYLEAFDHQNEAKSIHGFVDLLKKINIKMAVFDFDLTLIGKHSGTCNIMC
GYIDKLNDIEDIGTSVTNAFKILSKRLYENNIKITVATFSDDEAIRYSKVKSPSLIAGEELIQHCIKHSN
CETKIERVYAYYPYYYKEPKKYMALGLKEPMSNDKSYHLKRIRNEFSVNINEIIFFDDDVKNCISAKKEG
YITFNVTGKKGFNFKDIKLMQ</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites [Ref1972:Labaied et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1082">
        <gene_name>Py52</gene_name>
        <strain></strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id>15193061</ncbi_nucleotide_id>
        <ncbi_protein_id>15193062</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq>AAK91678.1</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>5861</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>Py52</protein_name>
        <protein_pi></protein_pi>
        <protein_weight></protein_weight>
        <protein_length></protein_length>
        <protein_note>member of the 6 cysteine family of Plasmodium proteins; putative membrane-bound protein; sporozoite expressed</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|15193061|gb|AF390552.1| Plasmodium yoelii Py52 mRNA, complete cds
ATGAAACGTCGAAGCATTTTCATGTACTACTGTTTCTGTTTCTTATTGAAATATGTAGCCTTTAGCAATG
TGCCAAATCCTAATACGACCATAGGACACTTTGAAATTTGTGAAGTAAATACATCTTCAGGTGATGCCGA
AGAATGTGTTTTAGAAAATGAATTTGGGAAAATGTTTTTATTTATTTGTGATATTGATTACAATGAGATG
TCAAAAAATATAGTGCTTCCGTCAGAATGTGCTAAAAAAACATATATAGACCATGTAAACCCAAATGGAA
CATCGCCAGAAGTTAATACTTATGATATATTTCCAGATTTGATCGCAGCAAATGAATCCCAATTTCGTGA
TAAATTTTATTTTTATGGAACCCCATATTCATCTAAAGACATTGATTTTATATGTTTATGTTTTTCTGAA
ACAAAACCAGATATAAAACATGTAATGAAAATGAGTTTTAAAAAAATGACAAAAAAAATAAAAGGATGTG
ATTTTGGAGATAATATACCAACGAAAAAAGATTTAACAAATGGGAAAGCATTATATGAAAATTCTAGTTG
TCATATATATGCATATCCAGGAGACGTAATTGGAATAAATTGTTATAAAAAAGACATTAATAATATTTAT
AATAATAATTTAGAATTACAGCCAAATAATTGTTTTCATAATGTTTATTATGAAGATGATATATTATTAT
CGTCAAAAAATTTAATACCTAATTCTAGAGTTATACCAGATCCGAGTAACGATGTTAAATTATCAAAAAT
GCATTCATATATGTCTTATATTATACTCCCTGACGAAATAAATGAAAATGTTAAAATTAGTTGTGCATGC
AAAAGAGATGAATATATCGGCACTATGTTTTTATATGTAAATACATCGAAAAATATTTTAACATCCCCTG
ACAACAACGTAGAAGAAATTGCTCCTTTGAATGACCACTATATTTCAATTGGAGACATGTGGGACATGGG
TTTACATGAAAACCCTGAGCAAATACAAGGCATTATTAGCAATCATGCAAATAAAAAATATTATGAACAT
ATGAAAATTTACAAAAGCAATAAAATGGATTCTAGTGATGATGATGAATCGAATGAGACTGAATCGAGTG
AGAATGAATCAAATGAGCGCACACACAATGGTAATAGAGCAAATAAAGATGCTAATAATAGTGAGAAAAT
GACTGGTAATAGAAGGAAAAAAAATAATTCTATCAATAATACTAATTACTATAGTAATTATGAGGATGAC
AATGGAATTAATATATCTACCCATGATAAATATTATGAGGACCAACATTTTGGTAACAATGGACCTTTGA
GAAAGAAAAGAACATTTTGGCAAAATATGTTTGGTACCTCTTCTTCTTATTATGAGGTCTTTAACTATTT
TTCAATCGCATTTATTCTAATTATTCATATGCTCCTCTTATGA</dna_sequence>
        <protein_sequence></protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice.  Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites [Ref1972:Labaied et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene144">
        <gene_name>RESA</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id>VO_0010959</vo_id>
        <ncbi_gene_id>813159</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>124505681</ncbi_protein_id>
        <gene_locus_tag>PF3D7_0102200</gene_locus_tag>
        <gene_refseq>AL844501</gene_refseq>
        <protein_refseq>XP_001350954</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>1</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>98818</gene_start>
        <gene_end>102281</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>RESA, ring-infected erythrocyte surface antigen, Pf155, MAL1P1.13</protein_name>
        <protein_pi>4.13</protein_pi>
        <protein_weight>117293.03</protein_weight>
        <protein_length>1085</protein_length>
        <protein_note>Also known as Pf155</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_004325.2:98818-102281 Plasmodium falciparum 3D7, chromosome 1
TATGAGACCTTTTCATGCATATAGTTGGATTTTTTCTCAACAATATATGGATACAAAAAATGTTAAGGAA
AAAAATCCCACCATATATTCATTTGATGATGAAGAAAAAAGAAATGAAAATAAGAGCTTTTTAAAGGTGT
TGTGTTCTAAACGTGGTGTTCTTCCAATTATTGGAATACTATATATCATTTTAAATGTAAGTTTTTTTTT
TTTTTTTTTTTTTTGAAATAAAATACATATTTTTTATATTTAATTTTTTATGTTAATGCTTATTTTATTT
TATTCTATTCTTTTTTATATGTCATGCATATTTTATATATTATAATACCGTTTTTAATAATATATAATAT
ATCTTTGTTATTATATATAATTTTTTTTTTTTTTTTTTTTTTTTTTTCATAGGGTAATCTTGGATATAAT
GGAAGTTCATCTTCTGGCGTACAATTTACTGATAGATGTTCAAGAAATTTATACGGGGAAACATTGCCAG
TAAACCCATATGCTGATTCTGAAAACCCAATAGTTGTAAGTCAGGTATTTGGTTTACCCTTCGAAAAACC
TACGTTTACCTTAGAAAGTCCTCCTGATATTGATCATACAAATATTTTGGGTTTTAATGAGAAGTTCATG
ACTGATGTAAATAGATATCGATATTCTAATAACTATGAAGCCATTCCTCATATAAGTGAGTTCAATCCAC
TTATTGTAGATAAAGTTCTTTTCGACTATAACGAAAAGGTTGATAACTTAGGAAGAAGTGGAGGAGACAT
TATAAAAAAAATGCAAACTTTATGGGATGAAATAATGGATATTAATAAAAGAAAATATGATTCTTTAAAA
GAAAAATTACAGAAAACTTACAGTCAGTACAAGGTTCAATATGATATGCCAAAAGAAGCATATGAGAGCA
AATGGACACAATGCATAAAACTTATTGATCAAGGAGGAGAGAACCTTGAAGAAAGATTGAACTCACAATT
TAAAAACTGGTACAGGCAGAAATATTTAAATCTTGAAGAATATAGAAGATTGACTGTGTTGAACCAAATC
GCTTGGAAAGCTTTATCCAACCAAATTCAATATTCATGCAGAAAAATTATGAATAGTGACATTTCTTCCT
TTAAACATATAAATGAATTGAAAAGTTTAGAACACAGAGCCGCAAAAGCTGCAGAAGCAGAAATGAAGAA
AAGAGCTCAAAAACCGAAGAAGAAAAAAAGTAGAAGAGGATGGTTATGTTGTGGGGGGGGAGATATCGAA
ACAGTTGAACCACAACAAGAAGAACCAGTCCAAACCGTTCAAGAACAACAAGTAAATGAATATGGTGATA
TATTACCATCATTAAGGGCCAGTATTACTAATTCAGCTATTAATTATTATGATACCGTAAAAGATGGTGT
ATACTTAGACCATGAAACATCAGATGCTCTTTATACAGATGAAGATTTGTTATTTGATTTGGAAAAACAA
AAATATATGGATATGTTAGATACATCTGAAGAAGAATCTGTTAAAGAAAATGAAGAAGAACACACTGTTG
ATGATGAACATGTAGAAGAACACACTGCTGATGACGAACATGTAGAAGAACCAACTGTTGCTGATGATGA
ACATGTAGAAGAACCAACTGTTGCTGATGAACACGTAGAAGAACCAACTGTTGCTGAAGAACATGTAGAA
GAACCAACTGTTGCTGAAGAACACGTAGAAGAACCAGCTAGTGATGTTCAACAAACTTCAGAAGCAGCTC
CAACAATTGAAATCCCCGATACATTATATTACGATATATTAGGTGTTGGTGTTAATGCTGATATGAACGA
AATTACTGAACGTTATTTTAAGTTAGCTGAAAATTACTATCCATACCAAAGATCAGGTTCTACTGTTTTC
CACAACTTTAGGAAAGTCAACGAAGCCTACCAAGTTTTAGGAGATATTGATAAAAAAAGATGGTACAATA
AATACGGATATGATGGAATAAAACAAGTCAACTTTATGAATCCATCCATCTTTTATTTATTATCTAGTTT
AGAAAAATTTAAAGATTTTACCGGAACACCCCAAATAGTAACTCTTTTGAGATTCTTTTTTGAAAAGAGA
TTATCTATGAATGATTTAGAGAATAAAAGTGAACATTTATTAAAATTTATGGAACAATATCAAAAAGAAA
GAGAAGCACATGTATCTGAATATTTATTAAATATATTACAACCATGTATAGCTGGTGATTCAAAATGGAA
TGTACCAATTATAACAAAACTTGAAGGTTTAAAAGGATCTCGCTTTGATATACCAATATTAGAATCTTTA
AGATGGATATTCAAACATGTCGCTAAAACACATTTGAAAAAATCCTCAAAATCAGCTAAGAAACTTCAAC
AGAGAACCCAGGCTAATAAACAAGAATTAGCAAATATAAATAATAACCTAATGAGTACATTGAAAGAATA
TGTAGGAAGTAGTGAACAAATGAATTCAATAACATACAATTTCGAAAACATCAATTCCAATGTTGATAAC
GGAAACCAATCAAAAAATATTTCAGATTTAAGTTATACAGATCAGAAGGAAATATTAGAAAAAATTGTTA
GTTATATAGTAGATATTTCCCTTTATGATATAGAGAACACAGCTTTAAATGCCGCTGAACAATTGTTGTC
AGATAATTCAGTAGATGAAAAAACTCTTAAAAAGAGAGCTCAATCATTAAAAAAATTATCATCCATTATG
GAGAGATATGCAGGTGGTAAAAGAAACGATAAAAAAGCAAAAAAATATGATACCCAAGATGTTGTAGGAT
ATATTATGCATGGAATTAGCACAATTAATAAAGAAATGAAAAACCAAAATGAAAATGTACCCGAACATGT
ACAACATAATGCTGAAGCAAATGTAGAACATGATGCTGAAGAAAATGTAGAACATGATGCTGAAGAAAAT
GTTGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAA
ATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTTGAAGAAAATGTAGAAGAAAATGTTGAAGA
AAATGTAGAAGAAAATGTAGAAGAAAATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAA
AATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAA
ATGTAGAAGAAAATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAA
TGTAGAAGAAAATGTTGAAGAAAATGTAGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAAT
GTAGAAGAAAATGTAGAAGAGAATGTTGAAGAGAATGTTGAAGAGAATGTTGAAGAATATGATGAAGAAA
ATGTTGAAGAACACAATGAAGAATATGATGAATA

</dna_sequence>
        <protein_sequence>>XP_001350954.1 ring-infected erythrocyte surface antigen [Plasmodium falciparum 3D7]
MRPFHAYSWIFSQQYMDTKNVKEKNPTIYSFDDEEKRNENKSFLKVLCSKRGVLPIIGILYIILNGNLGY
NGSSSSGVQFTDRCSRNLYGETLPVNPYADSENPIVVSQVFGLPFEKPTFTLESPPDIDHTNILGFNEKF
MTDVNRYRYSNNYEAIPHISEFNPLIVDKVLFDYNEKVDNLGRSGGDIIKKMQTLWDEIMDINKRKYDSL
KEKLQKTYSQYKVQYDMPKEAYESKWTQCIKLIDQGGENLEERLNSQFKNWYRQKYLNLEEYRRLTVLNQ
IAWKALSNQIQYSCRKIMNSDISSFKHINELKSLEHRAAKAAEAEMKKRAQKPKKKKSRRGWLCCGGGDI
ETVEPQQEEPVQTVQEQQVNEYGDILPSLRASITNSAINYYDTVKDGVYLDHETSDALYTDEDLLFDLEK
QKYMDMLDTSEEESVKENEEEHTVDDEHVEEHTADDEHVEEPTVADDEHVEEPTVADEHVEEPTVAEEHV
EEPTVAEEHVEEPASDVQQTSEAAPTIEIPDTLYYDILGVGVNADMNEITERYFKLAENYYPYQRSGSTV
FHNFRKVNEAYQVLGDIDKKRWYNKYGYDGIKQVNFMNPSIFYLLSSLEKFKDFTGTPQIVTLLRFFFEK
RLSMNDLENKSEHLLKFMEQYQKEREAHVSEYLLNILQPCIAGDSKWNVPIITKLEGLKGSRFDIPILES
LRWIFKHVAKTHLKKSSKSAKKLQQRTQANKQELANINNNLMSTLKEYVGSSEQMNSITYNFENINSNVD
NGNQSKNISDLSYTDQKEILEKIVSYIVDISLYDIENTALNAAEQLLSDNSVDEKTLKKRAQSLKKLSSI
MERYAGGKRNDKKAKKYDTQDVVGYIMHGISTINKEMKNQNENVPEHVQHNAEANVEHDAEENVEHDAEE
NVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEEYDEENVEEVE
ENVEEYDEENVEEVEENVEENVEENVEENVEEYDEENVEEVEENVEENVEENVEENVEENVEEVEENVEE
NVEENVEENVEENVEENVEEYDEENVEEHNEEYDE

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene626">
        <gene_name>SERA-5</gene_name>
        <strain>Plasmodium falciparum</strain>
        <vo_id>VO_0011210</vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>238629807</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id>3CH2</pdb_id>
        <xrefs>CDD:185641</xrefs>
        <taxonomy_id>5833</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>serine repeat antigen 5</protein_name>
        <protein_pi>6.14</protein_pi>
        <protein_weight>28688.67</protein_weight>
        <protein_length>362</protein_length>
        <protein_note>Serine-repeat antigen protein; Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>ACR49652.1 serine repeat antigen 5, partial [Plasmodium falciparum]
TGGGQAGNTGGGQAGNTGGGQAGNTVGDQAGSTGGSPQGSTGASQPGSSEPSNPVSSGHSVSTVSVSQTS
TSSEKQDTIQVKSALLKDYMGLKVTGPCNENFIMFLVPHIYIDVDTEDTNIELRTTLKKTNNAISFESNS
GSLEKKKYVKLPSNGTTGEQGSSTGTVRGDTEPISDSSSSSSSSSSSSSSSSSSSSSSSESLPANGPDSP
TVKPPRNLQNICETGKNFKLVVYIKENTLILKWKVYGETKDTTENNKVDVRKYLINEKETPFTNILIHAY
KEHNEQT

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Researchers constructed a new recombinant molecule of SERA5, namely SE36.  Vaccination of Squirrel monkeys with SE36 protein and aluminium hydroxyl gel (SE36/AHG) conferred protection against high parasitemia and boosted serum anti-SE36 IgG after P. falciparum parasite challenge [Ref1216:Horii et al., 2010].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1741">
        <gene_name>SSP2</gene_name>
        <strain>Plasmodium yoelii yoelii</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>45645179</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:240420
CDD:238748
CDD:214559</xrefs>
        <taxonomy_id>73239</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>Sporozoite surface protein 2</protein_name>
        <protein_pi>4.42</protein_pi>
        <protein_weight>90008.58</protein_weight>
        <protein_length>925</protein_length>
        <protein_note>sporozoite surface protein 2 (SSP2); Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>sp|Q01443.2|SSP2_PLAYO RecName: Full=Sporozoite surface protein 2; Flags: Precursor
MKLLGNSKYIFVVLLLCISVFLNGQETLDEIKYSEEVCTEQIDIHILLDGSGSIGYSNWKAHVIPMLNTL
VDNLNISNDEINVSLTLFSTNSRELIKLKGYGSTSKDSLRFILAHLQNNYSPNGNTNLTSALLVVDTLIN
ERMYRPDAIQLAIILTDGIPNDLPRSTAVVHQLKRKHVNVAIIGVGAGVNNEYNRILVGCDRYAPCPYYS
SGSWNEAQNMIKPFLTKVCQEVERIAHCGKWEEWSECSTTCDEGRKIRRRQILHPGCVSEMTTPCKVRDC
PQIPIPPVIPNKIPEKPSNPEEPVNPNDPNDPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNN
PNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNDPSNPNNPNPKKRNPKRRNPNKPKPNKPNPNKPNPNEP
SNPNKPNPNEPSNPNKPNPNEPSNPNKPNPNEPSNPNKPNPNEPLNPNEPSNPNEPSNPNAPSNPNEPSN
PNEPSNPNEPSNPNEPSNPNEPSNPKKPSNPNEPSNPNEPLNPNEPSNPNEPSNPNEPSNPEEPSNPKEP
SNPNEPSNPEEPNPEEPSNPKEPSNPEEPINPEELNPKEPSNPEESNPKEPINPEESNPKEPINPEDNEN
PLIIQDEPIEPRNDSNVIPILPIIPQKGNNIPSNLPENPSDSEVEYPRPNDNGENSNNTMKSKKNIPNEP
IPSPGDNPYKGHEERIPKPHRSNDDYVYDNNVNKNNKDEPEIPNNEYEEDKNKNQSKSNNGYKIAGGIIG
GLAILGCAGVGYNFIAGSSAAGLAGAEPAPFEDVIPDDDKDIVENEQFKLPEDNDWN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1744">
        <gene_name>SSP2 from P. knowlesi</gene_name>
        <strain>Plasmodium knowlesi strain H</strain>
        <vo_id></vo_id>
        <ncbi_gene_id></ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>221058683</ncbi_protein_id>
        <gene_locus_tag></gene_locus_tag>
        <gene_refseq></gene_refseq>
        <protein_refseq></protein_refseq>
        <pdb_id></pdb_id>
        <xrefs>CDD:240420
EnsemblGenomes-Gn:PKH_121770
EnsemblGenomes-Tr:PKH_121770
InterPro:IPR000884
InterPro:IPR002035
UniProtKB/TrEMBL:B3L8N1</xrefs>
        <taxonomy_id>5851</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start></gene_start>
        <gene_end></gene_end>
        <gene_strand>?</gene_strand>
        <protein_name>sporozoite surface protein 2, putative</protein_name>
        <protein_pi>4.27</protein_pi>
        <protein_weight>60249.802</protein_weight>
        <protein_length>675</protein_length>
        <protein_note>sporozoite surface protein 2 (SSP2); Provisional</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence></dna_sequence>
        <protein_sequence>>XP_002259987.1 sporozoite surface protein 2, putative [Plasmodium knowlesi strain H]
MKLLQNKSYLLVVFLLYVSIFARGDQKIVDEVKYNEEVCNEKVDLYLLVDGSGSIGYANWITRVIPMLTG
LIENLNLSKDSINLYMSLFASHTTELIRLGSGPSMDKKQALNVVRDLRKGYEPYGNTSMSSALSEVEMHL
KDRVNRPNAIQLVILMTDGIPNNKYRALELSRALKERNVKLAVIGIGQGINHQYNKLMAGCRPRERSCKF
YSSADWSEAISLIKPFIAKVCTEVERIAKCGPWDDWTPCSVTCGKGTHSRSRPLLHAGCTTHMVKECEMD
ECPVEPEPVPVPAPVPPTPEDENPRTTDEEDDHPNFHQGLDVPDVENDVPPENDGGDGNPFEENFFPPGD
DTVPDESNVIPVPPTVPGGSNSEFSSDVENAAQYPENPENPENPENSENPENPENQNNPEDFPMEPDMSA
DNKINEPTNPSDSGQGIPENVIPTPINNEKDIINKNKAVYPNGSNQSHDRYPKPHRNAGGYDNNPNANSD
IPEGPFSSEEEQPEDKGKKSSNNGYKIAGGVIAGLALVGCVGFAYNFVSSGGAAGMAGEPAPFDEAMAED
EKDAGEADQFKLPEDNDWN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene138">
        <gene_name>TRAP from P. falciparum</gene_name>
        <strain>Plasmodium falciparum 3D7</strain>
        <vo_id>VO_0010920</vo_id>
        <ncbi_gene_id>814170</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>124513464</ncbi_protein_id>
        <gene_locus_tag>PF3D7_1335900</gene_locus_tag>
        <gene_refseq>AL844509</gene_refseq>
        <protein_refseq>XP_001350088</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>36329</taxonomy_id>
        <chromosome>13</chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1464894</gene_start>
        <gene_end>1466618</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name>Thrombospondin-related anonymous protein (TRAP), SSP-2, SSP2, Sporozoite specific protein 2, Sporozoite surface protein 2</protein_name>
        <protein_pi>4.7</protein_pi>
        <protein_weight>61465.35</protein_weight>
        <protein_length>574</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_004331.3:1464894-1466618 Plasmodium falciparum 3D7 chromosome 13
TTTAATTCCACTCGTTTTCTTCAGGTAATCTGAATTGTTCAGGTTCGTCCAAATCTTTATCTTCTTCACC
TAATGTTTCATCAAAAGGTGCAGGTTCTCCGGCATAGGGTGTTGCTGCTCCTGGTACTACGAATTTATAA
GCAAGTCCAGCACATGCGAGTAAAGCTAATCCTCCAGCTATTCCACCTGCAATTTTATATTTATTATCTG
ATCCTGCTTTTTTTTTATTATTATCTGGCTTTTCATGTTCTTCCCTTTCAGGATGTTTTGGAGTATTGTT
ATGTTTTCTATTGTATGATCTATTTTCATTATTTCTACCATGTGGACGTGTTTCTCTATCTTCACTATTA
GGTACGTGCCTATTTCCATTATTATCTTGACTTTGGGGGTCACTTTGTTTCCTTTCATTATCCAAAACTT
TTGGAGATAATGGTGAATATGGAATATATCTATCACTTTTATCATTTGGTAAATTATTTTGATTATCGTG
CTTATTTTCGGGTTTCTTTGGAATATCAAAGTTTTCTTCTCGATCGTCTTCTGGATTTTTTGGAACATCA
GAAGGTACTTCTTTTTCTGAATCTTCAGGTATATTTGGTTCTTGTTCAGGAATATCTGGATTTGGTGGAT
TTGGTGGATTTGGTGGATTTGGTGGATTTGGTGGATTTGGTGGATTTTCTGGATTTTCATCTAAATCAAA
TCCGTTTGGATTTTCACCCTTTCCTTCTTCTGGATTTGGTGAAGGTTCTTGTGGATTATTATCTATTATA
TTTTCGTTTGGTTTTTCGACAGCAAAATTATCTCCTCTTGGTCTAGGTTGATCATCTTCGGGTTCATCTG
GAACATCTAATGGTTCCCGTTTTGGAAGACATCTTTCTTCTTCACATTGTTCTTGTAATTCACTTGTACA
TCCTTCGTGTAAGATTTCTCTTTTTCTTGACCTGGTACCTTTACCACAAGTTACACTACATGGAGACCAT
TCGTCCCAAACACCACAACTTGCTGTTTTTTCTACTTCAACACAAACAGCCTTCATAAAGGGTCCGATAA
CATTTTTTACATTTTCCCATGCAGAATCAGCATACAAGTTACATTTACCATCTGATGGATGACAACCTAC
AAGAAATCTGTTGAAAGCTACATTAATACCTTGTCCAATACCAAAAACAGCTATTTTAACACCACGATCA
CTTAATTTTCTTGATTCTTTTAATGAATCTTGAATACTATCTGGAATTCCATCTGTTAATATAACAACTA
ATTGATTAGCATTCTCTCTATTGATTCGGTCATTTAAATGTTTTCTTACTTGTAACAGTGCATCAGTTAA
GTTTGTTTTACCATATGGAAGATTTGTACTTAAGAGTGACTTTATAATAATTAAAGCCTTCTCTTTGTTT
TTAGATGCATCACTATGTAATCTAATAATTTCTCTTGCATTGTTTGAAAAAACACTAGCATATAAGTGAA
TTGCATTATCATTAAGATTTAATTGTTGTATCAATTTCATAGCTAGAGGTACTGCATGGTTCACCCAATT
ATGACGACGTATACTTCCAGAACAATCCATTAGAAGGTAAAGATCTACCTCATCATTACATACTTCTTCA
CGATATTTTATTTCATCCACTATATTGTTTTGCACATCTCTACCATTAACTAGAAACAAATCAAAGAAAA
TCAAAAACACAATGACTAAATATTTAACATTCCCAAGATGATTCA

</dna_sequence>
        <protein_sequence>>XP_001350088.1 thrombospondin-related anonymous protein [Plasmodium falciparum 3D7]
MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYREEVCNDEVDLYLLMDCSGSIRRHNWVNHAVP
LAMKLIQQLNLNDNAIHLYASVFSNNAREIIRLHSDASKNKEKALIIIKSLLSTNLPYGKTNLTDALLQV
RKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDG
KCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSELQEQ
CEEERCLPKREPLDVPDEPEDDQPRPRGDNFAVEKPNENIIDNNPQEPSPNPEEGKGENPNGFDLDENPE
NPPNPPNPPNPPNPPNPPNPDIPEQEPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLP
NDKSDRYIPYSPLSPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKHNNTPKHPE
REEHEKPDNNKKKAGSDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLD
EPEQFRLPEENEWN

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation></phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene1029">
        <gene_name>UIS3</gene_name>
        <strain>Plasmodium yoelii yoelii str. 17XNL</strain>
        <vo_id></vo_id>
        <ncbi_gene_id>3830198</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>83315853</ncbi_protein_id>
        <gene_locus_tag>PY03011</gene_locus_tag>
        <gene_refseq>AABL01000850</gene_refseq>
        <protein_refseq>XP_730972</protein_refseq>
        <pdb_id>2VWA</pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>352914</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>1385</gene_start>
        <gene_end>2296</gene_end>
        <gene_strand>-</gene_strand>
        <protein_name></protein_name>
        <protein_pi>9.63</protein_pi>
        <protein_weight>26806.7</protein_weight>
        <protein_length>241</protein_length>
        <protein_note></protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>gi|221228555:1385-2296 Plasmodium yoelii yoelii str. 17XNL MALPY00853, whole genome shotgun sequence
TTCATTTTGGTTGATATTGTTCTTTAAGAAAATGCTCCACGCCTAAAACTGCGATATCTTCTTGGGCTCT
TGAAATATTAACATCCTTATTTTCATCTAAAGTCTGGACAATTTTCCTTAAGTAATCATAATCCTTGATT
AAATATTTCTGTTGTTCATTTGATAAATTGCTGAAATGGTGTTTAGCAGCTAGTTTCACATTATCCATAA
ATGTATTAAACCTTTTCAAAGGAACATCAATATCATTATTGTTTTCTTTTAATTTTCCTTTTATATTTAC
TTTATTTACTCCTAATGGTTCTTCATATTTTGTACTAGTGCTTGGTTTTTCACCATCAGGTTGTTTATAT
TCTGTTTGTTTATTAAAGGGGAAAAAATTAAAACCTTTATTCCAATCATGTCTTCCTTTATTATGAGATT
TATACATATAATAAAGTACCCCAATAACACTTGCCACTAATCCTGATGATAACAAAGCAATTGCAACTGA
TTTCCTCTTCTTTTTTTTTTTTATAGCAGTATCAATGCTATCTAATGCCCCATCATCTATTTCTGAATAA
TAATCTGCATCCTCACAAAAGCAAGGGTTAAAAAAAAATGTAGTAATATATAACACATAAAAAACGAAAA
AAACTTTGAGAGTGTTCATTTTATACACTTTCATATATTTTTTATTTGTCTAAGTAATAAAAAAAATTAA
ATTACTATAAAGATCAAATAATTATGTACAAATTTTTATCATTATTATTGTTAATATTATATTTTTTTTT
TATGTGTCAACAAAAAATTATTAAGCAAAGAATAATCTTTGAGTCACAATGATAAATGTGATGCTATTAT
AAATAATATTTCCTGTCAATCATACTCTAAAATATTTATTAATATAAATTATGCATGTGAAAAATTGAGG
CA</dna_sequence>
        <protein_sequence>>gi|83315853|ref|XP_730972.1| early transcribed membrane protein [Plasmodium yoelii yoelii str. 17XNL]
MPQFFTCIIYINKYFRTNKKYMKVYKMNTLKVFFVFYVLYITTFFFNPCFCEDADYYSEIDDGALDSIDT
AIKKKKKRKSVAIALLSSGLVASVIGVLYYMYKSHNKGRHDWNKGFNFFPFNKQTEYKQPDGEKPSTSTK
YEEPLGVNKVNIKGKLKENNNDIDVPLKRFNTFMDNVKLAAKHHFSNLSNEQQKYLIKDYDYLRKIVQTL
DENKDVNISRAQEDIAVLGVEHFLKEQYQPK</protein_sequence>
        <phi_function>Virmugen</phi_function>
        <phi_annotation>Deletion of UIS3 in Plasmodium yoelii provided attenuation and full protection in mice by Pyuis3(-) sporozoites required at least 2 immunizations against challenges with infectious sporozoites [Ref1973:Tarun et al., 2007].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference251">
		<reference_name>Adams et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Adams S, Brown H, Turner G</authors>
		<title>Breaking down the blood-brain barrier: signaling a path to cerebral malaria?</title>
		<year>2002 Aug</year>
		<volume>18</volume>
		<issue>8</issue>
		<pages>360-6</pages>
		<journal_book_name>Trends in parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference507">
		<reference_name>Aidoo et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druihle P, Hill AV</authors>
		<title>Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3</title>
		<year>2000 Jan</year>
		<volume>68</volume>
		<issue>1</issue>
		<pages>227-32</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference539">
		<reference_name>Alonso et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J</authors>
		<title>Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial</title>
		<year>2004 Oct 16-22</year>
		<volume>364</volume>
		<issue>9443</issue>
		<pages>1411-20</pages>
		<journal_book_name>Lancet</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference528">
		<reference_name>Arevalo-Herrera et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S</authors>
		<title>Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein</title>
		<year>2005 Nov</year>
		<volume>73</volume>
		<issue>5 Suppl</issue>
		<pages>32-7</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference524">
		<reference_name>Audran et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F</authors>
		<title>Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen</title>
		<year>2005 Dec</year>
		<volume>73</volume>
		<issue>12</issue>
		<pages>8017-26</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3324">
		<reference_name>Bauza et al., 2014</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A</authors>
		<title>Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites</title>
		<year>2014</year>
		<volume>82</volume>
		<issue>3</issue>
		<pages>1277-1286</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference511">
		<reference_name>BenMohamed et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>BenMohamed L, Thomas A, Druilhe P</authors>
		<title>Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides</title>
		<year>2004 Aug</year>
		<volume>72</volume>
		<issue>8</issue>
		<pages>4376-84</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2779">
		<reference_name>Bergmann-Leitner et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC</authors>
		<title>C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>45</issue>
		<pages>7732-7736</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1641">
		<reference_name>Bergmann-Leitner et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E</authors>
		<title>Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei</title>
		<year>2010</year>
		<volume>5</volume>
		<issue>8</issue>
		<pages>e12294</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference245">
		<reference_name>Bledsoe, 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bledsoe GH</authors>
		<title>Malaria primer for clinicians in the United States</title>
		<year>2005 Dec</year>
		<volume>98</volume>
		<issue>12</issue>
		<pages>1197-204; quiz 1205, 1230</pages>
		<journal_book_name>Southern medical journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference535">
		<reference_name>Bojang et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T</authors>
		<title>Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial</title>
		<year>2001 Dec 8</year>
		<volume>358</volume>
		<issue>9297</issue>
		<pages>1927-34</pages>
		<journal_book_name>Lancet</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1244">
		<reference_name>Bonnefoy et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bonnefoy S, Gysin J, Blisnick T, Guillotte M, Carcy B, Pereira da Silva L, Mercereau-Puijalon O</authors>
		<title>Immunogenicity and antigenicity of a Plasmodium falciparum protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages</title>
		<year>1994</year>
		<volume>12</volume>
		<issue>1</issue>
		<pages>32-40</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1898">
		<reference_name>Bracho et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N</authors>
		<title>AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5</title>
		<year>2009</year>
		<volume>8</volume>
		<issue></issue>
		<pages>35</pages>
		<journal_book_name>Malaria journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference247">
		<reference_name>Breman, 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Breman JG</authors>
		<title>The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden</title>
		<year>2001 Jan-Feb</year>
		<volume>64</volume>
		<issue>1-2 Suppl</issue>
		<pages>1-11</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference481">
		<reference_name>Bruna-Romero et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT</authors>
		<title>Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif</title>
		<year>2004 Sep 9</year>
		<volume>22</volume>
		<issue>27-28</issue>
		<pages>3575-84</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference523">
		<reference_name>Burgess et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Burgess BR, Schuck P, Garboczi DN</authors>
		<title>Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule</title>
		<year>2005 Nov 4</year>
		<volume>280</volume>
		<issue>44</issue>
		<pages>37236-45</pages>
		<journal_book_name>The Journal of biological chemistry</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2068">
		<reference_name>Butler et al., 2011</reference_name>
		<reference_type>journal</reference_type>
		<authors>Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT</authors>
		<title>Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites</title>
		<year>2011</year>
		<volume>9</volume>
		<issue>6</issue>
		<pages>451-462</pages>
		<journal_book_name>Cell host &amp; microbe</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference530">
		<reference_name>Carter et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF</authors>
		<title>Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12</title>
		<year>1995 May</year>
		<volume>71</volume>
		<issue>2</issue>
		<pages>203-10</pages>
		<journal_book_name>Molecular and biochemical parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1451">
		<reference_name>Carvalho et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT</authors>
		<title>Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels</title>
		<year>2004</year>
		<volume>59</volume>
		<issue>4</issue>
		<pages>363-372</pages>
		<journal_book_name>Scandinavian journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference543">
		<reference_name>Castellanos et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Castellanos A, Arevalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S</authors>
		<title>Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys</title>
		<year>2007 Jun</year>
		<volume>102</volume>
		<issue>3</issue>
		<pages>411-6</pages>
		<journal_book_name>Memorias do Instituto Oswaldo Cruz</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference250">
		<reference_name>Chen et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Chen Q, Schlichtherle M, Wahlgren M</authors>
		<title>Molecular aspects of severe malaria</title>
		<year>2000 Jul</year>
		<volume>13</volume>
		<issue>3</issue>
		<pages>439-50</pages>
		<journal_book_name>Clinical microbiology reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3325">
		<reference_name>Coutant et al., 2012</reference_name>
		<reference_type>journal</reference_type>
		<authors>Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P</authors>
		<title>A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria</title>
		<year>2012</year>
		<volume>7</volume>
		<issue>11</issue>
		<pages>e48644</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1219">
		<reference_name>Daly and Long, 1993</reference_name>
		<reference_type>journal</reference_type>
		<authors>Daly TM, Long CA</authors>
		<title>A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice</title>
		<year>1993</year>
		<volume>61</volume>
		<issue>6</issue>
		<pages>2462-2467</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1489">
		<reference_name>Daubersies et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P</authors>
		<title>Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3</title>
		<year>2000</year>
		<volume>6</volume>
		<issue>11</issue>
		<pages>1258-1263</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1233">
		<reference_name>Dobaño and Doolan, 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dobaño C, Doolan DL</authors>
		<title>Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa</title>
		<year>2007</year>
		<volume>44</volume>
		<issue>11</issue>
		<pages>3037-3048</pages>
		<journal_book_name>Molecular immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1597">
		<reference_name>Doolan et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL</authors>
		<title>Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity</title>
		<year>1996</year>
		<volume>183</volume>
		<issue>4</issue>
		<pages>1739-1746</pages>
		<journal_book_name>The Journal of experimental medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1971">
		<reference_name>Douradinha et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Douradinha B, van Dijk MR, Ataide R, van Gemert GJ, Thompson J, Franetich JF, Mazier D, Luty AJ, Sauerwein R, Janse CJ, Waters AP, Mota MM</authors>
		<title>Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection</title>
		<year>2007</year>
		<volume>37</volume>
		<issue>13</issue>
		<pages>1511-1519</pages>
		<journal_book_name>International journal for parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference874">
		<reference_name>Dunachie et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV</authors>
		<title>A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge</title>
		<year>2006</year>
		<volume>74</volume>
		<issue>10</issue>
		<pages>5933-5942</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference529">
		<reference_name>Eksi et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC</authors>
		<title>Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production</title>
		<year>2006 Aug</year>
		<volume>61</volume>
		<issue>4</issue>
		<pages>991-8</pages>
		<journal_book_name>Molecular microbiology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1491">
		<reference_name>El et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Lee Sim BK, Long C, Keitel WA</authors>
		<title>The Safety and Immunogenicity of Recombinant EBA 175-RII NG Malaria Vaccine in Healthy Adults Living in a Non-Endemic Area</title>
		<year>2010</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Clinical and vaccine immunology : CVI</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference241">
		<reference_name>Escalante et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Escalante AA, Freeland DE, Collins WE, Lal AA</authors>
		<title>The evolution of primate malaria parasites based on the gene encoding cytochrome b from the linear mitochondrial genome</title>
		<year>1998 Jul 7</year>
		<volume>95</volume>
		<issue>14</issue>
		<pages>8124-9</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1218">
		<reference_name>Eslava et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Eslava I, Payares G, Pernia BM, Holder AA, Spencer LM</authors>
		<title>Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii</title>
		<year>2010</year>
		<volume>9</volume>
		<issue></issue>
		<pages>46</pages>
		<journal_book_name>Malaria journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1002">
		<reference_name>Etlinger et al., 1991</reference_name>
		<reference_type>journal</reference_type>
		<authors>Etlinger HM, Caspers P, Matile H, Schoenfeld HJ, Stueber D, Takacs B</authors>
		<title>Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum</title>
		<year>1991</year>
		<volume>59</volume>
		<issue>10</issue>
		<pages>3498-3503</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference483">
		<reference_name>Fanning et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Fanning SL, Czesny B, Sedegah M, Carucci DJ, van Gemert GJ, Eling W, Williamson KC</authors>
		<title>A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230</title>
		<year>2003 Jul 4</year>
		<volume>21</volume>
		<issue>23</issue>
		<pages>3228-35</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference541">
		<reference_name>Flanagan et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Flanagan KL, Mwangi T, Plebanski M, Odhiambo K, Ross A, Sheu E, Kortok M, Lowe B, Marsh K, Hill AV</authors>
		<title>Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection</title>
		<year>2003 Apr</year>
		<volume>68</volume>
		<issue>4</issue>
		<pages>421-30</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference544">
		<reference_name>Flanagan et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, Gelder C, Hart K, Kortok M, Lowe B, Robson KJ, Marsh K, Hill AV</authors>
		<title>Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation</title>
		<year>2006 Mar</year>
		<volume>74</volume>
		<issue>3</issue>
		<pages>367-75</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference542">
		<reference_name>Gantt et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V</authors>
		<title>Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo</title>
		<year>2000 Jun</year>
		<volume>68</volume>
		<issue>6</issue>
		<pages>3667-73</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference509">
		<reference_name>Garcia et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Garcia JE, Puentes A, Patarroyo ME</authors>
		<title>Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design</title>
		<year>2006 Oct</year>
		<volume>19</volume>
		<issue>4</issue>
		<pages>686-707</pages>
		<journal_book_name>Clinical microbiology reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference518">
		<reference_name>Genton et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP</authors>
		<title>Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children</title>
		<year>2003 Dec 8</year>
		<volume>22</volume>
		<issue>1</issue>
		<pages>30-41</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference531">
		<reference_name>Genton et al., 2003a</reference_name>
		<reference_type>journal</reference_type>
		<authors>Genton B, Anders RF, Alpers MP, Reeder JC</authors>
		<title>The malaria vaccine development program in Papua New Guinea</title>
		<year>2003 Jun</year>
		<volume>19</volume>
		<issue>6</issue>
		<pages>264-70</pages>
		<journal_book_name>Trends in parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference431">
		<reference_name>Gilbert et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV</authors>
		<title>Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis</title>
		<year>2006 May 22</year>
		<volume>24</volume>
		<issue>21</issue>
		<pages>4554-61</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference422">
		<reference_name>Girard et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Girard MP, Reed ZH, Friede M, Kieny MP</authors>
		<title>A review of human vaccine research and development: malaria</title>
		<year>2007 Feb 19</year>
		<volume>25</volume>
		<issue>9</issue>
		<pages>1567-80</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1224">
		<reference_name>Grüner et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Grüner AC, Mauduit M, Tewari R, Romero JF, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Crisanti A, Sinnis P, Mazier D, Corradin G, Snounou G, Rénia L</authors>
		<title>Sterile protection against malaria is independent of immune responses to the circumsporozoite protein</title>
		<year>2007</year>
		<volume>2</volume>
		<issue>12</issue>
		<pages>e1371</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference248">
		<reference_name>Greenwood et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Greenwood BM, Bojang K, Whitty CJ, Targett GA</authors>
		<title>Malaria</title>
		<year>2005 Apr 23-29</year>
		<volume>365</volume>
		<issue>9469</issue>
		<pages>1487-98</pages>
		<journal_book_name>Lancet</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference249">
		<reference_name>Hay et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW</authors>
		<title>The global distribution and population at risk of malaria: past, present, and future</title>
		<year>2004 Jun</year>
		<volume>4</volume>
		<issue>6</issue>
		<pages>327-36</pages>
		<journal_book_name>The Lancet infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference503">
		<reference_name>Heal et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW</authors>
		<title>Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids</title>
		<year>1999 Sep</year>
		<volume>18</volume>
		<issue>3-4</issue>
		<pages>251-8</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference526">
		<reference_name>Healer et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, Riley E</authors>
		<title>Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230</title>
		<year>1997 Aug</year>
		<volume>65</volume>
		<issue>8</issue>
		<pages>3017-23</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference490">
		<reference_name>Heppner et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J</authors>
		<title>Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research</title>
		<year>2005 Mar 18</year>
		<volume>23</volume>
		<issue>17-18</issue>
		<pages>2243-50</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference504">
		<reference_name>Hillier et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE</authors>
		<title>Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum</title>
		<year>2005 Apr</year>
		<volume>73</volume>
		<issue>4</issue>
		<pages>2109-15</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2774">
		<reference_name>Hoffman et al., 1994</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hoffman SL, Sedegah M, Hedstrom RC</authors>
		<title>Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine</title>
		<year>1994</year>
		<volume>12</volume>
		<issue>16</issue>
		<pages>1529-1533</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2775">
		<reference_name>Hoffman et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Hoffman SL, Doolan DL, Sedegah M, Aguiar JC, Wang R, Malik A, Gramzinski RA, Weiss WR, Hobart P, Norman JA, Margalith M, Hedstrom RC</authors>
		<title>Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use</title>
		<year>1997</year>
		<volume>15</volume>
		<issue>8</issue>
		<pages>842-845</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1216">
		<reference_name>Horii et al., 2010</reference_name>
		<reference_type>journal</reference_type>
		<authors>Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M</authors>
		<title>Evidences of Protection Against Blood-stage Infection of Plasmodium falciparum by the Novel Protein Vaccine SE36</title>
		<year>2010</year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name>Parasitology international</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3328">
		<reference_name>Iyori et al., 2013</reference_name>
		<reference_type>journal</reference_type>
		<authors>Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S</authors>
		<title>Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein</title>
		<year>2013</year>
		<volume>8</volume>
		<issue>8</issue>
		<pages>e70819</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference240">
		<reference_name>Joy et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ</authors>
		<title>Early origin and recent expansion of Plasmodium falciparum</title>
		<year>2003 Apr 11</year>
		<volume>300</volume>
		<issue>5617</issue>
		<pages>318-21</pages>
		<journal_book_name>Science (New York, N.Y.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1223">
		<reference_name>Kaba et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE</authors>
		<title>A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria</title>
		<year>2009</year>
		<volume>183</volume>
		<issue>11</issue>
		<pages>7268-7277</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference242">
		<reference_name>Kaufman et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kaufman TS, Ruveda EA</authors>
		<title>The quest for quinine: those who won the battles and those who won the war</title>
		<year>2005 Jan 28</year>
		<volume>44</volume>
		<issue>6</issue>
		<pages>854-85</pages>
		<journal_book_name>Angewandte Chemie (International ed. in English)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference538">
		<reference_name>Kester et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR</authors>
		<title>A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults</title>
		<year>2007 Jul 20</year>
		<volume>25</volume>
		<issue>29</issue>
		<pages>5359-66</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference424">
		<reference_name>Kocken et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW</authors>
		<title>High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion</title>
		<year>2002 Aug</year>
		<volume>70</volume>
		<issue>8</issue>
		<pages>4471-6</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference423">
		<reference_name>Komisar, 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Komisar JL</authors>
		<title>Malaria vaccines</title>
		<year>2007 May 1</year>
		<volume>12</volume>
		<issue></issue>
		<pages>3928-55</pages>
		<journal_book_name>Frontiers in bioscience : a journal and virtual library</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference421">
		<reference_name>Kristoff, 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kristoff J</authors>
		<title>Malaria stage-specific vaccine candidates</title>
		<year>2007</year>
		<volume>13</volume>
		<issue>19</issue>
		<pages>1989-99</pages>
		<journal_book_name>Current pharmaceutical design</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1222">
		<reference_name>Kumar et al., 1995</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC</authors>
		<title>Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys</title>
		<year>1995</year>
		<volume>1</volume>
		<issue>3</issue>
		<pages>325-332</pages>
		<journal_book_name>Molecular medicine (Cambridge, Mass.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference429">
		<reference_name>Kushwaha et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kushwaha A, Rao PP, Suresh RP, Chauhan VS</authors>
		<title>Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli</title>
		<year>2001 Aug</year>
		<volume>23</volume>
		<issue>8</issue>
		<pages>435-44</pages>
		<journal_book_name>Parasite immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference430">
		<reference_name>Kwiatkowski et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kwiatkowski D, Marsh K</authors>
		<title>Development of a malaria vaccine</title>
		<year>1997 Dec 6</year>
		<volume>350</volume>
		<issue>9092</issue>
		<pages>1696-701</pages>
		<journal_book_name>Lancet</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference482">
		<reference_name>Kwon et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kwon YU, Soucy RL, Snyder DA, Seeberger PH</authors>
		<title>Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides</title>
		<year>2005 Apr 8</year>
		<volume>11</volume>
		<issue>8</issue>
		<pages>2493-504</pages>
		<journal_book_name>Chemistry (Weinheim an der Bergstrasse, Germany)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1972">
		<reference_name>Labaied et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH</authors>
		<title>Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection</title>
		<year>2007</year>
		<volume>75</volume>
		<issue>8</issue>
		<pages>3758-3768</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference427">
		<reference_name>Lal et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lal AA, Hughes MA, Oliveira DA, Nelson C, Bloland PB, Oloo AJ, Hawley WE, Hightower AW, Nahlen BL, Udhayakumar V</authors>
		<title>Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria</title>
		<year>1996 Mar</year>
		<volume>64</volume>
		<issue>3</issue>
		<pages>1054-9</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3327">
		<reference_name>Lanar et al., 1996</reference_name>
		<reference_type>journal</reference_type>
		<authors>Lanar DE, Tine JA, de Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC</authors>
		<title>Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria</title>
		<year>1996</year>
		<volume>64</volume>
		<issue>5</issue>
		<pages>1666-1671</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference519">
		<reference_name>Langermans et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Langermans JA, Hensmann M, van Gijlswiik M, Zhang D, Pan W, Giersing BK, Locke E, Dubovsk F, Wittes J, Thomas AW</authors>
		<title>Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques</title>
		<year>2006 Sep-Oct</year>
		<volume>2</volume>
		<issue>5</issue>
		<pages>222-6</pages>
		<journal_book_name>Human vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2299">
		<reference_name>Le et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL</authors>
		<title>Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers</title>
		<year>2000</year>
		<volume>18</volume>
		<issue>18</issue>
		<pages>1893-1901</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1230">
		<reference_name>Li et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Li SL, Zhang DM, Cao Y, Pan WQ</authors>
		<title>[Expression and immunogenicity evaluation of ectodomain and subdomains of Plasmodium berghei apical membrane antigen 1]</title>
		<year>2007</year>
		<volume>25</volume>
		<issue>1</issue>
		<pages>1-5</pages>
		<journal_book_name>Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology &amp; parasitic diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3316">
		<reference_name>Matsumoto et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Matsumoto S, Yukitake H, Kanbara H, Yamada T</authors>
		<title>Recombinant Mycobacterium bovis bacillus Calmette-GuÃ©rin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies</title>
		<year>1998</year>
		<volume>188</volume>
		<issue>5</issue>
		<pages>845-854</pages>
		<journal_book_name>The Journal of experimental medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1225">
		<reference_name>Mauduit et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mauduit M, Grüner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Rénia L</authors>
		<title>A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites</title>
		<year>2009</year>
		<volume>4</volume>
		<issue>11</issue>
		<pages>e7717</pages>
		<journal_book_name>PloS one</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2301">
		<reference_name>McConkey et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV</authors>
		<title>Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans</title>
		<year>2003</year>
		<volume>9</volume>
		<issue>6</issue>
		<pages>729-735</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference243">
		<reference_name>Meis et al., 1983</reference_name>
		<reference_type>journal</reference_type>
		<authors>Meis JF, Verhave JP, Jap PH, Sinden RE, Meuwissen JH</authors>
		<title>Malaria parasites--discovery of the early liver form</title>
		<year>1983 Mar 31-Apr 6</year>
		<volume>302</volume>
		<issue>5907</issue>
		<pages>424-6</pages>
		<journal_book_name>Nature</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1238">
		<reference_name>Mohmmed et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mohmmed A, Kishore S, Patra KP, Dasaradhi PV, Malhotra P, Chauhan VS</authors>
		<title>Identification of karyopherin beta as an immunogenic antigen of the malaria parasite using immune mice and human sera</title>
		<year>2005</year>
		<volume>27</volume>
		<issue>5</issue>
		<pages>197-203</pages>
		<journal_book_name>Parasite immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1234">
		<reference_name>Moll et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moll K, Pettersson F, Vogt AM, Jonsson C, Rasti N, Ahuja S, Spångberg M, Mercereau-Puijalon O, Arnot DE, Wahlgren M, Chen Q</authors>
		<title>Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain</title>
		<year>2007</year>
		<volume>75</volume>
		<issue>1</issue>
		<pages>211-219</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference508">
		<reference_name>Moore et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moore AC, Hill AV</authors>
		<title>Progress in DNA-based heterologous prime-boost immunization strategies for malaria</title>
		<year>2004 Jun</year>
		<volume>199</volume>
		<issue></issue>
		<pages>126-43</pages>
		<journal_book_name>Immunological reviews</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference479">
		<reference_name>Moore et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC, Hill AV</authors>
		<title>Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance</title>
		<year>2005 Dec 1</year>
		<volume>175</volume>
		<issue>11</issue>
		<pages>7264-73</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference505">
		<reference_name>Moormann et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW</authors>
		<title>Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area</title>
		<year>2006 Apr</year>
		<volume>74</volume>
		<issue>4</issue>
		<pages>585-90</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference572">
		<reference_name>Morais et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM</authors>
		<title>Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity</title>
		<year>2006 Oct</year>
		<volume>75</volume>
		<issue>4</issue>
		<pages>582-7</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1655">
		<reference_name>Mueller et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Mueller AK, Labaied M, Kappe SH, Matuschewski K</authors>
		<title>Genetically modified Plasmodium parasites as a protective experimental malaria vaccine</title>
		<year>2005</year>
		<volume>433</volume>
		<issue>7022</issue>
		<pages>164-167</pages>
		<journal_book_name>Nature</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3321">
		<reference_name>Ockenhouse et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR</authors>
		<title>Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria</title>
		<year>1998</year>
		<volume>177</volume>
		<issue>6</issue>
		<pages>1664-1673</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2047">
		<reference_name>Oliveira-Ferreira et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F</authors>
		<title>Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus</title>
		<year>2000</year>
		<volume>18</volume>
		<issue>17</issue>
		<pages>1863-1869</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference506">
		<reference_name>Ong'echa et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Ong'echa JM, Lal AA, Terlouw DJ, Ter Kuile FO, Kariuki SK, Udhayakumar V, Orago AS, Hightower AW, Nahlen BL, Shi YP</authors>
		<title>Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project</title>
		<year>2003 May</year>
		<volume>68</volume>
		<issue>5</issue>
		<pages>590-7</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1229">
		<reference_name>Pal-Bhowmick et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pal-Bhowmick I, Mehta M, Coppens I, Sharma S, Jarori GK</authors>
		<title>Protective properties and surface localization of Plasmodium falciparum enolase</title>
		<year>2007</year>
		<volume>75</volume>
		<issue>11</issue>
		<pages>5500-5508</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2303">
		<reference_name>Parker et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, Hartikka J, Hobart P, Bentley CE, Chang A, Hedstrom R, Rogers WO, Kumar S, Hoffman SL, Norman JA</authors>
		<title>Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine</title>
		<year>2001</year>
		<volume>8</volume>
		<issue>13</issue>
		<pages>1011-1023</pages>
		<journal_book_name>Gene therapy</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1245">
		<reference_name>Pasquetto et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pasquetto V, Fidock DA, Gras H, Badell E, Eling W, Ballou WR, Belghiti J, Tartar A, Druilhe P</authors>
		<title>Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen</title>
		<year>1997</year>
		<volume>27</volume>
		<issue>10</issue>
		<pages>2502-2513</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference525">
		<reference_name>Pearce et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pearce JA, Hodder AN, Anders RF</authors>
		<title>The alanine-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3</title>
		<year>2004 Nov-Dec</year>
		<volume>108</volume>
		<issue>3-4</issue>
		<pages>186-9</pages>
		<journal_book_name>Experimental parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1227">
		<reference_name>Petritus and Burns, 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Petritus PM, Burns JM Jr</authors>
		<title>Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection</title>
		<year>2008</year>
		<volume>180</volume>
		<issue>1</issue>
		<pages>444-453</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference576">
		<reference_name>PF11_0344 in GeneDB</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>PF11_0344 in GeneDB</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.genedb.org/genedb/Dispatcher?formType=navBar&amp;organism=malaria&amp;desc=yes&amp;wildcard=yes&amp;name=PF11_0344&amp;ohmr=.&amp;ohmr2=.</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference575">
		<reference_name>PF13_0201 in GeneDB</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>PF13_0201 in GeneDB</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.genedb.org/genedb/Search?organism=malaria&amp;name=PF13_0201&amp;isid=true</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference574">
		<reference_name>PFL1385c in GeneDB</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>PFL1385c in GeneDB</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.genedb.org/genedb/Search?organism=malaria&amp;name=PFL1385c&amp;isid=true</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference515">
		<reference_name>Pichyangkul et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS</authors>
		<title>Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum</title>
		<year>2004 Sep 28</year>
		<volume>22</volume>
		<issue>29-30</issue>
		<pages>3831-40</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference426">
		<reference_name>Polhemus et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr</authors>
		<title>Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research</title>
		<year>2007 May 22</year>
		<volume>25</volume>
		<issue>21</issue>
		<pages>4203-12</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2044">
		<reference_name>Pye et al., 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF</authors>
		<title>Selection of an adjuvant for vaccination with the malaria antigen, MSA-2</title>
		<year>1997</year>
		<volume>15</volume>
		<issue>9</issue>
		<pages>1017-1023</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference3326">
		<reference_name>Reyes-Sandoval et al., 2008</reference_name>
		<reference_type>journal</reference_type>
		<authors>Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV</authors>
		<title>Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei</title>
		<year>2008</year>
		<volume>38</volume>
		<issue>3</issue>
		<pages>732-741</pages>
		<journal_book_name>European journal of immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference545">
		<reference_name>Robson et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, Sidibe T, Bosman A, Modiano D, Crisanti A</authors>
		<title>Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum</title>
		<year>1998 Jan</year>
		<volume>58</volume>
		<issue>1</issue>
		<pages>81-9</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2780">
		<reference_name>Rogers et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, Gowda K, Gwadz R, Kumar S, Gold M, Hoffman SL</authors>
		<title>Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques</title>
		<year>2001</year>
		<volume>69</volume>
		<issue>9</issue>
		<pages>5565-5572</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference521">
		<reference_name>Rosa et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM</authors>
		<title>The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate</title>
		<year>2004 Apr 15</year>
		<volume>92</volume>
		<issue>3</issue>
		<pages>259-68</pages>
		<journal_book_name>Immunology letters</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2778">
		<reference_name>Sakai et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sakai T, Hisaeda H, Nakano Y, Zhang M, Takashima M, Ishii K, Maekawa Y, Matsumoto S, Nitta Y, Miyazaki Ji, Yamamoto S, Himeno K</authors>
		<title>Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice</title>
		<year>2003</year>
		<volume>21</volume>
		<issue>13-14</issue>
		<pages>1432-1444</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2777">
		<reference_name>Sanchez et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sanchez GI, Sedegah M, Rogers WO, Jones TR, Sacci J, Witney A, Carucci DJ, Kumar N, Hoffman SL</authors>
		<title>Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice</title>
		<year>2001</year>
		<volume>69</volume>
		<issue>6</issue>
		<pages>3897-3905</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1858">
		<reference_name>Saul et al., 1992</reference_name>
		<reference_type>journal</reference_type>
		<authors>Saul A, Lord R, Jones GL, Spencer L</authors>
		<title>Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2</title>
		<year>1992</year>
		<volume>148</volume>
		<issue>1</issue>
		<pages>208-211</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference873">
		<reference_name>Schneider et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV</authors>
		<title>Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara</title>
		<year>1998</year>
		<volume>4</volume>
		<issue>4</issue>
		<pages>397-402</pages>
		<journal_book_name>Nature medicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference484">
		<reference_name>Seeberger et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Seeberger PH, Soucy RL, Kwon YU, Snyder DA, Kanemitsu T</authors>
		<title>A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines</title>
		<year>2004 Aug 7</year>
		<volume></volume>
		<issue>15</issue>
		<pages>1706-7</pages>
		<journal_book_name>Chemical communications (Cambridge, England)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1490">
		<reference_name>Sim et al., 2001</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sim BK, Narum DL, Liang H, Fuhrmann SR, Obaldia N 3rd, Gramzinski R, Aguiar J, Haynes JD, Moch JK, Hoffman SL</authors>
		<title>Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine</title>
		<year>2001</year>
		<volume>7</volume>
		<issue>4</issue>
		<pages>247-254</pages>
		<journal_book_name>Molecular medicine (Cambridge, Mass.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference516">
		<reference_name>Singh et al., 2003</reference_name>
		<reference_type>journal</reference_type>
		<authors>Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW</authors>
		<title>Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1</title>
		<year>2003 Dec</year>
		<volume>71</volume>
		<issue>12</issue>
		<pages>6766-74</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference522">
		<reference_name>Sirima et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O</authors>
		<title>Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa</title>
		<year>2007 Mar 30</year>
		<volume>25</volume>
		<issue>14</issue>
		<pages>2723-32</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference534">
		<reference_name>Stewart et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr</authors>
		<title>Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone</title>
		<year>2007 May</year>
		<volume>75</volume>
		<issue>5</issue>
		<pages>2283-90</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference537">
		<reference_name>Stoute et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR</authors>
		<title>Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya</title>
		<year>2006 Jul</year>
		<volume>75</volume>
		<issue>1</issue>
		<pages>166-70</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference520">
		<reference_name>Stowers et al., 2002</reference_name>
		<reference_type>journal</reference_type>
		<authors>Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH</authors>
		<title>A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum</title>
		<year>2002 Jan 8</year>
		<volume>99</volume>
		<issue>1</issue>
		<pages>339-44</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference246">
		<reference_name>Sturm et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok JM, Menard R, Heussler VT</authors>
		<title>Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids</title>
		<year>2006 Sep 1</year>
		<volume>313</volume>
		<issue>5791</issue>
		<pages>1287-90</pages>
		<journal_book_name>Science (New York, N.Y.)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference244">
		<reference_name>Talman et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V</authors>
		<title>Gametocytogenesis: the puberty of Plasmodium falciparum</title>
		<year>2004 Jul 14</year>
		<volume>3</volume>
		<issue></issue>
		<pages>24</pages>
		<journal_book_name>Malaria journal</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1973">
		<reference_name>Tarun et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, Takagi A, Wang R, Kappe SH</authors>
		<title>Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells</title>
		<year>2007</year>
		<volume>196</volume>
		<issue>4</issue>
		<pages>608-616</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference517">
		<reference_name>Thera et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV</authors>
		<title>Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial</title>
		<year>2006 Nov 24</year>
		<volume>1</volume>
		<issue>7</issue>
		<pages>e34</pages>
		<journal_book_name>PLoS clinical trials</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1226">
		<reference_name>Tsai et al., 2009</reference_name>
		<reference_type>journal</reference_type>
		<authors>Tsai CW, Duggan PF, Jin AJ, Macdonald NJ, Kotova S, Lebowitz J, Hurt DE, Shimp RL Jr, Lambert L, Miller LH, Long CA, Saul A, Narum DL</authors>
		<title>Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure</title>
		<year>2009</year>
		<volume>164</volume>
		<issue>1</issue>
		<pages>45-56</pages>
		<journal_book_name>Molecular and biochemical parasitology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1235">
		<reference_name>Valderrama-Aguirre et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S</authors>
		<title>Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit</title>
		<year>2005</year>
		<volume>73</volume>
		<issue>5 Suppl</issue>
		<pages>16-24</pages>
		<journal_book_name>The American journal of tropical medicine and hygiene</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference527">
		<reference_name>Vincent et al., 1999</reference_name>
		<reference_type>journal</reference_type>
		<authors>Vincent AA, Fanning S, Caira FC, Williamson KC</authors>
		<title>Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid</title>
		<year>1999 Nov</year>
		<volume>21</volume>
		<issue>11</issue>
		<pages>573-81</pages>
		<journal_book_name>Parasite immunology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1231">
		<reference_name>Wan et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wan Omar A, Roslaini AM, Ngah ZU, Azahari AA, Zahedi M, Baharudin O</authors>
		<title>A recombinant 19 kDa Plasmodium berghei merozoite surface protein 1 formulated with alum induces protective immune response in mice</title>
		<year>2007</year>
		<volume>24</volume>
		<issue>1</issue>
		<pages>119-126</pages>
		<journal_book_name>Tropical biomedicine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1241">
		<reference_name>Wang et al., 2004</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang L, Goschnick MW, Coppel RL</authors>
		<title>Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge</title>
		<year>2004</year>
		<volume>72</volume>
		<issue>10</issue>
		<pages>6172-6175</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2300">
		<reference_name>Wang et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL</authors>
		<title>Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites</title>
		<year>2005</year>
		<volume>73</volume>
		<issue>5</issue>
		<pages>2863-2872</pages>
		<journal_book_name>Infection and immunity</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2302">
		<reference_name>Webster et al., 2005</reference_name>
		<reference_type>journal</reference_type>
		<authors>Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV</authors>
		<title>Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara</title>
		<year>2005</year>
		<volume>102</volume>
		<issue>13</issue>
		<pages>4836-4841</pages>
		<journal_book_name>Proceedings of the National Academy of Sciences of the United States of America</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1242">
		<reference_name>Xu et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Xu H, Hodder AN, Yan H, Crewther PE, Anders RF, Good MF</authors>
		<title>CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization</title>
		<year>2000</year>
		<volume>165</volume>
		<issue>1</issue>
		<pages>389-396</pages>
		<journal_book_name>Journal of immunology (Baltimore, Md. : 1950)</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference2776">
		<reference_name>Yoshida et al., 2000</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yoshida S, Kashiwamura SI, Hosoya Y, Luo E, Matsuoka H, Ishii A, Fujimura A, Kobayashi E</authors>
		<title>Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite</title>
		<year>2000</year>
		<volume>271</volume>
		<issue>1</issue>
		<pages>107-115</pages>
		<journal_book_name>Biochemical and biophysical research communications</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference577">
		<reference_name>Yuen et al., 2007</reference_name>
		<reference_type>journal</reference_type>
		<authors>Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G</authors>
		<title>Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development</title>
		<year>2007 Jan 5</year>
		<volume>25</volume>
		<issue>3</issue>
		<pages>490-9</pages>
		<journal_book_name>Vaccine</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference425">
		<reference_name>Zhou et al., 2006</reference_name>
		<reference_type>journal</reference_type>
		<authors>Zhou Z, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, Bonner PC, Martin AM, Goldman IF, De La Vega P, Udhayakumar V, Lal AA</authors>
		<title>Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli</title>
		<year>2006 Jan-Feb</year>
		<volume>2</volume>
		<issue>1</issue>
		<pages>14-23</pages>
		<journal_book_name>Human vaccines</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


